@prefix : <http://www.semanticweb.org/root/ontologies/2018/6/ctro#> .
@prefix owl: <http://www.w3.org/2002/07/owl#> .
@prefix rdf: <http://www.w3.org/1999/02/22-rdf-syntax-ns#> .
@prefix xml: <http://www.w3.org/XML/1998/namespace> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .
@prefix ctro: <http://www.semanticweb.org/root/ontologies/2018/6/ctro#> .
@prefix rdfs: <http://www.w3.org/2000/01/rdf-schema#> .
@base <http://www.semanticweb.org/root/ontologies/2018/6/ctro> .

<http://www.semanticweb.org/root/ontologies/2018/6/ctro> rdf:type owl:Ontology .

#################################################################
#    Datatypes
#################################################################

###  http://www.w3.org/2006/time#Interval
<http://www.w3.org/2006/time#Interval> rdf:type rdfs:Datatype .


#################################################################
#    Object Properties
#################################################################

###  http://www.semanticweb.org/root/ontologies/2018/6/ctro#analysesHealthCondition
ctro:analysesHealthCondition rdf:type owl:ObjectProperty ;
                             rdfs:domain ctro:ClinicalTrial ;
                             rdfs:range ctro:DisorderOrSyndrome .


###  http://www.semanticweb.org/root/ontologies/2018/6/ctro#describes
ctro:describes rdf:type owl:ObjectProperty ;
               rdfs:domain ctro:Publication ;
               rdfs:range ctro:ClinicalTrial .


###  http://www.semanticweb.org/root/ontologies/2018/6/ctro#hasAEname
ctro:hasAEname rdf:type owl:ObjectProperty ;
               rdfs:domain ctro:AdverseEffect ;
               rdfs:range ctro:AdverseEffectName .


###  http://www.semanticweb.org/root/ontologies/2018/6/ctro#hasAdverseEffect
ctro:hasAdverseEffect rdf:type owl:ObjectProperty ;
                      rdfs:domain ctro:Arm ;
                      rdfs:range ctro:AdverseEffect .


###  http://www.semanticweb.org/root/ontologies/2018/6/ctro#hasAggregationMethod
ctro:hasAggregationMethod rdf:type owl:ObjectProperty ;
                          rdfs:domain ctro:EndPoint ;
                          rdfs:range ctro:AgreggationMethod .


###  http://www.semanticweb.org/root/ontologies/2018/6/ctro#hasAnalysisApproach
ctro:hasAnalysisApproach rdf:type owl:ObjectProperty ;
                         rdfs:domain ctro:ClinicalTrial ;
                         rdfs:range ctro:CTAnalysisApproach .


###  http://www.semanticweb.org/root/ontologies/2018/6/ctro#hasAnalysisMetric
ctro:hasAnalysisMetric rdf:type owl:ObjectProperty ;
                       rdfs:domain ctro:Outcome ;
                       rdfs:range ctro:AnalysisMetric .


###  http://www.semanticweb.org/root/ontologies/2018/6/ctro#hasArm
ctro:hasArm rdf:type owl:ObjectProperty ;
            rdfs:domain ctro:ClinicalTrial ;
            rdfs:range ctro:Arm .


###  http://www.semanticweb.org/root/ontologies/2018/6/ctro#hasCTDesign
ctro:hasCTDesign rdf:type owl:ObjectProperty ;
                 rdfs:domain ctro:ClinicalTrial ;
                 rdfs:range ctro:CTDesign .


###  http://www.semanticweb.org/root/ontologies/2018/6/ctro#hasConfidenceInterval
ctro:hasConfidenceInterval rdf:type owl:ObjectProperty ;
                           rdfs:subPropertyOf owl:topObjectProperty ;
                           rdfs:domain ctro:StatisticalMeasure ;
                           rdfs:range ctro:ConfidenceInterval .


###  http://www.semanticweb.org/root/ontologies/2018/6/ctro#hasCountry
ctro:hasCountry rdf:type owl:ObjectProperty ;
                rdfs:domain ctro:Population ;
                rdfs:range <http://www.bpiresearch.com/BPMO/2004/03/03/cdl/Countries#Country> .


###  http://www.semanticweb.org/root/ontologies/2018/6/ctro#hasDeliveryMethod
ctro:hasDeliveryMethod rdf:type owl:ObjectProperty ;
                       rdfs:domain ctro:Medication ;
                       rdfs:range ctro:DeliveryMethod .


###  http://www.semanticweb.org/root/ontologies/2018/6/ctro#hasDesiredEffectDirection
ctro:hasDesiredEffectDirection rdf:type owl:ObjectProperty ;
                               rdfs:domain ctro:Outcome ;
                               rdfs:range ctro:DesiredEffectDirection .


###  http://www.semanticweb.org/root/ontologies/2018/6/ctro#hasDesiredEndpoint
ctro:hasDesiredEndpoint rdf:type owl:ObjectProperty ;
                        rdfs:domain ctro:DesiredOutcome ;
                        rdfs:range ctro:EndPoint .


###  http://www.semanticweb.org/root/ontologies/2018/6/ctro#hasDesiredOutcome
ctro:hasDesiredOutcome rdf:type owl:ObjectProperty ;
                       rdfs:subPropertyOf owl:topObjectProperty ;
                       rdfs:domain ctro:ClinicalTrial ;
                       rdfs:range ctro:DesiredOutcome .


###  http://www.semanticweb.org/root/ontologies/2018/6/ctro#hasDoseUnit
ctro:hasDoseUnit rdf:type owl:ObjectProperty ;
                 rdfs:domain ctro:Medication ;
                 rdfs:range <http://data.nasa.gov/qudt/owl/qudt#BioAndMedicalUnit> .


###  http://www.semanticweb.org/root/ontologies/2018/6/ctro#hasDrug
ctro:hasDrug rdf:type owl:ObjectProperty ,
                      owl:FunctionalProperty ;
             rdfs:domain ctro:Medication ;
             rdfs:range ctro:Drug .


###  http://www.semanticweb.org/root/ontologies/2018/6/ctro#hasEffectSize
ctro:hasEffectSize rdf:type owl:ObjectProperty ;
                   rdfs:domain ctro:Outcome ;
                   rdfs:range ctro:EffectSize .


###  http://www.semanticweb.org/root/ontologies/2018/6/ctro#hasEffectSizeMethod
ctro:hasEffectSizeMethod rdf:type owl:ObjectProperty ;
                         rdfs:domain ctro:EffectSize ;
                         rdfs:range ctro:EffectSizeMethod .


###  http://www.semanticweb.org/root/ontologies/2018/6/ctro#hasEndPoint
ctro:hasEndPoint rdf:type owl:ObjectProperty ;
                 rdfs:domain ctro:Outcome ;
                 rdfs:range ctro:EndPoint .


###  http://www.semanticweb.org/root/ontologies/2018/6/ctro#hasEndpointDescription
ctro:hasEndpointDescription rdf:type owl:ObjectProperty ;
                            rdfs:subPropertyOf owl:topObjectProperty ;
                            rdfs:domain ctro:EndPoint ;
                            rdfs:range ctro:EndpointDescription .


###  http://www.semanticweb.org/root/ontologies/2018/6/ctro#hasEndpointUnit
ctro:hasEndpointUnit rdf:type owl:ObjectProperty ;
                     rdfs:domain ctro:EndPoint ;
                     rdfs:range <http://data.nasa.gov/qudt/owl/qudt#BioAndMedicalUnit> .


###  http://www.semanticweb.org/root/ontologies/2018/6/ctro#hasEthnicity
ctro:hasEthnicity rdf:type owl:ObjectProperty ;
                  rdfs:domain ctro:Population ;
                  rdfs:range ctro:Ethnicity .


###  http://www.semanticweb.org/root/ontologies/2018/6/ctro#hasInterval
ctro:hasInterval rdf:type owl:ObjectProperty ,
                          owl:FunctionalProperty ;
                 rdfs:domain ctro:Intervention ;
                 rdfs:range ctro:Interval .


###  http://www.semanticweb.org/root/ontologies/2018/6/ctro#hasIntervention
ctro:hasIntervention rdf:type owl:ObjectProperty ,
                              owl:FunctionalProperty ;
                     rdfs:domain ctro:Arm ;
                     rdfs:range ctro:Intervention .


###  http://www.semanticweb.org/root/ontologies/2018/6/ctro#hasMeasurementDevice
ctro:hasMeasurementDevice rdf:type owl:ObjectProperty ;
                          rdfs:domain ctro:Outcome ;
                          rdfs:range ctro:MeasurementDevice .


###  http://www.semanticweb.org/root/ontologies/2018/6/ctro#hasMedication
ctro:hasMedication rdf:type owl:ObjectProperty ,
                            owl:TransitiveProperty ;
                   rdfs:domain ctro:Intervention ;
                   rdfs:range ctro:Medication .


###  http://www.semanticweb.org/root/ontologies/2018/6/ctro#hasOutcome
ctro:hasOutcome rdf:type owl:ObjectProperty ;
                rdfs:domain ctro:Arm ;
                rdfs:range ctro:Outcome .


###  http://www.semanticweb.org/root/ontologies/2018/6/ctro#hasPopulation
ctro:hasPopulation rdf:type owl:ObjectProperty ,
                            owl:FunctionalProperty ;
                   rdfs:domain ctro:ClinicalTrial ;
                   rdfs:range ctro:Population .


###  http://www.semanticweb.org/root/ontologies/2018/6/ctro#hasQualityIndicator
ctro:hasQualityIndicator rdf:type owl:ObjectProperty ;
                         rdfs:subPropertyOf owl:topObjectProperty ;
                         rdfs:domain ctro:ClinicalTrial ;
                         rdfs:range ctro:EvidenceQuality .


###  http://www.semanticweb.org/root/ontologies/2018/6/ctro#hasResult
ctro:hasResult rdf:type owl:ObjectProperty ;
               rdfs:domain ctro:Outcome ;
               rdfs:range ctro:Result .


###  http://www.semanticweb.org/root/ontologies/2018/6/ctro#hasStatisticalMeasure
ctro:hasStatisticalMeasure rdf:type owl:ObjectProperty ;
                           rdfs:domain ctro:Result ;
                           rdfs:range ctro:StatisticalMeasure .


###  http://www.semanticweb.org/root/ontologies/2018/6/ctro#hasStatisticalTest
ctro:hasStatisticalTest rdf:type owl:ObjectProperty ;
                        rdfs:domain ctro:Outcome ;
                        rdfs:range ctro:StatisticalTest .


###  http://www.semanticweb.org/root/ontologies/2018/6/ctro#hasValue
ctro:hasValue rdf:type owl:ObjectProperty ;
              rdfs:domain ctro:DesiredOutcome ;
              rdfs:range ctro:Result .


#################################################################
#    Data properties
#################################################################

###  http://www.semanticweb.org/root/ontologies/2018/6/ctro#hasAbsoluteValue
ctro:hasAbsoluteValue rdf:type owl:DatatypeProperty ,
                               owl:FunctionalProperty ;
                      rdfs:domain ctro:Result ;
                      rdfs:range xsd:float .


###  http://www.semanticweb.org/root/ontologies/2018/6/ctro#hasAbstract
ctro:hasAbstract rdf:type owl:DatatypeProperty ;
                 rdfs:domain ctro:Publication ;
                 rdfs:range xsd:string .


###  http://www.semanticweb.org/root/ontologies/2018/6/ctro#hasAllocationRatio
ctro:hasAllocationRatio rdf:type owl:DatatypeProperty ,
                                 owl:FunctionalProperty ;
                        rdfs:domain ctro:ClinicalTrial ;
                        rdfs:range rdfs:Literal .


###  http://www.semanticweb.org/root/ontologies/2018/6/ctro#hasAuthor
ctro:hasAuthor rdf:type owl:DatatypeProperty ,
                        owl:FunctionalProperty ;
               rdfs:domain ctro:Publication ;
               rdfs:range xsd:string .


###  http://www.semanticweb.org/root/ontologies/2018/6/ctro#hasAuthorAffilations
ctro:hasAuthorAffilations rdf:type owl:DatatypeProperty ;
                          rdfs:domain ctro:EvidenceQuality ;
                          rdfs:range rdfs:Literal .


###  http://www.semanticweb.org/root/ontologies/2018/6/ctro#hasAvgAge
ctro:hasAvgAge rdf:type owl:DatatypeProperty ;
               rdfs:domain ctro:Population ;
               rdfs:range xsd:integer .


###  http://www.semanticweb.org/root/ontologies/2018/6/ctro#hasBaselineValue
ctro:hasBaselineValue rdf:type owl:DatatypeProperty ,
                               owl:FunctionalProperty ;
                      rdfs:domain ctro:EndPoint ;
                      rdfs:range xsd:float .


###  http://www.semanticweb.org/root/ontologies/2018/6/ctro#hasBiasSponsor
ctro:hasBiasSponsor rdf:type owl:DatatypeProperty ;
                    rdfs:domain ctro:EvidenceQuality ;
                    rdfs:range xsd:string .


###  http://www.semanticweb.org/root/ontologies/2018/6/ctro#hasCIvalue
ctro:hasCIvalue rdf:type owl:DatatypeProperty ;
                rdfs:domain ctro:ConfidenceInterval ;
                rdfs:range xsd:float .


###  http://www.semanticweb.org/root/ontologies/2018/6/ctro#hasCTduration
ctro:hasCTduration rdf:type owl:DatatypeProperty ,
                            owl:FunctionalProperty ;
                   rdfs:domain ctro:ClinicalTrial ;
                   rdfs:range rdfs:Literal .


###  http://www.semanticweb.org/root/ontologies/2018/6/ctro#hasConclusionComment
ctro:hasConclusionComment rdf:type owl:DatatypeProperty ;
                          rdfs:domain ctro:ClinicalTrial ;
                          rdfs:range xsd:string .


###  http://www.semanticweb.org/root/ontologies/2018/6/ctro#hasConflictInterest
ctro:hasConflictInterest rdf:type owl:DatatypeProperty ;
                         rdfs:domain ctro:EvidenceQuality ;
                         rdfs:range xsd:string .


###  http://www.semanticweb.org/root/ontologies/2018/6/ctro#hasDesiredEffectDir
ctro:hasDesiredEffectDir rdf:type owl:DatatypeProperty ;
                         rdfs:domain ctro:EndPoint ;
                         rdfs:range xsd:string .


###  http://www.semanticweb.org/root/ontologies/2018/6/ctro#hasDoseValue
ctro:hasDoseValue rdf:type owl:DatatypeProperty ,
                           owl:FunctionalProperty ;
                  rdfs:domain ctro:Medication ;
                  rdfs:range rdfs:Literal .


###  http://www.semanticweb.org/root/ontologies/2018/6/ctro#hasDrug_Id
ctro:hasDrug_Id rdf:type owl:DatatypeProperty ,
                         owl:FunctionalProperty ;
                rdfs:domain ctro:Drug ;
                rdfs:range xsd:string .


###  http://www.semanticweb.org/root/ontologies/2018/6/ctro#hasDuration
ctro:hasDuration rdf:type owl:DatatypeProperty ;
                 rdfs:domain ctro:Intervention ;
                 rdfs:range rdfs:Literal .


###  http://www.semanticweb.org/root/ontologies/2018/6/ctro#hasEffectSizeValue
ctro:hasEffectSizeValue rdf:type owl:DatatypeProperty ;
                        rdfs:domain ctro:EffectSize ;
                        rdfs:range xsd:float .


###  http://www.semanticweb.org/root/ontologies/2018/6/ctro#hasFinalNumberPatients
ctro:hasFinalNumberPatients rdf:type owl:DatatypeProperty ,
                                     owl:FunctionalProperty ;
                            rdfs:domain ctro:Outcome ;
                            rdfs:range xsd:positiveInteger .


###  http://www.semanticweb.org/root/ontologies/2018/6/ctro#hasFrequency
ctro:hasFrequency rdf:type owl:DatatypeProperty ;
                  rdfs:domain ctro:Intervention ;
                  rdfs:range rdfs:Literal .


###  http://www.semanticweb.org/root/ontologies/2018/6/ctro#hasGender
ctro:hasGender rdf:type owl:DatatypeProperty ,
                        owl:FunctionalProperty ;
               rdfs:domain ctro:Population ;
               rdfs:range [ rdf:type rdfs:Datatype ;
                            owl:oneOf [ rdf:type rdf:List ;
                                        rdf:first "Female" ;
                                        rdf:rest [ rdf:type rdf:List ;
                                                   rdf:first "Male" ;
                                                   rdf:rest [ rdf:type rdf:List ;
                                                              rdf:first "Mixed" ;
                                                              rdf:rest rdf:nil
                                                            ]
                                                 ]
                                      ]
                          ] .


###  http://www.semanticweb.org/root/ontologies/2018/6/ctro#hasInfMargin
ctro:hasInfMargin rdf:type owl:DatatypeProperty ;
                  rdfs:domain ctro:ConfidenceInterval ;
                  rdfs:range xsd:float .


###  http://www.semanticweb.org/root/ontologies/2018/6/ctro#hasJournal
ctro:hasJournal rdf:type owl:DatatypeProperty ,
                         owl:FunctionalProperty ;
                rdfs:domain ctro:Publication ;
                rdfs:range xsd:string .


###  http://www.semanticweb.org/root/ontologies/2018/6/ctro#hasMarginError
ctro:hasMarginError rdf:type owl:DatatypeProperty ;
                    rdfs:domain ctro:ConfidenceInterval ;
                    rdfs:range xsd:float .


###  http://www.semanticweb.org/root/ontologies/2018/6/ctro#hasMaxAge
ctro:hasMaxAge rdf:type owl:DatatypeProperty ,
                        owl:FunctionalProperty ;
               rdfs:domain ctro:Population ;
               rdfs:range xsd:positiveInteger .


###  http://www.semanticweb.org/root/ontologies/2018/6/ctro#hasMinAge
ctro:hasMinAge rdf:type owl:DatatypeProperty ,
                        owl:FunctionalProperty ;
               rdfs:domain ctro:Population ;
               rdfs:range xsd:positiveInteger .


###  http://www.semanticweb.org/root/ontologies/2018/6/ctro#hasNumAffectedAE
ctro:hasNumAffectedAE rdf:type owl:DatatypeProperty ;
                      rdfs:domain ctro:AdverseEffect ;
                      rdfs:range xsd:integer .


###  http://www.semanticweb.org/root/ontologies/2018/6/ctro#hasNumberAffected
ctro:hasNumberAffected rdf:type owl:DatatypeProperty ,
                                owl:FunctionalProperty ;
                       rdfs:domain ctro:Result ;
                       rdfs:range xsd:integer .


###  http://www.semanticweb.org/root/ontologies/2018/6/ctro#hasNumberPatientsArm
ctro:hasNumberPatientsArm rdf:type owl:DatatypeProperty ,
                                   owl:FunctionalProperty ;
                          rdfs:domain ctro:Arm ;
                          rdfs:range xsd:positiveInteger .


###  http://www.semanticweb.org/root/ontologies/2018/6/ctro#hasNumberPatientsCT
ctro:hasNumberPatientsCT rdf:type owl:DatatypeProperty ,
                                  owl:FunctionalProperty ;
                         rdfs:domain ctro:ClinicalTrial ;
                         rdfs:range xsd:positiveInteger .


###  http://www.semanticweb.org/root/ontologies/2018/6/ctro#hasObjectiveDescription
ctro:hasObjectiveDescription rdf:type owl:DatatypeProperty ,
                                      owl:FunctionalProperty ;
                             rdfs:domain ctro:ClinicalTrial ;
                             rdfs:range xsd:string .


###  http://www.semanticweb.org/root/ontologies/2018/6/ctro#hasObservedResult
ctro:hasObservedResult rdf:type owl:DatatypeProperty ,
                                owl:FunctionalProperty ;
                       rdfs:domain ctro:Result ;
                       rdfs:range xsd:string .


###  http://www.semanticweb.org/root/ontologies/2018/6/ctro#hasPMID
ctro:hasPMID rdf:type owl:DatatypeProperty ,
                      owl:FunctionalProperty ;
             rdfs:domain ctro:Publication ;
             rdfs:range rdfs:Literal .


###  http://www.semanticweb.org/root/ontologies/2018/6/ctro#hasPValue
ctro:hasPValue rdf:type owl:DatatypeProperty ,
                        owl:FunctionalProperty ;
               rdfs:domain ctro:StatisticalTest ;
               rdfs:range xsd:string ;
               rdfs:comment "P value gives the statistical significance (i.e., the probability that the observed difference between two groups is due to chance). If the P value is larger than the alpha level chosen (eg, .05), any observed difference is assumed to be explained by sampling variability" .


###  http://www.semanticweb.org/root/ontologies/2018/6/ctro#hasPercentageAffected
ctro:hasPercentageAffected rdf:type owl:DatatypeProperty ,
                                    owl:FunctionalProperty ;
                           rdfs:domain ctro:EffectSize ;
                           rdfs:range xsd:float .


###  http://www.semanticweb.org/root/ontologies/2018/6/ctro#hasPreconditionDescription
ctro:hasPreconditionDescription rdf:type owl:DatatypeProperty ;
                                rdfs:domain ctro:Population ;
                                rdfs:range xsd:string .


###  http://www.semanticweb.org/root/ontologies/2018/6/ctro#hasPublicationYear
ctro:hasPublicationYear rdf:type owl:DatatypeProperty ,
                                 owl:FunctionalProperty ;
                        rdfs:domain ctro:Publication ;
                        rdfs:range xsd:positiveInteger .


###  http://www.semanticweb.org/root/ontologies/2018/6/ctro#hasRelativeValue
ctro:hasRelativeValue rdf:type owl:DatatypeProperty ;
                      rdfs:domain ctro:Result ;
                      rdfs:range xsd:float .


###  http://www.semanticweb.org/root/ontologies/2018/6/ctro#hasResultDirection
ctro:hasResultDirection rdf:type owl:DatatypeProperty ;
                        rdfs:domain ctro:Result ;
                        rdfs:range xsd:string .


###  http://www.semanticweb.org/root/ontologies/2018/6/ctro#hasSNOMED_id
ctro:hasSNOMED_id rdf:type owl:DatatypeProperty ;
                  rdfs:domain ctro:DisorderOrSyndrome ;
                  rdfs:range xsd:string .


###  http://www.semanticweb.org/root/ontologies/2018/6/ctro#hasSponsor
ctro:hasSponsor rdf:type owl:DatatypeProperty ;
                rdfs:domain ctro:EvidenceQuality ;
                rdfs:range xsd:string .


###  http://www.semanticweb.org/root/ontologies/2018/6/ctro#hasStandardDev
ctro:hasStandardDev rdf:type owl:DatatypeProperty ,
                             owl:FunctionalProperty ;
                    rdfs:domain ctro:EffectSize ;
                    rdfs:range xsd:float .


###  http://www.semanticweb.org/root/ontologies/2018/6/ctro#hasStandardError
ctro:hasStandardError rdf:type owl:DatatypeProperty ;
                      rdfs:domain ctro:EffectSize ;
                      rdfs:range xsd:float .


###  http://www.semanticweb.org/root/ontologies/2018/6/ctro#hasStatisticalTestName
ctro:hasStatisticalTestName rdf:type owl:DatatypeProperty ,
                                     owl:FunctionalProperty ;
                            rdfs:domain ctro:StatisticalTest ;
                            rdfs:range xsd:string .


###  http://www.semanticweb.org/root/ontologies/2018/6/ctro#hasStatisticalTestValue
ctro:hasStatisticalTestValue rdf:type owl:DatatypeProperty ,
                                      owl:FunctionalProperty ;
                             rdfs:domain ctro:StatisticalTest ;
                             rdfs:range xsd:float ;
                             rdfs:comment "The result of the statistical test that was applied" .


###  http://www.semanticweb.org/root/ontologies/2018/6/ctro#hasSupMargin
ctro:hasSupMargin rdf:type owl:DatatypeProperty ;
                  rdfs:subPropertyOf owl:topDataProperty ;
                  rdfs:domain ctro:ConfidenceInterval ;
                  rdfs:range xsd:float .


###  http://www.semanticweb.org/root/ontologies/2018/6/ctro#hasTimePoints
ctro:hasTimePoints rdf:type owl:DatatypeProperty ;
                   rdfs:domain ctro:Outcome ;
                   rdfs:range rdfs:Literal .


###  http://www.semanticweb.org/root/ontologies/2018/6/ctro#hasTitle
ctro:hasTitle rdf:type owl:DatatypeProperty ,
                       owl:FunctionalProperty ;
              rdfs:domain ctro:Publication ;
              rdfs:range xsd:string .


###  http://www.semanticweb.org/root/ontologies/2018/6/ctro#isControl
ctro:isControl rdf:type owl:DatatypeProperty ;
               rdfs:domain ctro:Medication ;
               rdfs:range xsd:boolean .


#################################################################
#    Classes
#################################################################

###  http://data.nasa.gov/qudt/owl/qudt#BioAndMedicalUnit
<http://data.nasa.gov/qudt/owl/qudt#BioAndMedicalUnit> rdf:type owl:Class .


###  http://www.bpiresearch.com/BPMO/2004/03/03/cdl/Countries#Country
<http://www.bpiresearch.com/BPMO/2004/03/03/cdl/Countries#Country> rdf:type owl:Class .


###  http://www.semanticweb.org/root/ontologies/2018/6/ctro#AdverseEffect
ctro:AdverseEffect rdf:type owl:Class .


###  http://www.semanticweb.org/root/ontologies/2018/6/ctro#AdverseEffectName
ctro:AdverseEffectName rdf:type owl:Class .


###  http://www.semanticweb.org/root/ontologies/2018/6/ctro#AgreggationMethod
ctro:AgreggationMethod rdf:type owl:Class .


###  http://www.semanticweb.org/root/ontologies/2018/6/ctro#AnalysisMetric
ctro:AnalysisMetric rdf:type owl:Class .


###  http://www.semanticweb.org/root/ontologies/2018/6/ctro#Arm
ctro:Arm rdf:type owl:Class ;
         rdfs:comment "An arm of a clinical trial is a group of patients (or study subjects) receiving a specific treatment (or no treatment- i.e. placebo)"^^xsd:string .


###  http://www.semanticweb.org/root/ontologies/2018/6/ctro#CTAnalysisApproach
ctro:CTAnalysisApproach rdf:type owl:Class ;
                        rdfs:comment "Type of analysis carried out in the clinical trial (i.e, Intention To Treat, Per Protocol) relative to the number of patients treated" .


###  http://www.semanticweb.org/root/ontologies/2018/6/ctro#CTDesign
ctro:CTDesign rdf:type owl:Class .


###  http://www.semanticweb.org/root/ontologies/2018/6/ctro#ClinicalTrial
ctro:ClinicalTrial rdf:type owl:Class ;
                   rdfs:comment "Controlled study that assigns groups of humans to one or more health-related interventions to evaluate the respective effects on health outcomes"^^xsd:string .


###  http://www.semanticweb.org/root/ontologies/2018/6/ctro#Concentration
ctro:Concentration rdf:type owl:Class ;
                   rdfs:subClassOf <http://data.nasa.gov/qudt/owl/qudt#BioAndMedicalUnit> .


###  http://www.semanticweb.org/root/ontologies/2018/6/ctro#ConfidenceInterval
ctro:ConfidenceInterval rdf:type owl:Class .


###  http://www.semanticweb.org/root/ontologies/2018/6/ctro#DeliveryMethod
ctro:DeliveryMethod rdf:type owl:Class .


###  http://www.semanticweb.org/root/ontologies/2018/6/ctro#DesiredEffectDirection
ctro:DesiredEffectDirection rdf:type owl:Class .


###  http://www.semanticweb.org/root/ontologies/2018/6/ctro#DesiredOutcome
ctro:DesiredOutcome rdf:type owl:Class .


###  http://www.semanticweb.org/root/ontologies/2018/6/ctro#DisorderOrSyndrome
ctro:DisorderOrSyndrome rdf:type owl:Class ;
                        rdfs:comment "Name of the disease or problem that is studied in the clinical trial"^^xsd:string .


###  http://www.semanticweb.org/root/ontologies/2018/6/ctro#Drug
ctro:Drug rdf:type owl:Class .


###  http://www.semanticweb.org/root/ontologies/2018/6/ctro#EffectSize
ctro:EffectSize rdf:type owl:Class ;
                rdfs:comment "An effect size estimate can place an easily interpretable value on the direction and magnitude of an effect of a treatment. It allows clinically meaningful comparisons of efficacy between treatment trials. Several measures of effect size are in current practice."^^xsd:string .


###  http://www.semanticweb.org/root/ontologies/2018/6/ctro#EffectSizeMethod
ctro:EffectSizeMethod rdf:type owl:Class ;
                      rdfs:comment "The type of size of effect reported (e.g. relative risk)"^^xsd:string .


###  http://www.semanticweb.org/root/ontologies/2018/6/ctro#EndPoint
ctro:EndPoint rdf:type owl:Class ;
              rdfs:comment "Corresponds to the data collected directly from the trial participants (e.g., IOP pressure)"^^xsd:string .


###  http://www.semanticweb.org/root/ontologies/2018/6/ctro#EndpointDescription
ctro:EndpointDescription rdf:type owl:Class .


###  http://www.semanticweb.org/root/ontologies/2018/6/ctro#Ethnicity
ctro:Ethnicity rdf:type owl:Class ;
               rdfs:comment "Ethnicity of the population"^^xsd:string .


###  http://www.semanticweb.org/root/ontologies/2018/6/ctro#EvidenceQuality
ctro:EvidenceQuality rdf:type owl:Class .


###  http://www.semanticweb.org/root/ontologies/2018/6/ctro#Frequency
ctro:Frequency rdf:type owl:Class .


###  http://www.semanticweb.org/root/ontologies/2018/6/ctro#Interval
ctro:Interval rdf:type owl:Class .


###  http://www.semanticweb.org/root/ontologies/2018/6/ctro#Intervention
ctro:Intervention rdf:type owl:Class ;
                  rdfs:comment "A treatment or action taken to prevent or treat disease, or improve health in other ways. Interventions include but are not restricted to drugs."^^xsd:string .


###  http://www.semanticweb.org/root/ontologies/2018/6/ctro#MeasurementDevice
ctro:MeasurementDevice rdf:type owl:Class .


###  http://www.semanticweb.org/root/ontologies/2018/6/ctro#Medication
ctro:Medication rdf:type owl:Class .


###  http://www.semanticweb.org/root/ontologies/2018/6/ctro#Other
ctro:Other rdf:type owl:Class ;
           rdfs:subClassOf <http://data.nasa.gov/qudt/owl/qudt#BioAndMedicalUnit> .


###  http://www.semanticweb.org/root/ontologies/2018/6/ctro#Outcome
ctro:Outcome rdf:type owl:Class ;
             rdfs:comment "What is expected to be accomplish, measure, improve, or affect in the clinical trial. There are primary or not primary outcomes."^^xsd:string .


###  http://www.semanticweb.org/root/ontologies/2018/6/ctro#Population
ctro:Population rdf:type owl:Class ;
                rdfs:comment "Population of patients or any other study unit (e.g. eyes) with certain characteristics and preconditions according with the problem/disease studied"^^xsd:string .


###  http://www.semanticweb.org/root/ontologies/2018/6/ctro#Pressure
ctro:Pressure rdf:type owl:Class ;
              rdfs:subClassOf <http://data.nasa.gov/qudt/owl/qudt#BioAndMedicalUnit> .


###  http://www.semanticweb.org/root/ontologies/2018/6/ctro#PrimaryOutcomeName
ctro:PrimaryOutcomeName rdf:type owl:Class ;
                        rdfs:subClassOf ctro:EndpointDescription .


###  http://www.semanticweb.org/root/ontologies/2018/6/ctro#Publication
ctro:Publication rdf:type owl:Class .


###  http://www.semanticweb.org/root/ontologies/2018/6/ctro#Result
ctro:Result rdf:type owl:Class ;
            rdfs:comment "Results of an outcome reported in different ways"^^xsd:string .


###  http://www.semanticweb.org/root/ontologies/2018/6/ctro#SecondaryOutcomeName
ctro:SecondaryOutcomeName rdf:type owl:Class ;
                          rdfs:subClassOf ctro:EndpointDescription .


###  http://www.semanticweb.org/root/ontologies/2018/6/ctro#StatisticalMeasure
ctro:StatisticalMeasure rdf:type owl:Class .


###  http://www.semanticweb.org/root/ontologies/2018/6/ctro#StatisticalTest
ctro:StatisticalTest rdf:type owl:Class ;
                     rdfs:comment "It is a group of mathematical operations used to determine the statistical significance of an intervention"^^xsd:string .


###  http://www.semanticweb.org/root/ontologies/2018/6/ctro#TimeUnit
ctro:TimeUnit rdf:type owl:Class .


###  http://www.semanticweb.org/root/ontologies/2018/6/ctro#Weight
ctro:Weight rdf:type owl:Class ;
            rdfs:subClassOf <http://data.nasa.gov/qudt/owl/qudt#BioAndMedicalUnit> .


###  http://www.w3.org/2002/07/owl#Thing
owl:Thing rdf:type owl:Class .


#################################################################
#    Individuals
#################################################################

###  http://www.semanticweb.org/root/ontologies/2018/6/ctro#
ctro: rdf:type owl:NamedIndividual ,
               ctro:Frequency .


###  http://www.semanticweb.org/root/ontologies/2018/6/ctro#Adjusted
ctro:Adjusted rdf:type owl:NamedIndividual ,
                       ctro:Other ;
              rdfs:label "Solution Adjusted" .


###  http://www.semanticweb.org/root/ontologies/2018/6/ctro#Arm_101
ctro:Arm_101 rdf:type owl:NamedIndividual ,
                      ctro:Arm ;
             ctro:hasAdverseEffect ctro:CT10_A1_AE1 ;
             ctro:hasIntervention ctro:CT10_Intervention1 ;
             ctro:hasOutcome ctro:CT10_A1_OC1 ;
             ctro:hasNumberPatientsArm 7 .


###  http://www.semanticweb.org/root/ontologies/2018/6/ctro#Arm_102
ctro:Arm_102 rdf:type owl:NamedIndividual ,
                      ctro:Arm ;
             ctro:hasAdverseEffect ctro:CT10_A2_AE1 ;
             ctro:hasIntervention ctro:CT10_Intervention2 ;
             ctro:hasOutcome ctro:CT10_A2_OC1 ;
             ctro:hasNumberPatientsArm 8 .


###  http://www.semanticweb.org/root/ontologies/2018/6/ctro#Arm_11
ctro:Arm_11 rdf:type owl:NamedIndividual ,
                     ctro:Arm ;
            ctro:hasAdverseEffect ctro:CT1_A1_AE1 ;
            ctro:hasIntervention ctro:CT1_Intervention1 ;
            ctro:hasOutcome ctro:CT1_A1_OC1 ;
            ctro:hasNumberPatientsArm 84 .


###  http://www.semanticweb.org/root/ontologies/2018/6/ctro#Arm_111
ctro:Arm_111 rdf:type owl:NamedIndividual ,
                      ctro:Arm ;
             ctro:hasAdverseEffect ctro:CT11_A1_AE1 ;
             ctro:hasIntervention ctro:CT11_Intervention1 ;
             ctro:hasOutcome ctro:CT11_A1_OC1 ;
             ctro:hasNumberPatientsArm 18 .


###  http://www.semanticweb.org/root/ontologies/2018/6/ctro#Arm_112
ctro:Arm_112 rdf:type owl:NamedIndividual ,
                      ctro:Arm ;
             ctro:hasAdverseEffect ctro:CT11_A2_AE1 ;
             ctro:hasIntervention ctro:CT11_Intervention2 ;
             ctro:hasOutcome ctro:CT11_A2_OC1 ;
             ctro:hasNumberPatientsArm 18 .


###  http://www.semanticweb.org/root/ontologies/2018/6/ctro#Arm_12
ctro:Arm_12 rdf:type owl:NamedIndividual ,
                     ctro:Arm ;
            ctro:hasAdverseEffect ctro:CT1_A2_AE1 ;
            ctro:hasIntervention ctro:CT1_Intervention2 ;
            ctro:hasOutcome ctro:CT1_A2_OC1 ;
            ctro:hasNumberPatientsArm 89 .


###  http://www.semanticweb.org/root/ontologies/2018/6/ctro#Arm_21
ctro:Arm_21 rdf:type owl:NamedIndividual ,
                     ctro:Arm ;
            ctro:hasAdverseEffect ctro:CT2_A1_AE1 ;
            ctro:hasIntervention ctro:CT2_Intervention1 ;
            ctro:hasOutcome ctro:CT2_A1_OC1 ;
            ctro:hasNumberPatientsArm 30 .


###  http://www.semanticweb.org/root/ontologies/2018/6/ctro#Arm_211
ctro:Arm_211 rdf:type owl:NamedIndividual ,
                      ctro:Arm ;
             ctro:hasAdverseEffect ctro:CT21_A1_AE1 ;
             ctro:hasIntervention ctro:CT21_Intervention1 ;
             ctro:hasOutcome ctro:CT21_A1_OC1 .


###  http://www.semanticweb.org/root/ontologies/2018/6/ctro#Arm_212
ctro:Arm_212 rdf:type owl:NamedIndividual ,
                      ctro:Arm ;
             ctro:hasAdverseEffect ctro:CT21_A2_AE1 ;
             ctro:hasIntervention ctro:CT21_Intervention2 ;
             ctro:hasOutcome ctro:CT21_A2_OC1 .


###  http://www.semanticweb.org/root/ontologies/2018/6/ctro#Arm_22
ctro:Arm_22 rdf:type owl:NamedIndividual ,
                     ctro:Arm ;
            ctro:hasAdverseEffect ctro:CT2_A2_AE1 ;
            ctro:hasIntervention ctro:CT2_Intervention2 ;
            ctro:hasOutcome ctro:CT2_A2_OC1 ;
            ctro:hasNumberPatientsArm 30 .


###  http://www.semanticweb.org/root/ontologies/2018/6/ctro#Arm_221
ctro:Arm_221 rdf:type owl:NamedIndividual ,
                      ctro:Arm ;
             ctro:hasAdverseEffect ctro:CT22_A1_AE1 ;
             ctro:hasIntervention ctro:CT22_Intervention1 ;
             ctro:hasOutcome ctro:CT22_A1_OC1 .


###  http://www.semanticweb.org/root/ontologies/2018/6/ctro#Arm_222
ctro:Arm_222 rdf:type owl:NamedIndividual ,
                      ctro:Arm ;
             ctro:hasAdverseEffect ctro:CT22_A2_AE1 ;
             ctro:hasIntervention ctro:CT22_Intervention2 ;
             ctro:hasOutcome ctro:CT22_A2_OC1 .


###  http://www.semanticweb.org/root/ontologies/2018/6/ctro#Arm_231
ctro:Arm_231 rdf:type owl:NamedIndividual ,
                      ctro:Arm ;
             ctro:hasAdverseEffect ctro:CT23_A1_AE1 ;
             ctro:hasIntervention ctro:CT23_Intervention1 ;
             ctro:hasOutcome ctro:CT23_A1_OC1 .


###  http://www.semanticweb.org/root/ontologies/2018/6/ctro#Arm_232
ctro:Arm_232 rdf:type owl:NamedIndividual ,
                      ctro:Arm ;
             ctro:hasAdverseEffect ctro:CT23_A2_AE1 ;
             ctro:hasIntervention ctro:CT23_Intervention2 ;
             ctro:hasOutcome ctro:CT23_A2_OC1 .


###  http://www.semanticweb.org/root/ontologies/2018/6/ctro#Arm_241
ctro:Arm_241 rdf:type owl:NamedIndividual ,
                      ctro:Arm ;
             ctro:hasAdverseEffect ctro:CT24_A1_AE1 ;
             ctro:hasIntervention ctro:CT24_Intervention1 ;
             ctro:hasOutcome ctro:CT24_A1_OC1 .


###  http://www.semanticweb.org/root/ontologies/2018/6/ctro#Arm_242
ctro:Arm_242 rdf:type owl:NamedIndividual ,
                      ctro:Arm ;
             ctro:hasAdverseEffect ctro:CT24_A2_AE1 ;
             ctro:hasIntervention ctro:CT24_Intervention2 ;
             ctro:hasOutcome ctro:CT24_A2_OC1 .


###  http://www.semanticweb.org/root/ontologies/2018/6/ctro#Arm_251
ctro:Arm_251 rdf:type owl:NamedIndividual ,
                      ctro:Arm ;
             ctro:hasAdverseEffect ctro:CT25_A1_AE1 ;
             ctro:hasIntervention ctro:CT25_Intervention1 ;
             ctro:hasOutcome ctro:CT25_A1_OC1 .


###  http://www.semanticweb.org/root/ontologies/2018/6/ctro#Arm_252
ctro:Arm_252 rdf:type owl:NamedIndividual ,
                      ctro:Arm ;
             ctro:hasAdverseEffect ctro:CT25_A2_AE1 ;
             ctro:hasIntervention ctro:CT25_Intervention2 ;
             ctro:hasOutcome ctro:CT25_A2_OC1 .


###  http://www.semanticweb.org/root/ontologies/2018/6/ctro#Arm_261
ctro:Arm_261 rdf:type owl:NamedIndividual ,
                      ctro:Arm ;
             ctro:hasAdverseEffect ctro:CT26_A1_AE1 ;
             ctro:hasIntervention ctro:CT26_Intervention1 ;
             ctro:hasOutcome ctro:CT26_A1_OC1 .


###  http://www.semanticweb.org/root/ontologies/2018/6/ctro#Arm_262
ctro:Arm_262 rdf:type owl:NamedIndividual ,
                      ctro:Arm ;
             ctro:hasAdverseEffect ctro:CT26_A2_AE1 ;
             ctro:hasIntervention ctro:CT26_Intervention2 ;
             ctro:hasOutcome ctro:CT26_A2_OC1 .


###  http://www.semanticweb.org/root/ontologies/2018/6/ctro#Arm_271
ctro:Arm_271 rdf:type owl:NamedIndividual ,
                      ctro:Arm ;
             ctro:hasAdverseEffect ctro:CT27_A1_AE1 ;
             ctro:hasIntervention ctro:CT27_Intervention1 ;
             ctro:hasOutcome ctro:CT27_A1_OC1 .


###  http://www.semanticweb.org/root/ontologies/2018/6/ctro#Arm_272
ctro:Arm_272 rdf:type owl:NamedIndividual ,
                      ctro:Arm ;
             ctro:hasAdverseEffect ctro:CT27_A2_AE1 ;
             ctro:hasIntervention ctro:CT27_Intervention2 ;
             ctro:hasOutcome ctro:CT27_A2_OC1 .


###  http://www.semanticweb.org/root/ontologies/2018/6/ctro#Arm_281
ctro:Arm_281 rdf:type owl:NamedIndividual ,
                      ctro:Arm ;
             ctro:hasAdverseEffect ctro:CT28_A1_AE1 ;
             ctro:hasIntervention ctro:CT28_Intervention1 ;
             ctro:hasOutcome ctro:CT28_A1_OC1 .


###  http://www.semanticweb.org/root/ontologies/2018/6/ctro#Arm_282
ctro:Arm_282 rdf:type owl:NamedIndividual ,
                      ctro:Arm ;
             ctro:hasAdverseEffect ctro:CT28_A2_AE1 ;
             ctro:hasIntervention ctro:CT28_Intervention2 ;
             ctro:hasOutcome ctro:CT28_A2_OC1 .


###  http://www.semanticweb.org/root/ontologies/2018/6/ctro#Arm_291
ctro:Arm_291 rdf:type owl:NamedIndividual ,
                      ctro:Arm ;
             ctro:hasAdverseEffect ctro:CT29_A1_AE1 ;
             ctro:hasIntervention ctro:CT29_Intervention1 ;
             ctro:hasOutcome ctro:CT29_A1_OC1 .


###  http://www.semanticweb.org/root/ontologies/2018/6/ctro#Arm_292
ctro:Arm_292 rdf:type owl:NamedIndividual ,
                      ctro:Arm ;
             ctro:hasAdverseEffect ctro:CT29_A2_AE1 ;
             ctro:hasIntervention ctro:CT29_Intervention2 ;
             ctro:hasOutcome ctro:CT29_A2_OC1 .


###  http://www.semanticweb.org/root/ontologies/2018/6/ctro#Arm_31
ctro:Arm_31 rdf:type owl:NamedIndividual ,
                     ctro:Arm ;
            ctro:hasAdverseEffect ctro:CT3_A1_AE1 ;
            ctro:hasIntervention ctro:CT3_Intervention1 ;
            ctro:hasOutcome ctro:CT3_A1_OC1 ;
            ctro:hasNumberPatientsArm 134 .


###  http://www.semanticweb.org/root/ontologies/2018/6/ctro#Arm_32
ctro:Arm_32 rdf:type owl:NamedIndividual ,
                     ctro:Arm ;
            ctro:hasAdverseEffect ctro:CT3_A2_AE1 ;
            ctro:hasIntervention ctro:CT3_Intervention2 ;
            ctro:hasOutcome ctro:CT3_A2_OC1 ;
            ctro:hasNumberPatientsArm 134 .


###  http://www.semanticweb.org/root/ontologies/2018/6/ctro#Arm_41
ctro:Arm_41 rdf:type owl:NamedIndividual ,
                     ctro:Arm ;
            ctro:hasAdverseEffect ctro:CT4_A1_AE1 ;
            ctro:hasIntervention ctro:CT4_Intervention1 ;
            ctro:hasOutcome ctro:CT4_A1_OC1 ;
            ctro:hasNumberPatientsArm 47 .


###  http://www.semanticweb.org/root/ontologies/2018/6/ctro#Arm_42
ctro:Arm_42 rdf:type owl:NamedIndividual ,
                     ctro:Arm ;
            ctro:hasAdverseEffect ctro:CT4_A2_AE1 ;
            ctro:hasIntervention ctro:CT4_Intervention2 ;
            ctro:hasOutcome ctro:CT4_A2_OC1 ;
            ctro:hasNumberPatientsArm 46 .


###  http://www.semanticweb.org/root/ontologies/2018/6/ctro#Arm_51
ctro:Arm_51 rdf:type owl:NamedIndividual ,
                     ctro:Arm ;
            ctro:hasAdverseEffect ctro:CT5_A1_AE1 ;
            ctro:hasIntervention ctro:CT5_Intervention1 ;
            ctro:hasOutcome ctro:CT5_A1_OC1 ;
            ctro:hasNumberPatientsArm 18 .


###  http://www.semanticweb.org/root/ontologies/2018/6/ctro#Arm_52
ctro:Arm_52 rdf:type owl:NamedIndividual ,
                     ctro:Arm ;
            ctro:hasAdverseEffect ctro:CT5_A2_AE1 ;
            ctro:hasIntervention ctro:CT5_Intervention2 ;
            ctro:hasOutcome ctro:CT5_A2_OC1 ;
            ctro:hasNumberPatientsArm 18 .


###  http://www.semanticweb.org/root/ontologies/2018/6/ctro#Arm_61
ctro:Arm_61 rdf:type owl:NamedIndividual ,
                     ctro:Arm ;
            ctro:hasAdverseEffect ctro:CT6_A1_AE1 ;
            ctro:hasIntervention ctro:CT6_Intervention1 ;
            ctro:hasOutcome ctro:CT6_A1_OC1 ;
            ctro:hasNumberPatientsArm 92 .


###  http://www.semanticweb.org/root/ontologies/2018/6/ctro#Arm_62
ctro:Arm_62 rdf:type owl:NamedIndividual ,
                     ctro:Arm ;
            ctro:hasAdverseEffect ctro:CT6_A2_AE1 ;
            ctro:hasIntervention ctro:CT6_Intervention2 ;
            ctro:hasOutcome ctro:CT6_A2_OC1 ;
            ctro:hasNumberPatientsArm 92 .


###  http://www.semanticweb.org/root/ontologies/2018/6/ctro#Arm_71
ctro:Arm_71 rdf:type owl:NamedIndividual ,
                     ctro:Arm ;
            ctro:hasAdverseEffect ctro:CT7_A1_AE1 ;
            ctro:hasIntervention ctro:CT7_Intervention1 ;
            ctro:hasOutcome ctro:CT7_A1_OC1 ;
            ctro:hasNumberPatientsArm 10 .


###  http://www.semanticweb.org/root/ontologies/2018/6/ctro#Arm_72
ctro:Arm_72 rdf:type owl:NamedIndividual ,
                     ctro:Arm ;
            ctro:hasAdverseEffect ctro:CT7_A2_AE1 ;
            ctro:hasIntervention ctro:CT7_Intervention2 ;
            ctro:hasOutcome ctro:CT7_A2_OC1 ;
            ctro:hasNumberPatientsArm 10 .


###  http://www.semanticweb.org/root/ontologies/2018/6/ctro#Arm_81
ctro:Arm_81 rdf:type owl:NamedIndividual ,
                     ctro:Arm ;
            ctro:hasAdverseEffect ctro:CT8_A1_AE1 ;
            ctro:hasIntervention ctro:CT8_Intervention1 ;
            ctro:hasOutcome ctro:CT8_A1_OC1 ;
            ctro:hasNumberPatientsArm 147 .


###  http://www.semanticweb.org/root/ontologies/2018/6/ctro#Arm_82
ctro:Arm_82 rdf:type owl:NamedIndividual ,
                     ctro:Arm ;
            ctro:hasAdverseEffect ctro:CT8_A2_AE1 ;
            ctro:hasIntervention ctro:CT8_Intervention2 ;
            ctro:hasOutcome ctro:CT8_A2_OC1 ;
            ctro:hasNumberPatientsArm 147 .


###  http://www.semanticweb.org/root/ontologies/2018/6/ctro#Arm_91
ctro:Arm_91 rdf:type owl:NamedIndividual ,
                     ctro:Arm ;
            ctro:hasAdverseEffect ctro:CT9_A1_AE1 ;
            ctro:hasIntervention ctro:CT9_Intervention1 ;
            ctro:hasOutcome ctro:CT9_A1_OC1 ;
            ctro:hasNumberPatientsArm 20 .


###  http://www.semanticweb.org/root/ontologies/2018/6/ctro#Arm_92
ctro:Arm_92 rdf:type owl:NamedIndividual ,
                     ctro:Arm ;
            ctro:hasAdverseEffect ctro:CT9_A2_AE1 ;
            ctro:hasIntervention ctro:CT9_Intervention2 ;
            ctro:hasOutcome ctro:CT9_A2_OC1 ;
            ctro:hasNumberPatientsArm 10 .


###  http://www.semanticweb.org/root/ontologies/2018/6/ctro#Blind
ctro:Blind rdf:type owl:NamedIndividual ,
                    ctro:CTDesign ;
           rdfs:label "Single-Blinded"^^xsd:string .


###  http://www.semanticweb.org/root/ontologies/2018/6/ctro#CT10_A1_AE1
ctro:CT10_A1_AE1 rdf:type owl:NamedIndividual ,
                          ctro:AdverseEffect ;
                 ctro:hasAEname ctro:Conjunctival_hyperemia ;
                 ctro:hasNumAffectedAE "0"^^xsd:string .


###  http://www.semanticweb.org/root/ontologies/2018/6/ctro#CT10_A1_M1
ctro:CT10_A1_M1 rdf:type owl:NamedIndividual ,
                         ctro:Medication ;
                ctro:hasDeliveryMethod ctro:Eyedrops ;
                ctro:hasDoseUnit ctro:Percentage ;
                ctro:hasDrug ctro:Latanoprost ;
                ctro:hasDoseValue "0.005"^^xsd:string ;
                ctro:isControl "no"^^xsd:string .


###  http://www.semanticweb.org/root/ontologies/2018/6/ctro#CT10_A1_OC1
ctro:CT10_A1_OC1 rdf:type owl:NamedIndividual ,
                          ctro:Outcome ;
                 ctro:hasAnalysisMetric ctro:ChangeFromBaseline ;
                 ctro:hasDesiredEffectDirection ctro:Reduction ;
                 ctro:hasEndPoint ctro:EndPoint_CT10_A1_OC1 ;
                 ctro:hasResult ctro:R_CT10_A1_OC1 ;
                 ctro:hasBaselineValue "26.7"^^xsd:float ;
                 ctro:hasTimePoints "EndPoint"^^xsd:string .


###  http://www.semanticweb.org/root/ontologies/2018/6/ctro#CT10_A2_AE1
ctro:CT10_A2_AE1 rdf:type owl:NamedIndividual ,
                          ctro:AdverseEffect ;
                 ctro:hasAEname ctro:Conjunctival_hyperemia ;
                 ctro:hasNumAffectedAE "0"^^xsd:string .


###  http://www.semanticweb.org/root/ontologies/2018/6/ctro#CT10_A2_M1
ctro:CT10_A2_M1 rdf:type owl:NamedIndividual ,
                         ctro:Medication ;
                ctro:hasDeliveryMethod ctro:Eyedrops ;
                ctro:hasDoseUnit ctro:Percentage ;
                ctro:hasDrug ctro:Timolol ;
                ctro:hasDoseValue "0.5"^^xsd:string ;
                ctro:isControl "no"^^xsd:string .


###  http://www.semanticweb.org/root/ontologies/2018/6/ctro#CT10_A2_OC1
ctro:CT10_A2_OC1 rdf:type owl:NamedIndividual ,
                          ctro:Outcome ;
                 ctro:hasAnalysisMetric ctro:ChangeFromBaseline ;
                 ctro:hasDesiredEffectDirection ctro:Reduction ;
                 ctro:hasEndPoint ctro:EndPoint_CT10_A2_OC1 ;
                 ctro:hasResult ctro:R_CT10_A2_OC1 ;
                 ctro:hasBaselineValue "26.7"^^xsd:float ;
                 ctro:hasTimePoints "EndPoint"^^xsd:string .


###  http://www.semanticweb.org/root/ontologies/2018/6/ctro#CT10_Intervention1
ctro:CT10_Intervention1 rdf:type owl:NamedIndividual ,
                                 ctro:Intervention ;
                        ctro:hasInterval ctro:Daily ;
                        ctro:hasMedication ctro:CT10_A1_M1 ;
                        ctro:hasDuration "1 week"^^xsd:string ;
                        ctro:hasFrequency "once daily"^^xsd:string .


###  http://www.semanticweb.org/root/ontologies/2018/6/ctro#CT10_Intervention2
ctro:CT10_Intervention2 rdf:type owl:NamedIndividual ,
                                 ctro:Intervention ;
                        ctro:hasInterval ctro:Daily ;
                        ctro:hasMedication ctro:CT10_A2_M1 ;
                        ctro:hasDuration "1 week"^^xsd:string ;
                        ctro:hasFrequency "twice daily"^^xsd:string .


###  http://www.semanticweb.org/root/ontologies/2018/6/ctro#CT10_Population
ctro:CT10_Population rdf:type owl:NamedIndividual ,
                              ctro:Population ;
                     ctro:hasCountry ctro:Canada ;
                     ctro:hasAvgAge 63 ;
                     ctro:hasGender "Mixed"^^xsd:string ;
                     ctro:hasMaxAge 80 ;
                     ctro:hasMinAge 47 ;
                     ctro:hasPreconditionDescription "3-week washout before administration of each drug"^^xsd:string .


###  http://www.semanticweb.org/root/ontologies/2018/6/ctro#CT11_A1_AE1
ctro:CT11_A1_AE1 rdf:type owl:NamedIndividual ,
                          ctro:AdverseEffect ;
                 ctro:hasAEname ctro:Conjunctival_hyperemia ;
                 ctro:hasNumAffectedAE "0"^^xsd:string .


###  http://www.semanticweb.org/root/ontologies/2018/6/ctro#CT11_A1_M1
ctro:CT11_A1_M1 rdf:type owl:NamedIndividual ,
                         ctro:Medication ;
                ctro:hasDeliveryMethod ctro:Eyedrops ;
                ctro:hasDoseUnit ctro:Percentage ;
                ctro:hasDrug ctro:Latanoprost ;
                ctro:hasDoseValue "0.005"^^xsd:string ;
                ctro:isControl "no"^^xsd:string .


###  http://www.semanticweb.org/root/ontologies/2018/6/ctro#CT11_A1_OC1
ctro:CT11_A1_OC1 rdf:type owl:NamedIndividual ,
                          ctro:Outcome ;
                 ctro:hasAnalysisMetric ctro:ChangeFromBaseline ;
                 ctro:hasDesiredEffectDirection ctro:Reduction ;
                 ctro:hasEndPoint ctro:EndPoint_CT11_A1_OC1 ;
                 ctro:hasResult ctro:R_CT11_A1_OC1 ;
                 ctro:hasBaselineValue "15.4"^^xsd:float ;
                 ctro:hasTimePoints "EndPoint"^^xsd:string .


###  http://www.semanticweb.org/root/ontologies/2018/6/ctro#CT11_A2_AE1
ctro:CT11_A2_AE1 rdf:type owl:NamedIndividual ,
                          ctro:AdverseEffect ;
                 ctro:hasAEname ctro:Conjunctival_hyperemia ;
                 ctro:hasNumAffectedAE "0"^^xsd:string .


###  http://www.semanticweb.org/root/ontologies/2018/6/ctro#CT11_A2_M1
ctro:CT11_A2_M1 rdf:type owl:NamedIndividual ,
                         ctro:Medication ;
                ctro:hasDeliveryMethod ctro:Eyedrops ;
                ctro:hasDoseUnit ctro:Percentage ;
                ctro:hasDrug ctro:Timolol ;
                ctro:hasDoseValue "0.5"^^xsd:string ;
                ctro:isControl "no"^^xsd:string .


###  http://www.semanticweb.org/root/ontologies/2018/6/ctro#CT11_A2_OC1
ctro:CT11_A2_OC1 rdf:type owl:NamedIndividual ,
                          ctro:Outcome ;
                 ctro:hasAnalysisMetric ctro:ChangeFromBaseline ;
                 ctro:hasDesiredEffectDirection ctro:Reduction ;
                 ctro:hasEndPoint ctro:EndPoint_CT11_A2_OC1 ;
                 ctro:hasResult ctro:R_CT11_A2_OC1 ;
                 ctro:hasBaselineValue "15.3"^^xsd:float ;
                 ctro:hasTimePoints "EndPoint"^^xsd:string .


###  http://www.semanticweb.org/root/ontologies/2018/6/ctro#CT11_Intervention1
ctro:CT11_Intervention1 rdf:type owl:NamedIndividual ,
                                 ctro:Intervention ;
                        ctro:hasInterval ctro:Daily ;
                        ctro:hasMedication ctro:CT11_A1_M1 ;
                        ctro:hasDuration "3 weeks"^^xsd:string ;
                        ctro:hasFrequency "once daily"^^xsd:string .


###  http://www.semanticweb.org/root/ontologies/2018/6/ctro#CT11_Intervention2
ctro:CT11_Intervention2 rdf:type owl:NamedIndividual ,
                                 ctro:Intervention ;
                        ctro:hasInterval ctro:Daily ;
                        ctro:hasMedication ctro:CT11_A2_M1 ;
                        ctro:hasDuration "3 weeks"^^xsd:string ;
                        ctro:hasFrequency "twice daily"^^xsd:string .


###  http://www.semanticweb.org/root/ontologies/2018/6/ctro#CT11_Population
ctro:CT11_Population rdf:type owl:NamedIndividual ,
                              ctro:Population ;
                     ctro:hasCountry ctro:Canada ;
                     ctro:hasAvgAge 67 ;
                     ctro:hasGender "Mixed"^^xsd:string ;
                     ctro:hasMaxAge 67 ;
                     ctro:hasMinAge 0 ;
                     ctro:hasPreconditionDescription "patients with normal-tension glaucoma"^^xsd:string .


###  http://www.semanticweb.org/root/ontologies/2018/6/ctro#CT1_A1_AE1
ctro:CT1_A1_AE1 rdf:type owl:NamedIndividual ,
                         ctro:AdverseEffect ;
                ctro:hasAEname ctro:Conjunctival_hyperemia ;
                ctro:hasNumAffectedAE "28"^^xsd:string .


###  http://www.semanticweb.org/root/ontologies/2018/6/ctro#CT1_A1_M1
ctro:CT1_A1_M1 rdf:type owl:NamedIndividual ,
                        ctro:Medication ;
               ctro:hasDeliveryMethod ctro:Eyedrops ;
               ctro:hasDoseUnit ctro:Percentage ;
               ctro:hasDrug ctro:Latanoprost ;
               ctro:hasDoseValue "0.005"^^xsd:string ;
               ctro:isControl "no"^^xsd:string .


###  http://www.semanticweb.org/root/ontologies/2018/6/ctro#CT1_A1_OC1
ctro:CT1_A1_OC1 rdf:type owl:NamedIndividual ,
                         ctro:Outcome ;
                ctro:hasAnalysisMetric ctro:ChangeFromBaseline ;
                ctro:hasDesiredEffectDirection ctro:Reduction ;
                ctro:hasEndPoint ctro:EndPoint_CT1_A1_OC1 ;
                ctro:hasResult ctro:R_CT1_A1_OC1 ;
                ctro:hasBaselineValue "24.6"^^xsd:float ;
                ctro:hasFinalNumberPatients 84 ;
                ctro:hasTimePoints "EndPoint"^^xsd:string .


###  http://www.semanticweb.org/root/ontologies/2018/6/ctro#CT1_A2_AE1
ctro:CT1_A2_AE1 rdf:type owl:NamedIndividual ,
                         ctro:AdverseEffect ;
                ctro:hasAEname ctro:Conjunctival_hyperemia ;
                ctro:hasNumAffectedAE "13"^^xsd:string .


###  http://www.semanticweb.org/root/ontologies/2018/6/ctro#CT1_A2_M1
ctro:CT1_A2_M1 rdf:type owl:NamedIndividual ,
                        ctro:Medication ;
               ctro:hasDeliveryMethod ctro:Eyedrops ;
               ctro:hasDoseUnit ctro:Percentage ;
               ctro:hasDrug ctro:Timolol ;
               ctro:hasDoseValue "0.5"^^xsd:string ;
               ctro:isControl "no"^^xsd:string .


###  http://www.semanticweb.org/root/ontologies/2018/6/ctro#CT1_A2_OC1
ctro:CT1_A2_OC1 rdf:type owl:NamedIndividual ,
                         ctro:Outcome ;
                ctro:hasAnalysisMetric ctro:ChangeFromBaseline ;
                ctro:hasDesiredEffectDirection ctro:Reduction ;
                ctro:hasEndPoint ctro:EndPoint_CT1_A2_OC1 ;
                ctro:hasResult ctro:R_CT1_A2_OC1 ;
                ctro:hasBaselineValue "25.5"^^xsd:float ;
                ctro:hasFinalNumberPatients 89 ;
                ctro:hasTimePoints "EndPoint"^^xsd:string .


###  http://www.semanticweb.org/root/ontologies/2018/6/ctro#CT1_Intervention1
ctro:CT1_Intervention1 rdf:type owl:NamedIndividual ,
                                ctro:Intervention ;
                       ctro:hasInterval ctro:Daily ;
                       ctro:hasMedication ctro:CT1_A1_M1 ;
                       ctro:hasDuration "6 months"^^xsd:string ;
                       ctro:hasFrequency "once daily"^^xsd:string .


###  http://www.semanticweb.org/root/ontologies/2018/6/ctro#CT1_Intervention2
ctro:CT1_Intervention2 rdf:type owl:NamedIndividual ,
                                ctro:Intervention ;
                       ctro:hasInterval ctro:Daily ;
                       ctro:hasMedication ctro:CT1_A2_M1 ;
                       ctro:hasDuration "3 months"^^xsd:string ;
                       ctro:hasFrequency "twice daily"^^xsd:string .


###  http://www.semanticweb.org/root/ontologies/2018/6/ctro#CT1_Population
ctro:CT1_Population rdf:type owl:NamedIndividual ,
                             ctro:Population ;
                    ctro:hasCountry ctro:Sweden ;
                    ctro:hasAvgAge 67 ;
                    ctro:hasGender "Mixed"^^xsd:string ;
                    ctro:hasMaxAge 85 ;
                    ctro:hasMinAge 40 ;
                    ctro:hasPreconditionDescription "Patients with Glaucoma"^^xsd:string .


###  http://www.semanticweb.org/root/ontologies/2018/6/ctro#CT21_A1_AE1
ctro:CT21_A1_AE1 rdf:type owl:NamedIndividual ,
                          ctro:AdverseEffect ;
                 ctro:hasAEname ctro:Nocturnal_hypoglycemia ;
                 ctro:hasNumAffectedAE "23"^^xsd:string .


###  http://www.semanticweb.org/root/ontologies/2018/6/ctro#CT21_A1_M1
ctro:CT21_A1_M1 rdf:type owl:NamedIndividual ,
                         ctro:Medication ;
                ctro:hasDoseUnit ctro:NA ;
                ctro:hasDrug ctro:Glargine_Insulin ;
                ctro:hasDoseValue "Titration"^^xsd:string ;
                ctro:isControl "no"^^xsd:string .


###  http://www.semanticweb.org/root/ontologies/2018/6/ctro#CT21_A1_OC1
ctro:CT21_A1_OC1 rdf:type owl:NamedIndividual ,
                          ctro:Outcome ;
                 ctro:hasAnalysisMetric ctro:ChangeFromBaseline ;
                 ctro:hasDesiredEffectDirection ctro:Reduction ;
                 ctro:hasEndPoint ctro:EndPoint_CT21_A1_OC1 ;
                 ctro:hasResult ctro:R_CT21_A1_OC1 ;
                 ctro:hasTimePoints "EndPoint"^^xsd:string .


###  http://www.semanticweb.org/root/ontologies/2018/6/ctro#CT21_A2_AE1
ctro:CT21_A2_AE1 rdf:type owl:NamedIndividual ,
                          ctro:AdverseEffect ;
                 ctro:hasAEname ctro:Nocturnal_hypoglycemia ;
                 ctro:hasNumAffectedAE "37"^^xsd:string .


###  http://www.semanticweb.org/root/ontologies/2018/6/ctro#CT21_A2_M1
ctro:CT21_A2_M1 rdf:type owl:NamedIndividual ,
                         ctro:Medication ;
                ctro:hasDoseUnit ctro:NA ;
                ctro:hasDrug ctro:NPH_Insulin ;
                ctro:hasDoseValue "Titration"^^xsd:string ;
                ctro:isControl "no"^^xsd:string .


###  http://www.semanticweb.org/root/ontologies/2018/6/ctro#CT21_A2_OC1
ctro:CT21_A2_OC1 rdf:type owl:NamedIndividual ,
                          ctro:Outcome ;
                 ctro:hasAnalysisMetric ctro:ChangeFromBaseline ;
                 ctro:hasDesiredEffectDirection ctro:Reduction ;
                 ctro:hasEndPoint ctro:EndPoint_CT21_A2_OC1 ;
                 ctro:hasResult ctro:R_CT21_A2_OC1 ;
                 ctro:hasTimePoints "EndPoint"^^xsd:string .


###  http://www.semanticweb.org/root/ontologies/2018/6/ctro#CT21_Intervention1
ctro:CT21_Intervention1 rdf:type owl:NamedIndividual ,
                                 ctro:Intervention ;
                        ctro:hasInterval ctro:Daily ;
                        ctro:hasMedication ctro:CT21_A1_M1 ;
                        ctro:hasFrequency "once daily"^^xsd:string .


###  http://www.semanticweb.org/root/ontologies/2018/6/ctro#CT21_Intervention2
ctro:CT21_Intervention2 rdf:type owl:NamedIndividual ,
                                 ctro:Intervention ;
                        ctro:hasInterval ctro:Daily ;
                        ctro:hasMedication ctro:CT21_A2_M1 ;
                        ctro:hasFrequency "once daily"^^xsd:string .


###  http://www.semanticweb.org/root/ontologies/2018/6/ctro#CT21_Population
ctro:CT21_Population rdf:type owl:NamedIndividual ,
                              ctro:Population ;
                     ctro:hasCountry ctro:USA ;
                     ctro:hasAvgAge 53.2 ;
                     ctro:hasGender "Mixed"^^xsd:string .


###  http://www.semanticweb.org/root/ontologies/2018/6/ctro#CT22_A1_AE1
ctro:CT22_A1_AE1 rdf:type owl:NamedIndividual ,
                          ctro:AdverseEffect ;
                 ctro:hasAEname ctro:Nocturnal_hypoglycemia ;
                 ctro:hasNumAffectedAE "0"^^xsd:string .


###  http://www.semanticweb.org/root/ontologies/2018/6/ctro#CT22_A1_M1
ctro:CT22_A1_M1 rdf:type owl:NamedIndividual ,
                         ctro:Medication ;
                ctro:hasDoseUnit ctro:NA ;
                ctro:hasDrug ctro:Glargine_Insulin ;
                ctro:hasDoseValue "Titration"^^xsd:string ;
                ctro:isControl "no"^^xsd:string .


###  http://www.semanticweb.org/root/ontologies/2018/6/ctro#CT22_A1_OC1
ctro:CT22_A1_OC1 rdf:type owl:NamedIndividual ,
                          ctro:Outcome ;
                 ctro:hasAnalysisMetric ctro:ChangeFromBaseline ;
                 ctro:hasDesiredEffectDirection ctro:Reduction ;
                 ctro:hasEndPoint ctro:EndPoint_CT22_A1_OC1 ;
                 ctro:hasResult ctro:R_CT22_A1_OC1 ;
                 ctro:hasTimePoints "EndPoint"^^xsd:string .


###  http://www.semanticweb.org/root/ontologies/2018/6/ctro#CT22_A2_AE1
ctro:CT22_A2_AE1 rdf:type owl:NamedIndividual ,
                          ctro:AdverseEffect ;
                 ctro:hasAEname ctro:Nocturnal_hypoglycemia ;
                 ctro:hasNumAffectedAE "2"^^xsd:string .


###  http://www.semanticweb.org/root/ontologies/2018/6/ctro#CT22_A2_M1
ctro:CT22_A2_M1 rdf:type owl:NamedIndividual ,
                         ctro:Medication ;
                ctro:hasDoseUnit ctro:NA ;
                ctro:hasDrug ctro:NPH_Insulin ;
                ctro:hasDoseValue "Titration"^^xsd:string ;
                ctro:isControl "no"^^xsd:string .


###  http://www.semanticweb.org/root/ontologies/2018/6/ctro#CT22_A2_OC1
ctro:CT22_A2_OC1 rdf:type owl:NamedIndividual ,
                          ctro:Outcome ;
                 ctro:hasAnalysisMetric ctro:ChangeFromBaseline ;
                 ctro:hasDesiredEffectDirection ctro:Reduction ;
                 ctro:hasEndPoint ctro:EndPoint_CT22_A2_OC1 ;
                 ctro:hasResult ctro:R_CT22_A2_OC1 ;
                 ctro:hasTimePoints "EndPoint"^^xsd:string .


###  http://www.semanticweb.org/root/ontologies/2018/6/ctro#CT22_Intervention1
ctro:CT22_Intervention1 rdf:type owl:NamedIndividual ,
                                 ctro:Intervention ;
                        ctro:hasInterval ctro:Daily ;
                        ctro:hasMedication ctro:CT22_A1_M1 ;
                        ctro:hasFrequency "once daily"^^xsd:string .


###  http://www.semanticweb.org/root/ontologies/2018/6/ctro#CT22_Intervention2
ctro:CT22_Intervention2 rdf:type owl:NamedIndividual ,
                                 ctro:Intervention ;
                        ctro:hasInterval ctro:Daily ;
                        ctro:hasMedication ctro:CT22_A2_M1 ;
                        ctro:hasFrequency "once daily"^^xsd:string .


###  http://www.semanticweb.org/root/ontologies/2018/6/ctro#CT22_Population
ctro:CT22_Population rdf:type owl:NamedIndividual ,
                              ctro:Population ;
                     ctro:hasCountry ctro:Germany ;
                     ctro:hasAvgAge 61.5 ;
                     ctro:hasGender "Mixed"^^xsd:string .


###  http://www.semanticweb.org/root/ontologies/2018/6/ctro#CT23_A1_AE1
ctro:CT23_A1_AE1 rdf:type owl:NamedIndividual ,
                          ctro:AdverseEffect ;
                 ctro:hasAEname ctro:Nocturnal_hypoglycemia ;
                 ctro:hasNumAffectedAE "37"^^xsd:string .


###  http://www.semanticweb.org/root/ontologies/2018/6/ctro#CT23_A1_M1
ctro:CT23_A1_M1 rdf:type owl:NamedIndividual ,
                         ctro:Medication ;
                ctro:hasDoseUnit ctro:IU ;
                ctro:hasDrug ctro:Glargine_Insulin ;
                ctro:hasDoseValue "10"^^xsd:string ;
                ctro:isControl "no"^^xsd:string .


###  http://www.semanticweb.org/root/ontologies/2018/6/ctro#CT23_A1_OC1
ctro:CT23_A1_OC1 rdf:type owl:NamedIndividual ,
                          ctro:Outcome ;
                 ctro:hasAnalysisMetric ctro:ChangeFromBaseline ;
                 ctro:hasDesiredEffectDirection ctro:Reduction ;
                 ctro:hasEndPoint ctro:EndPoint_CT23_A1_OC1 ;
                 ctro:hasResult ctro:R_CT23_A1_OC1 ;
                 ctro:hasTimePoints "EndPoint"^^xsd:string .


###  http://www.semanticweb.org/root/ontologies/2018/6/ctro#CT23_A2_AE1
ctro:CT23_A2_AE1 rdf:type owl:NamedIndividual ,
                          ctro:AdverseEffect ;
                 ctro:hasAEname ctro:Nocturnal_hypoglycemia ;
                 ctro:hasNumAffectedAE "41"^^xsd:string .


###  http://www.semanticweb.org/root/ontologies/2018/6/ctro#CT23_A2_M1
ctro:CT23_A2_M1 rdf:type owl:NamedIndividual ,
                         ctro:Medication ;
                ctro:hasDoseUnit ctro:IU ;
                ctro:hasDrug ctro:NPH_Insulin ;
                ctro:hasDoseValue "10"^^xsd:string ;
                ctro:isControl "no"^^xsd:string .


###  http://www.semanticweb.org/root/ontologies/2018/6/ctro#CT23_A2_OC1
ctro:CT23_A2_OC1 rdf:type owl:NamedIndividual ,
                          ctro:Outcome ;
                 ctro:hasAnalysisMetric ctro:ChangeFromBaseline ;
                 ctro:hasDesiredEffectDirection ctro:Reduction ;
                 ctro:hasEndPoint ctro:EndPoint_CT23_A2_OC1 ;
                 ctro:hasResult ctro:R_CT23_A2_OC1 ;
                 ctro:hasTimePoints "EndPoint"^^xsd:string .


###  http://www.semanticweb.org/root/ontologies/2018/6/ctro#CT23_Intervention1
ctro:CT23_Intervention1 rdf:type owl:NamedIndividual ,
                                 ctro:Intervention ;
                        ctro:hasInterval ctro:Daily ;
                        ctro:hasMedication ctro:CT23_A1_M1 ;
                        ctro:hasFrequency "once daily"^^xsd:string .


###  http://www.semanticweb.org/root/ontologies/2018/6/ctro#CT23_Intervention2
ctro:CT23_Intervention2 rdf:type owl:NamedIndividual ,
                                 ctro:Intervention ;
                        ctro:hasInterval ctro:Daily ;
                        ctro:hasMedication ctro:CT23_A2_M1 ;
                        ctro:hasFrequency "once daily"^^xsd:string .


###  http://www.semanticweb.org/root/ontologies/2018/6/ctro#CT23_Population
ctro:CT23_Population rdf:type owl:NamedIndividual ,
                              ctro:Population ;
                     ctro:hasCountry ctro:Italy ;
                     ctro:hasAvgAge 54.9 ;
                     ctro:hasGender "Mixed"^^xsd:string .


###  http://www.semanticweb.org/root/ontologies/2018/6/ctro#CT24_A1_AE1
ctro:CT24_A1_AE1 rdf:type owl:NamedIndividual ,
                          ctro:AdverseEffect ;
                 ctro:hasAEname ctro:Nocturnal_hypoglycemia ;
                 ctro:hasNumAffectedAE "122"^^xsd:string .


###  http://www.semanticweb.org/root/ontologies/2018/6/ctro#CT24_A1_M1
ctro:CT24_A1_M1 rdf:type owl:NamedIndividual ,
                         ctro:Medication ;
                ctro:hasDoseUnit ctro:NA ;
                ctro:hasDrug ctro:Glargine_Insulin ;
                ctro:hasDoseValue "Titration"^^xsd:string ;
                ctro:isControl "no"^^xsd:string .


###  http://www.semanticweb.org/root/ontologies/2018/6/ctro#CT24_A1_OC1
ctro:CT24_A1_OC1 rdf:type owl:NamedIndividual ,
                          ctro:Outcome ;
                 ctro:hasAnalysisMetric ctro:ChangeFromBaseline ;
                 ctro:hasDesiredEffectDirection ctro:Reduction ;
                 ctro:hasEndPoint ctro:EndPoint_CT24_A1_OC1 ;
                 ctro:hasResult ctro:R_CT24_A1_OC1 ;
                 ctro:hasTimePoints "EndPoint"^^xsd:string .


###  http://www.semanticweb.org/root/ontologies/2018/6/ctro#CT24_A2_AE1
ctro:CT24_A2_AE1 rdf:type owl:NamedIndividual ,
                          ctro:AdverseEffect ;
                 ctro:hasAEname ctro:Nocturnal_hypoglycemia ;
                 ctro:hasNumAffectedAE "157"^^xsd:string .


###  http://www.semanticweb.org/root/ontologies/2018/6/ctro#CT24_A2_M1
ctro:CT24_A2_M1 rdf:type owl:NamedIndividual ,
                         ctro:Medication ;
                ctro:hasDoseUnit ctro:NA ;
                ctro:hasDrug ctro:NPH_Insulin ;
                ctro:hasDoseValue "Titration"^^xsd:string ;
                ctro:isControl "no"^^xsd:string .


###  http://www.semanticweb.org/root/ontologies/2018/6/ctro#CT24_A2_OC1
ctro:CT24_A2_OC1 rdf:type owl:NamedIndividual ,
                          ctro:Outcome ;
                 ctro:hasAnalysisMetric ctro:ChangeFromBaseline ;
                 ctro:hasDesiredEffectDirection ctro:Reduction ;
                 ctro:hasEndPoint ctro:EndPoint_CT24_A2_OC1 ;
                 ctro:hasResult ctro:R_CT24_A2_OC1 ;
                 ctro:hasTimePoints "EndPoint"^^xsd:string .


###  http://www.semanticweb.org/root/ontologies/2018/6/ctro#CT24_Intervention1
ctro:CT24_Intervention1 rdf:type owl:NamedIndividual ,
                                 ctro:Intervention ;
                        ctro:hasInterval ctro:Daily ;
                        ctro:hasMedication ctro:CT24_A1_M1 ;
                        ctro:hasFrequency "once daily"^^xsd:string .


###  http://www.semanticweb.org/root/ontologies/2018/6/ctro#CT24_Intervention2
ctro:CT24_Intervention2 rdf:type owl:NamedIndividual ,
                                 ctro:Intervention ;
                        ctro:hasInterval ctro:Daily ;
                        ctro:hasMedication ctro:CT24_A2_M1 ;
                        ctro:hasFrequency "once daily"^^xsd:string .


###  http://www.semanticweb.org/root/ontologies/2018/6/ctro#CT24_Population
ctro:CT24_Population rdf:type owl:NamedIndividual ,
                              ctro:Population ;
                     ctro:hasCountry ctro:LatinAmerica ;
                     ctro:hasAvgAge 56.1 ;
                     ctro:hasGender "Mixed"^^xsd:string .


###  http://www.semanticweb.org/root/ontologies/2018/6/ctro#CT25_A1_AE1
ctro:CT25_A1_AE1 rdf:type owl:NamedIndividual ,
                          ctro:AdverseEffect ;
                 ctro:hasAEname ctro:Nocturnal_hypoglycemia ;
                 ctro:hasNumAffectedAE "39"^^xsd:string .


###  http://www.semanticweb.org/root/ontologies/2018/6/ctro#CT25_A1_M1
ctro:CT25_A1_M1 rdf:type owl:NamedIndividual ,
                         ctro:Medication ;
                ctro:hasDoseUnit ctro:NA ;
                ctro:hasDrug ctro:Glargine_Insulin ;
                ctro:hasDoseValue "NA"^^xsd:string ;
                ctro:isControl "no"^^xsd:string .


###  http://www.semanticweb.org/root/ontologies/2018/6/ctro#CT25_A1_OC1
ctro:CT25_A1_OC1 rdf:type owl:NamedIndividual ,
                          ctro:Outcome ;
                 ctro:hasAnalysisMetric ctro:ChangeFromBaseline ;
                 ctro:hasDesiredEffectDirection ctro:Reduction ;
                 ctro:hasEndPoint ctro:EndPoint_CT25_A1_OC1 ;
                 ctro:hasResult ctro:R_CT25_A1_OC1 ;
                 ctro:hasTimePoints "EndPoint"^^xsd:string .


###  http://www.semanticweb.org/root/ontologies/2018/6/ctro#CT25_A2_AE1
ctro:CT25_A2_AE1 rdf:type owl:NamedIndividual ,
                          ctro:AdverseEffect ;
                 ctro:hasAEname ctro:Nocturnal_hypoglycemia ;
                 ctro:hasNumAffectedAE "84"^^xsd:string .


###  http://www.semanticweb.org/root/ontologies/2018/6/ctro#CT25_A2_M1
ctro:CT25_A2_M1 rdf:type owl:NamedIndividual ,
                         ctro:Medication ;
                ctro:hasDoseUnit ctro:NA ;
                ctro:hasDrug ctro:NPH_Insulin ;
                ctro:hasDoseValue "NA"^^xsd:string ;
                ctro:isControl "no"^^xsd:string .


###  http://www.semanticweb.org/root/ontologies/2018/6/ctro#CT25_A2_OC1
ctro:CT25_A2_OC1 rdf:type owl:NamedIndividual ,
                          ctro:Outcome ;
                 ctro:hasAnalysisMetric ctro:ChangeFromBaseline ;
                 ctro:hasDesiredEffectDirection ctro:Reduction ;
                 ctro:hasEndPoint ctro:EndPoint_CT25_A2_OC1 ;
                 ctro:hasResult ctro:R_CT25_A2_OC1 ;
                 ctro:hasTimePoints "EndPoint"^^xsd:string .


###  http://www.semanticweb.org/root/ontologies/2018/6/ctro#CT25_Intervention1
ctro:CT25_Intervention1 rdf:type owl:NamedIndividual ,
                                 ctro:Intervention ;
                        ctro:hasInterval ctro:Daily ;
                        ctro:hasMedication ctro:CT25_A1_M1 ;
                        ctro:hasFrequency "once daily"^^xsd:string .


###  http://www.semanticweb.org/root/ontologies/2018/6/ctro#CT25_Intervention2
ctro:CT25_Intervention2 rdf:type owl:NamedIndividual ,
                                 ctro:Intervention ;
                        ctro:hasInterval ctro:Daily ;
                        ctro:hasMedication ctro:CT25_A2_M1 ;
                        ctro:hasFrequency "once daily"^^xsd:string .


###  http://www.semanticweb.org/root/ontologies/2018/6/ctro#CT25_Population
ctro:CT25_Population rdf:type owl:NamedIndividual ,
                              ctro:Population ;
                     ctro:hasCountry ctro:Europe ;
                     ctro:hasAvgAge 60.5 ;
                     ctro:hasGender "Mixed"^^xsd:string .


###  http://www.semanticweb.org/root/ontologies/2018/6/ctro#CT26_A1_AE1
ctro:CT26_A1_AE1 rdf:type owl:NamedIndividual ,
                          ctro:AdverseEffect ;
                 ctro:hasAEname ctro:Nocturnal_hypoglycemia ;
                 ctro:hasNumAffectedAE "24"^^xsd:string .


###  http://www.semanticweb.org/root/ontologies/2018/6/ctro#CT26_A1_M1
ctro:CT26_A1_M1 rdf:type owl:NamedIndividual ,
                         ctro:Medication ;
                ctro:hasDoseUnit ctro:Adjusted ;
                ctro:hasDrug ctro:Glargine_Insulin ;
                ctro:hasDoseValue "Adjusted"^^xsd:string ;
                ctro:isControl "no"^^xsd:string .


###  http://www.semanticweb.org/root/ontologies/2018/6/ctro#CT26_A1_OC1
ctro:CT26_A1_OC1 rdf:type owl:NamedIndividual ,
                          ctro:Outcome ;
                 ctro:hasAnalysisMetric ctro:ChangeFromBaseline ;
                 ctro:hasDesiredEffectDirection ctro:Reduction ;
                 ctro:hasEndPoint ctro:EndPoint_CT26_A1_OC1 ;
                 ctro:hasResult ctro:R_CT26_A1_OC1 ;
                 ctro:hasTimePoints "EndPoint"^^xsd:string .


###  http://www.semanticweb.org/root/ontologies/2018/6/ctro#CT26_A2_AE1
ctro:CT26_A2_AE1 rdf:type owl:NamedIndividual ,
                          ctro:AdverseEffect ;
                 ctro:hasAEname ctro:Nocturnal_hypoglycemia ;
                 ctro:hasNumAffectedAE "33"^^xsd:string .


###  http://www.semanticweb.org/root/ontologies/2018/6/ctro#CT26_A2_M1
ctro:CT26_A2_M1 rdf:type owl:NamedIndividual ,
                         ctro:Medication ;
                ctro:hasDoseUnit ctro:Adjusted ;
                ctro:hasDrug ctro:NPH_Insulin ;
                ctro:hasDoseValue "Adjusted"^^xsd:string ;
                ctro:isControl "no"^^xsd:string .


###  http://www.semanticweb.org/root/ontologies/2018/6/ctro#CT26_A2_OC1
ctro:CT26_A2_OC1 rdf:type owl:NamedIndividual ,
                          ctro:Outcome ;
                 ctro:hasAnalysisMetric ctro:ChangeFromBaseline ;
                 ctro:hasDesiredEffectDirection ctro:Reduction ;
                 ctro:hasEndPoint ctro:EndPoint_CT26_A2_OC1 ;
                 ctro:hasResult ctro:R_CT26_A2_OC1 ;
                 ctro:hasTimePoints "EndPoint"^^xsd:string .


###  http://www.semanticweb.org/root/ontologies/2018/6/ctro#CT26_Intervention1
ctro:CT26_Intervention1 rdf:type owl:NamedIndividual ,
                                 ctro:Intervention ;
                        ctro:hasInterval ctro:Daily ;
                        ctro:hasMedication ctro:CT26_A1_M1 ;
                        ctro:hasFrequency "once daily"^^xsd:string .


###  http://www.semanticweb.org/root/ontologies/2018/6/ctro#CT26_Intervention2
ctro:CT26_Intervention2 rdf:type owl:NamedIndividual ,
                                 ctro:Intervention ;
                        ctro:hasInterval ctro:Daily ;
                        ctro:hasMedication ctro:CT26_A2_M1 ;
                        ctro:hasFrequency "once daily"^^xsd:string .


###  http://www.semanticweb.org/root/ontologies/2018/6/ctro#CT26_Population
ctro:CT26_Population rdf:type owl:NamedIndividual ,
                              ctro:Population ;
                     ctro:hasCountry ctro:Finland ;
                     ctro:hasAvgAge 56 ;
                     ctro:hasGender "Mixed"^^xsd:string .


###  http://www.semanticweb.org/root/ontologies/2018/6/ctro#CT27_A1_AE1
ctro:CT27_A1_AE1 rdf:type owl:NamedIndividual ,
                          ctro:AdverseEffect ;
                 ctro:hasAEname ctro:Nocturnal_hypoglycemia ;
                 ctro:hasNumAffectedAE "142"^^xsd:string .


###  http://www.semanticweb.org/root/ontologies/2018/6/ctro#CT27_A1_M1
ctro:CT27_A1_M1 rdf:type owl:NamedIndividual ,
                         ctro:Medication ;
                ctro:hasDoseUnit ctro:NA ;
                ctro:hasDrug ctro:Glargine_Insulin ;
                ctro:hasDoseValue "NA"^^xsd:string ;
                ctro:isControl "no"^^xsd:string .


###  http://www.semanticweb.org/root/ontologies/2018/6/ctro#CT27_A1_OC1
ctro:CT27_A1_OC1 rdf:type owl:NamedIndividual ,
                          ctro:Outcome ;
                 ctro:hasAnalysisMetric ctro:ChangeFromBaseline ;
                 ctro:hasDesiredEffectDirection ctro:Reduction ;
                 ctro:hasEndPoint ctro:EndPoint_CT27_A1_OC1 ;
                 ctro:hasResult ctro:R_CT27_A1_OC1 ;
                 ctro:hasTimePoints "EndPoint"^^xsd:string .


###  http://www.semanticweb.org/root/ontologies/2018/6/ctro#CT27_A2_AE1
ctro:CT27_A2_AE1 rdf:type owl:NamedIndividual ,
                          ctro:AdverseEffect ;
                 ctro:hasAEname ctro:Nocturnal_hypoglycemia ;
                 ctro:hasNumAffectedAE "164"^^xsd:string .


###  http://www.semanticweb.org/root/ontologies/2018/6/ctro#CT27_A2_M1
ctro:CT27_A2_M1 rdf:type owl:NamedIndividual ,
                         ctro:Medication ;
                ctro:hasDoseUnit ctro:NA ;
                ctro:hasDrug ctro:NPH_Insulin ;
                ctro:hasDoseValue "NA"^^xsd:string ;
                ctro:isControl "no"^^xsd:string .


###  http://www.semanticweb.org/root/ontologies/2018/6/ctro#CT27_A2_OC1
ctro:CT27_A2_OC1 rdf:type owl:NamedIndividual ,
                          ctro:Outcome ;
                 ctro:hasAnalysisMetric ctro:ChangeFromBaseline ;
                 ctro:hasDesiredEffectDirection ctro:Reduction ;
                 ctro:hasEndPoint ctro:EndPoint_CT27_A2_OC1 ;
                 ctro:hasResult ctro:R_CT27_A2_OC1 ;
                 ctro:hasTimePoints "EndPoint"^^xsd:string .


###  http://www.semanticweb.org/root/ontologies/2018/6/ctro#CT27_Intervention1
ctro:CT27_Intervention1 rdf:type owl:NamedIndividual ,
                                 ctro:Intervention ;
                        ctro:hasInterval ctro:Daily ;
                        ctro:hasMedication ctro:CT27_A1_M1 ;
                        ctro:hasFrequency "once daily"^^xsd:string .


###  http://www.semanticweb.org/root/ontologies/2018/6/ctro#CT27_Intervention2
ctro:CT27_Intervention2 rdf:type owl:NamedIndividual ,
                                 ctro:Intervention ;
                        ctro:hasInterval ctro:Daily ;
                        ctro:hasMedication ctro:CT27_A2_M1 ;
                        ctro:hasFrequency "once daily"^^xsd:string .


###  http://www.semanticweb.org/root/ontologies/2018/6/ctro#CT27_Population
ctro:CT27_Population rdf:type owl:NamedIndividual ,
                              ctro:Population ;
                     ctro:hasCountry ctro:NorthAmerica ;
                     ctro:hasAvgAge 55 ;
                     ctro:hasGender "Mixed"^^xsd:string .


###  http://www.semanticweb.org/root/ontologies/2018/6/ctro#CT28_A1_AE1
ctro:CT28_A1_AE1 rdf:type owl:NamedIndividual ,
                          ctro:AdverseEffect ;
                 ctro:hasAEname ctro:Nocturnal_hypoglycemia ;
                 ctro:hasNumAffectedAE "34"^^xsd:string .


###  http://www.semanticweb.org/root/ontologies/2018/6/ctro#CT28_A1_M1
ctro:CT28_A1_M1 rdf:type owl:NamedIndividual ,
                         ctro:Medication ;
                ctro:hasDoseUnit ctro:NA ;
                ctro:hasDrug ctro:Glargine_Insulin ;
                ctro:hasDoseValue "NA"^^xsd:string ;
                ctro:isControl "no"^^xsd:string .


###  http://www.semanticweb.org/root/ontologies/2018/6/ctro#CT28_A1_OC1
ctro:CT28_A1_OC1 rdf:type owl:NamedIndividual ,
                          ctro:Outcome ;
                 ctro:hasAnalysisMetric ctro:ChangeFromBaseline ;
                 ctro:hasDesiredEffectDirection ctro:Reduction ;
                 ctro:hasEndPoint ctro:EndPoint_CT28_A1_OC1 ;
                 ctro:hasResult ctro:R_CT28_A1_OC1 ;
                 ctro:hasTimePoints "EndPoint"^^xsd:string .


###  http://www.semanticweb.org/root/ontologies/2018/6/ctro#CT28_A2_AE1
ctro:CT28_A2_AE1 rdf:type owl:NamedIndividual ,
                          ctro:AdverseEffect ;
                 ctro:hasAEname ctro:Nocturnal_hypoglycemia ;
                 ctro:hasNumAffectedAE "69"^^xsd:string .


###  http://www.semanticweb.org/root/ontologies/2018/6/ctro#CT28_A2_M1
ctro:CT28_A2_M1 rdf:type owl:NamedIndividual ,
                         ctro:Medication ;
                ctro:hasDoseUnit ctro:NA ;
                ctro:hasDrug ctro:NPH_Insulin ;
                ctro:hasDoseValue "NA"^^xsd:string ;
                ctro:isControl "no"^^xsd:string .


###  http://www.semanticweb.org/root/ontologies/2018/6/ctro#CT28_A2_OC1
ctro:CT28_A2_OC1 rdf:type owl:NamedIndividual ,
                          ctro:Outcome ;
                 ctro:hasAnalysisMetric ctro:ChangeFromBaseline ;
                 ctro:hasDesiredEffectDirection ctro:Reduction ;
                 ctro:hasEndPoint ctro:EndPoint_CT28_A2_OC1 ;
                 ctro:hasResult ctro:R_CT28_A2_OC1 ;
                 ctro:hasTimePoints "EndPoint"^^xsd:string .


###  http://www.semanticweb.org/root/ontologies/2018/6/ctro#CT28_Intervention1
ctro:CT28_Intervention1 rdf:type owl:NamedIndividual ,
                                 ctro:Intervention ;
                        ctro:hasInterval ctro:Daily ;
                        ctro:hasMedication ctro:CT28_A1_M1 ;
                        ctro:hasFrequency "once daily"^^xsd:string .


###  http://www.semanticweb.org/root/ontologies/2018/6/ctro#CT28_Intervention2
ctro:CT28_Intervention2 rdf:type owl:NamedIndividual ,
                                 ctro:Intervention ;
                        ctro:hasInterval ctro:Daily ;
                        ctro:hasMedication ctro:CT28_A2_M1 ;
                        ctro:hasFrequency "once daily"^^xsd:string .


###  http://www.semanticweb.org/root/ontologies/2018/6/ctro#CT28_Population
ctro:CT28_Population rdf:type owl:NamedIndividual ,
                              ctro:Population ;
                     ctro:hasCountry ctro:Europe-SouthAfrica ;
                     ctro:hasAvgAge 59.6 ;
                     ctro:hasGender "Mixed"^^xsd:string .


###  http://www.semanticweb.org/root/ontologies/2018/6/ctro#CT29_A1_AE1
ctro:CT29_A1_AE1 rdf:type owl:NamedIndividual ,
                          ctro:AdverseEffect ;
                 ctro:hasAEname ctro:Nocturnal_hypoglycemia ;
                 ctro:hasNumAffectedAE "87"^^xsd:string .


###  http://www.semanticweb.org/root/ontologies/2018/6/ctro#CT29_A1_M1
ctro:CT29_A1_M1 rdf:type owl:NamedIndividual ,
                         ctro:Medication ;
                ctro:hasDoseUnit ctro:NA ;
                ctro:hasDrug ctro:Glargine_Insulin ;
                ctro:hasDoseValue "Titration"^^xsd:string ;
                ctro:isControl "no"^^xsd:string .


###  http://www.semanticweb.org/root/ontologies/2018/6/ctro#CT29_A1_OC1
ctro:CT29_A1_OC1 rdf:type owl:NamedIndividual ,
                          ctro:Outcome ;
                 ctro:hasAnalysisMetric ctro:ChangeFromBaseline ;
                 ctro:hasDesiredEffectDirection ctro:Reduction ;
                 ctro:hasEndPoint ctro:EndPoint_CT29_A1_OC1 ;
                 ctro:hasResult ctro:R_CT29_A1_OC1 ;
                 ctro:hasTimePoints "EndPoint"^^xsd:string .


###  http://www.semanticweb.org/root/ontologies/2018/6/ctro#CT29_A2_AE1
ctro:CT29_A2_AE1 rdf:type owl:NamedIndividual ,
                          ctro:AdverseEffect ;
                 ctro:hasAEname ctro:Nocturnal_hypoglycemia ;
                 ctro:hasNumAffectedAE "114"^^xsd:string .


###  http://www.semanticweb.org/root/ontologies/2018/6/ctro#CT29_A2_M1
ctro:CT29_A2_M1 rdf:type owl:NamedIndividual ,
                         ctro:Medication ;
                ctro:hasDoseUnit ctro:NA ;
                ctro:hasDrug ctro:NPH_Insulin ;
                ctro:hasDoseValue "Titration"^^xsd:string ;
                ctro:isControl "no"^^xsd:string .


###  http://www.semanticweb.org/root/ontologies/2018/6/ctro#CT29_A2_OC1
ctro:CT29_A2_OC1 rdf:type owl:NamedIndividual ,
                          ctro:Outcome ;
                 ctro:hasAnalysisMetric ctro:ChangeFromBaseline ;
                 ctro:hasDesiredEffectDirection ctro:Reduction ;
                 ctro:hasEndPoint ctro:EndPoint_CT29_A2_OC1 ;
                 ctro:hasResult ctro:R_CT29_A2_OC1 ;
                 ctro:hasTimePoints "EndPoint"^^xsd:string .


###  http://www.semanticweb.org/root/ontologies/2018/6/ctro#CT29_Intervention1
ctro:CT29_Intervention1 rdf:type owl:NamedIndividual ,
                                 ctro:Intervention ;
                        ctro:hasInterval ctro:Daily ;
                        ctro:hasMedication ctro:CT29_A1_M1 ;
                        ctro:hasFrequency "once daily"^^xsd:string .


###  http://www.semanticweb.org/root/ontologies/2018/6/ctro#CT29_Intervention2
ctro:CT29_Intervention2 rdf:type owl:NamedIndividual ,
                                 ctro:Intervention ;
                        ctro:hasInterval ctro:Daily ;
                        ctro:hasMedication ctro:CT29_A2_M1 ;
                        ctro:hasFrequency "twice daily"^^xsd:string .


###  http://www.semanticweb.org/root/ontologies/2018/6/ctro#CT29_Population
ctro:CT29_Population rdf:type owl:NamedIndividual ,
                              ctro:Population ;
                     ctro:hasCountry ctro:Multinational ;
                     ctro:hasAvgAge 57.3 ;
                     ctro:hasGender "Mixed"^^xsd:string .


###  http://www.semanticweb.org/root/ontologies/2018/6/ctro#CT2_A1_AE1
ctro:CT2_A1_AE1 rdf:type owl:NamedIndividual ,
                         ctro:AdverseEffect ;
                ctro:hasAEname ctro:Conjunctival_hyperemia ;
                ctro:hasNumAffectedAE "0"^^xsd:string .


###  http://www.semanticweb.org/root/ontologies/2018/6/ctro#CT2_A1_M1
ctro:CT2_A1_M1 rdf:type owl:NamedIndividual ,
                        ctro:Medication ;
               ctro:hasDeliveryMethod ctro:Eyedrops ;
               ctro:hasDoseUnit ctro:Percentage ;
               ctro:hasDrug ctro:Latanoprost ;
               ctro:hasDoseValue "0.005"^^xsd:string ;
               ctro:isControl "no"^^xsd:string .


###  http://www.semanticweb.org/root/ontologies/2018/6/ctro#CT2_A1_OC1
ctro:CT2_A1_OC1 rdf:type owl:NamedIndividual ,
                         ctro:Outcome ;
                ctro:hasAnalysisMetric ctro:ChangeFromBaseline ;
                ctro:hasDesiredEffectDirection ctro:Reduction ;
                ctro:hasEffectSize ctro:ESIZE_CT2_A1_OC1 ;
                ctro:hasEndPoint ctro:EndPoint_CT2_A1_OC1 ;
                ctro:hasResult ctro:R_CT2_A1_OC1 ;
                ctro:hasBaselineValue "29.9"^^xsd:float ;
                ctro:hasFinalNumberPatients 30 ;
                ctro:hasTimePoints "EndPoint"^^xsd:string .


###  http://www.semanticweb.org/root/ontologies/2018/6/ctro#CT2_A2_AE1
ctro:CT2_A2_AE1 rdf:type owl:NamedIndividual ,
                         ctro:AdverseEffect ;
                ctro:hasAEname ctro:Conjunctival_hyperemia ;
                ctro:hasNumAffectedAE "0"^^xsd:string .


###  http://www.semanticweb.org/root/ontologies/2018/6/ctro#CT2_A2_M1
ctro:CT2_A2_M1 rdf:type owl:NamedIndividual ,
                        ctro:Medication ;
               ctro:hasDeliveryMethod ctro:Eyedrops ;
               ctro:hasDoseUnit ctro:Percentage ;
               ctro:hasDrug ctro:Timolol ;
               ctro:hasDoseValue "0.5"^^xsd:string ;
               ctro:isControl "no"^^xsd:string .


###  http://www.semanticweb.org/root/ontologies/2018/6/ctro#CT2_A2_OC1
ctro:CT2_A2_OC1 rdf:type owl:NamedIndividual ,
                         ctro:Outcome ;
                ctro:hasAnalysisMetric ctro:ChangeFromBaseline ;
                ctro:hasDesiredEffectDirection ctro:Reduction ;
                ctro:hasEffectSize ctro:ESIZE_CT2_A2_OC1 ;
                ctro:hasEndPoint ctro:EndPoint_CT2_A2_OC1 ;
                ctro:hasResult ctro:R_CT2_A2_OC1 ;
                ctro:hasBaselineValue "29.0"^^xsd:float ;
                ctro:hasFinalNumberPatients 30 ;
                ctro:hasTimePoints "EndPoint"^^xsd:string .


###  http://www.semanticweb.org/root/ontologies/2018/6/ctro#CT2_Intervention1
ctro:CT2_Intervention1 rdf:type owl:NamedIndividual ,
                                ctro:Intervention ;
                       ctro:hasInterval ctro:Daily ;
                       ctro:hasMedication ctro:CT2_A1_M1 ;
                       ctro:hasDuration "12 weeks"^^xsd:string ;
                       ctro:hasFrequency "once daily"^^xsd:string .


###  http://www.semanticweb.org/root/ontologies/2018/6/ctro#CT2_Intervention2
ctro:CT2_Intervention2 rdf:type owl:NamedIndividual ,
                                ctro:Intervention ;
                       ctro:hasInterval ctro:Daily ;
                       ctro:hasMedication ctro:CT2_A2_M1 ;
                       ctro:hasDuration "12 weeks"^^xsd:string ;
                       ctro:hasFrequency "twice daily"^^xsd:string .


###  http://www.semanticweb.org/root/ontologies/2018/6/ctro#CT2_Population
ctro:CT2_Population rdf:type owl:NamedIndividual ,
                             ctro:Population ;
                    ctro:hasCountry ctro:Philippines ;
                    ctro:hasAvgAge 0 ;
                    ctro:hasGender "Mixed"^^xsd:string ;
                    ctro:hasMaxAge 0 ;
                    ctro:hasMinAge 0 ;
                    ctro:hasPreconditionDescription "Administration of previous ocular hypotensive medication necessitated a wash-out period of 5 to 21 days before the start of the study treatment"^^xsd:string .


###  http://www.semanticweb.org/root/ontologies/2018/6/ctro#CT3_A1_AE1
ctro:CT3_A1_AE1 rdf:type owl:NamedIndividual ,
                         ctro:AdverseEffect ;
                ctro:hasAEname ctro:Conjunctival_hyperemia ;
                ctro:hasNumAffectedAE "2"^^xsd:string .


###  http://www.semanticweb.org/root/ontologies/2018/6/ctro#CT3_A1_M1
ctro:CT3_A1_M1 rdf:type owl:NamedIndividual ,
                        ctro:Medication ;
               ctro:hasDeliveryMethod ctro:Eyedrops ;
               ctro:hasDoseUnit ctro:Percentage ;
               ctro:hasDrug ctro:Latanoprost ;
               ctro:hasDoseValue "0.005"^^xsd:string ;
               ctro:isControl "no"^^xsd:string .


###  http://www.semanticweb.org/root/ontologies/2018/6/ctro#CT3_A1_OC1
ctro:CT3_A1_OC1 rdf:type owl:NamedIndividual ,
                         ctro:Outcome ;
                ctro:hasAnalysisMetric ctro:ChangeFromBaseline ;
                ctro:hasDesiredEffectDirection ctro:Reduction ;
                ctro:hasEndPoint ctro:EndPoint_CT3_A1_OC1 ;
                ctro:hasResult ctro:R_CT3_A1_OC1 ;
                ctro:hasBaselineValue "25.3"^^xsd:float ;
                ctro:hasFinalNumberPatients 134 ;
                ctro:hasTimePoints "EndPoint"^^xsd:string .


###  http://www.semanticweb.org/root/ontologies/2018/6/ctro#CT3_A2_AE1
ctro:CT3_A2_AE1 rdf:type owl:NamedIndividual ,
                         ctro:AdverseEffect ;
                ctro:hasAEname ctro:Conjunctival_hyperemia ;
                ctro:hasNumAffectedAE "1"^^xsd:string .


###  http://www.semanticweb.org/root/ontologies/2018/6/ctro#CT3_A2_M1
ctro:CT3_A2_M1 rdf:type owl:NamedIndividual ,
                        ctro:Medication ;
               ctro:hasDeliveryMethod ctro:Eyedrops ;
               ctro:hasDoseUnit ctro:Percentage ;
               ctro:hasDrug ctro:Timolol ;
               ctro:hasDoseValue "0.5"^^xsd:string ;
               ctro:isControl "no"^^xsd:string .


###  http://www.semanticweb.org/root/ontologies/2018/6/ctro#CT3_A2_OC1
ctro:CT3_A2_OC1 rdf:type owl:NamedIndividual ,
                         ctro:Outcome ;
                ctro:hasAnalysisMetric ctro:ChangeFromBaseline ;
                ctro:hasDesiredEffectDirection ctro:Reduction ;
                ctro:hasEndPoint ctro:EndPoint_CT3_A2_OC1 ;
                ctro:hasResult ctro:R_CT3_A2_OC1 ;
                ctro:hasBaselineValue "25.3"^^xsd:float ;
                ctro:hasFinalNumberPatients 134 ;
                ctro:hasTimePoints "EndPoint"^^xsd:string .


###  http://www.semanticweb.org/root/ontologies/2018/6/ctro#CT3_Intervention1
ctro:CT3_Intervention1 rdf:type owl:NamedIndividual ,
                                ctro:Intervention ;
                       ctro:hasInterval ctro:Daily ;
                       ctro:hasMedication ctro:CT3_A1_M1 ;
                       ctro:hasDuration "6 months"^^xsd:string ;
                       ctro:hasFrequency "once daily"^^xsd:string .


###  http://www.semanticweb.org/root/ontologies/2018/6/ctro#CT3_Intervention2
ctro:CT3_Intervention2 rdf:type owl:NamedIndividual ,
                                ctro:Intervention ;
                       ctro:hasInterval ctro:Daily ;
                       ctro:hasMedication ctro:CT3_A2_M1 ;
                       ctro:hasDuration "6 months"^^xsd:string ;
                       ctro:hasFrequency "twice daily"^^xsd:string .


###  http://www.semanticweb.org/root/ontologies/2018/6/ctro#CT3_Population
ctro:CT3_Population rdf:type owl:NamedIndividual ,
                             ctro:Population ;
                    ctro:hasCountry ctro:USA ;
                    ctro:hasAvgAge 62 ;
                    ctro:hasGender "Mixed"^^xsd:string ;
                    ctro:hasMaxAge 90 ;
                    ctro:hasMinAge 30 ;
                    ctro:hasPreconditionDescription "Ocular hypertension and glaucoma"^^xsd:string .


###  http://www.semanticweb.org/root/ontologies/2018/6/ctro#CT4_A1_AE1
ctro:CT4_A1_AE1 rdf:type owl:NamedIndividual ,
                         ctro:AdverseEffect ;
                ctro:hasAEname ctro:Conjunctival_hyperemia ;
                ctro:hasNumAffectedAE "4"^^xsd:string .


###  http://www.semanticweb.org/root/ontologies/2018/6/ctro#CT4_A1_M1
ctro:CT4_A1_M1 rdf:type owl:NamedIndividual ,
                        ctro:Medication ;
               ctro:hasDeliveryMethod ctro:Eyedrops ;
               ctro:hasDoseUnit ctro:Percentage ;
               ctro:hasDrug ctro:Latanoprost ;
               ctro:hasDoseValue "0.005"^^xsd:string ;
               ctro:isControl "no"^^xsd:string .


###  http://www.semanticweb.org/root/ontologies/2018/6/ctro#CT4_A1_OC1
ctro:CT4_A1_OC1 rdf:type owl:NamedIndividual ,
                         ctro:Outcome ;
                ctro:hasAnalysisMetric ctro:ChangeFromBaseline ;
                ctro:hasDesiredEffectDirection ctro:Reduction ;
                ctro:hasEndPoint ctro:EndPoint_CT4_A1_OC1 ;
                ctro:hasResult ctro:R_CT4_A1_OC1 ;
                ctro:hasBaselineValue "24.8"^^xsd:float ;
                ctro:hasTimePoints "EndPoint"^^xsd:string .


###  http://www.semanticweb.org/root/ontologies/2018/6/ctro#CT4_A2_AE1
ctro:CT4_A2_AE1 rdf:type owl:NamedIndividual ,
                         ctro:AdverseEffect ;
                ctro:hasAEname ctro:Conjunctival_hyperemia ;
                ctro:hasNumAffectedAE "3"^^xsd:string .


###  http://www.semanticweb.org/root/ontologies/2018/6/ctro#CT4_A2_M1
ctro:CT4_A2_M1 rdf:type owl:NamedIndividual ,
                        ctro:Medication ;
               ctro:hasDeliveryMethod ctro:Eyedrops ;
               ctro:hasDoseUnit ctro:Percentage ;
               ctro:hasDrug ctro:Timolol ;
               ctro:hasDoseValue "0.5"^^xsd:string ;
               ctro:isControl "no"^^xsd:string .


###  http://www.semanticweb.org/root/ontologies/2018/6/ctro#CT4_A2_OC1
ctro:CT4_A2_OC1 rdf:type owl:NamedIndividual ,
                         ctro:Outcome ;
                ctro:hasAnalysisMetric ctro:ChangeFromBaseline ;
                ctro:hasDesiredEffectDirection ctro:Reduction ;
                ctro:hasEndPoint ctro:EndPoint_CT4_A2_OC1 ;
                ctro:hasResult ctro:R_CT4_A2_OC1 ;
                ctro:hasBaselineValue "24.1"^^xsd:float ;
                ctro:hasTimePoints "EndPoint"^^xsd:string .


###  http://www.semanticweb.org/root/ontologies/2018/6/ctro#CT4_Intervention1
ctro:CT4_Intervention1 rdf:type owl:NamedIndividual ,
                                ctro:Intervention ;
                       ctro:hasInterval ctro:Daily ;
                       ctro:hasMedication ctro:CT4_A1_M1 ;
                       ctro:hasDuration "3 weeks"^^xsd:string ;
                       ctro:hasFrequency "once daily"^^xsd:string .


###  http://www.semanticweb.org/root/ontologies/2018/6/ctro#CT4_Intervention2
ctro:CT4_Intervention2 rdf:type owl:NamedIndividual ,
                                ctro:Intervention ;
                       ctro:hasInterval ctro:Daily ;
                       ctro:hasMedication ctro:CT4_A2_M1 ;
                       ctro:hasDuration "3 weeks"^^xsd:string ;
                       ctro:hasFrequency "twice daily"^^xsd:string .


###  http://www.semanticweb.org/root/ontologies/2018/6/ctro#CT4_Population
ctro:CT4_Population rdf:type owl:NamedIndividual ,
                             ctro:Population ;
                    ctro:hasCountry ctro:Germany ;
                    ctro:hasEthnicity ctro:Caucasian ;
                    ctro:hasAvgAge 60 ;
                    ctro:hasGender "Mixed"^^xsd:string ;
                    ctro:hasMaxAge 77 ;
                    ctro:hasMinAge 20 ;
                    ctro:hasPreconditionDescription "Patients with open-angle glaucoma following a 1-week run-in period on timolol 0.5% once daily"^^xsd:string .


###  http://www.semanticweb.org/root/ontologies/2018/6/ctro#CT5_A1_AE1
ctro:CT5_A1_AE1 rdf:type owl:NamedIndividual ,
                         ctro:AdverseEffect ;
                ctro:hasAEname ctro:Conjunctival_hyperemia ;
                ctro:hasNumAffectedAE "5"^^xsd:string .


###  http://www.semanticweb.org/root/ontologies/2018/6/ctro#CT5_A1_M1
ctro:CT5_A1_M1 rdf:type owl:NamedIndividual ,
                        ctro:Medication ;
               ctro:hasDeliveryMethod ctro:Eyedrops ;
               ctro:hasDoseUnit ctro:Percentage ;
               ctro:hasDrug ctro:Latanoprost ;
               ctro:hasDoseValue "0.005"^^xsd:string ;
               ctro:isControl "no"^^xsd:string .


###  http://www.semanticweb.org/root/ontologies/2018/6/ctro#CT5_A1_OC1
ctro:CT5_A1_OC1 rdf:type owl:NamedIndividual ,
                         ctro:Outcome ;
                ctro:hasAnalysisMetric ctro:ChangeFromBaseline ;
                ctro:hasDesiredEffectDirection ctro:Reduction ;
                ctro:hasEndPoint ctro:EndPoint_CT5_A1_OC1 ;
                ctro:hasResult ctro:R_CT5_A1_OC1 ;
                ctro:hasBaselineValue "24.5"^^xsd:float ;
                ctro:hasFinalNumberPatients 18 ;
                ctro:hasTimePoints "EndPoint"^^xsd:string .


###  http://www.semanticweb.org/root/ontologies/2018/6/ctro#CT5_A2_AE1
ctro:CT5_A2_AE1 rdf:type owl:NamedIndividual ,
                         ctro:AdverseEffect ;
                ctro:hasAEname ctro:Conjunctival_hyperemia ;
                ctro:hasNumAffectedAE "3"^^xsd:string .


###  http://www.semanticweb.org/root/ontologies/2018/6/ctro#CT5_A2_M1
ctro:CT5_A2_M1 rdf:type owl:NamedIndividual ,
                        ctro:Medication ;
               ctro:hasDeliveryMethod ctro:Eyedrops ;
               ctro:hasDoseUnit ctro:Percentage ;
               ctro:hasDrug ctro:Timolol ;
               ctro:hasDoseValue "0.5"^^xsd:string ;
               ctro:isControl "no"^^xsd:string .


###  http://www.semanticweb.org/root/ontologies/2018/6/ctro#CT5_A2_OC1
ctro:CT5_A2_OC1 rdf:type owl:NamedIndividual ,
                         ctro:Outcome ;
                ctro:hasAnalysisMetric ctro:ChangeFromBaseline ;
                ctro:hasDesiredEffectDirection ctro:Reduction ;
                ctro:hasEndPoint ctro:EndPoint_CT5_A2_OC1 ;
                ctro:hasResult ctro:R_CT5_A2_OC1 ;
                ctro:hasBaselineValue "24.0"^^xsd:float ;
                ctro:hasFinalNumberPatients 18 ;
                ctro:hasTimePoints "EndPoint"^^xsd:string .


###  http://www.semanticweb.org/root/ontologies/2018/6/ctro#CT5_Intervention1
ctro:CT5_Intervention1 rdf:type owl:NamedIndividual ,
                                ctro:Intervention ;
                       ctro:hasInterval ctro:Daily ;
                       ctro:hasMedication ctro:CT5_A1_M1 ;
                       ctro:hasDuration "12 months"^^xsd:string ;
                       ctro:hasFrequency "once daily"^^xsd:string .


###  http://www.semanticweb.org/root/ontologies/2018/6/ctro#CT5_Intervention2
ctro:CT5_Intervention2 rdf:type owl:NamedIndividual ,
                                ctro:Intervention ;
                       ctro:hasInterval ctro:Daily ;
                       ctro:hasMedication ctro:CT5_A2_M1 ;
                       ctro:hasDuration "12 months"^^xsd:string ;
                       ctro:hasFrequency "twice daily"^^xsd:string .


###  http://www.semanticweb.org/root/ontologies/2018/6/ctro#CT5_Population
ctro:CT5_Population rdf:type owl:NamedIndividual ,
                             ctro:Population ;
                    ctro:hasCountry ctro:Italy ;
                    ctro:hasAvgAge 46 ;
                    ctro:hasGender "Mixed"^^xsd:string ;
                    ctro:hasMaxAge 58 ;
                    ctro:hasMinAge 35 ;
                    ctro:hasPreconditionDescription "Patients affected with bilateral pigmentary glaucoma controlled with no more than a single hypotensive medication"^^xsd:string .


###  http://www.semanticweb.org/root/ontologies/2018/6/ctro#CT6_A1_AE1
ctro:CT6_A1_AE1 rdf:type owl:NamedIndividual ,
                         ctro:AdverseEffect ;
                ctro:hasAEname ctro:Conjunctival_hyperemia ;
                ctro:hasNumAffectedAE "0"^^xsd:string .


###  http://www.semanticweb.org/root/ontologies/2018/6/ctro#CT6_A1_M1
ctro:CT6_A1_M1 rdf:type owl:NamedIndividual ,
                        ctro:Medication ;
               ctro:hasDeliveryMethod ctro:Eyedrops ;
               ctro:hasDoseUnit ctro:Percentage ;
               ctro:hasDrug ctro:Latanoprost ;
               ctro:hasDoseValue "0.005"^^xsd:string ;
               ctro:isControl "no"^^xsd:string .


###  http://www.semanticweb.org/root/ontologies/2018/6/ctro#CT6_A1_OC1
ctro:CT6_A1_OC1 rdf:type owl:NamedIndividual ,
                         ctro:Outcome ;
                ctro:hasAnalysisMetric ctro:ChangeFromBaseline ;
                ctro:hasDesiredEffectDirection ctro:Reduction ;
                ctro:hasEndPoint ctro:EndPoint_CT6_A1_OC1 ;
                ctro:hasResult ctro:R_CT6_A1_OC1 ;
                ctro:hasBaselineValue "23.1"^^xsd:float ;
                ctro:hasFinalNumberPatients 71 ;
                ctro:hasTimePoints "EndPoint"^^xsd:string .


###  http://www.semanticweb.org/root/ontologies/2018/6/ctro#CT6_A2_AE1
ctro:CT6_A2_AE1 rdf:type owl:NamedIndividual ,
                         ctro:AdverseEffect ;
                ctro:hasAEname ctro:Conjunctival_hyperemia ;
                ctro:hasNumAffectedAE "0"^^xsd:string .


###  http://www.semanticweb.org/root/ontologies/2018/6/ctro#CT6_A2_M1
ctro:CT6_A2_M1 rdf:type owl:NamedIndividual ,
                        ctro:Medication ;
               ctro:hasDeliveryMethod ctro:Eyedrops ;
               ctro:hasDoseUnit ctro:Percentage ;
               ctro:hasDrug ctro:Timolol ;
               ctro:hasDoseValue "0.5"^^xsd:string ;
               ctro:isControl "no"^^xsd:string .


###  http://www.semanticweb.org/root/ontologies/2018/6/ctro#CT6_A2_OC1
ctro:CT6_A2_OC1 rdf:type owl:NamedIndividual ,
                         ctro:Outcome ;
                ctro:hasAnalysisMetric ctro:ChangeFromBaseline ;
                ctro:hasDesiredEffectDirection ctro:Reduction ;
                ctro:hasEndPoint ctro:EndPoint_CT6_A2_OC1 ;
                ctro:hasResult ctro:R_CT6_A2_OC1 ;
                ctro:hasBaselineValue "23.1"^^xsd:float ;
                ctro:hasFinalNumberPatients 81 ;
                ctro:hasTimePoints "EndPoint"^^xsd:string .


###  http://www.semanticweb.org/root/ontologies/2018/6/ctro#CT6_Intervention1
ctro:CT6_Intervention1 rdf:type owl:NamedIndividual ,
                                ctro:Intervention ;
                       ctro:hasInterval ctro:Daily ;
                       ctro:hasMedication ctro:CT6_A1_M1 ;
                       ctro:hasDuration "12 weeks"^^xsd:string ;
                       ctro:hasFrequency "once daily"^^xsd:string .


###  http://www.semanticweb.org/root/ontologies/2018/6/ctro#CT6_Intervention2
ctro:CT6_Intervention2 rdf:type owl:NamedIndividual ,
                                ctro:Intervention ;
                       ctro:hasInterval ctro:Daily ;
                       ctro:hasMedication ctro:CT6_A2_M1 ;
                       ctro:hasDuration "12 weeks"^^xsd:string ;
                       ctro:hasFrequency "twice daily"^^xsd:string .


###  http://www.semanticweb.org/root/ontologies/2018/6/ctro#CT6_Population
ctro:CT6_Population rdf:type owl:NamedIndividual ,
                             ctro:Population ;
                    ctro:hasCountry ctro:Japan ;
                    ctro:hasAvgAge 57 ;
                    ctro:hasGender "Mixed"^^xsd:string ;
                    ctro:hasMaxAge 81 ;
                    ctro:hasMinAge 22 ;
                    ctro:hasPreconditionDescription "patients with elevated IOP"^^xsd:string .


###  http://www.semanticweb.org/root/ontologies/2018/6/ctro#CT7_A1_AE1
ctro:CT7_A1_AE1 rdf:type owl:NamedIndividual ,
                         ctro:AdverseEffect ;
                ctro:hasAEname ctro:Conjunctival_hyperemia ;
                ctro:hasNumAffectedAE "5"^^xsd:string .


###  http://www.semanticweb.org/root/ontologies/2018/6/ctro#CT7_A1_M1
ctro:CT7_A1_M1 rdf:type owl:NamedIndividual ,
                        ctro:Medication ;
               ctro:hasDeliveryMethod ctro:Eyedrops ;
               ctro:hasDoseUnit ctro:Percentage ;
               ctro:hasDrug ctro:Latanoprost ;
               ctro:hasDoseValue "0.006"^^xsd:string ;
               ctro:isControl "no"^^xsd:string .


###  http://www.semanticweb.org/root/ontologies/2018/6/ctro#CT7_A1_OC1
ctro:CT7_A1_OC1 rdf:type owl:NamedIndividual ,
                         ctro:Outcome ;
                ctro:hasAnalysisMetric ctro:ChangeFromBaseline ;
                ctro:hasDesiredEffectDirection ctro:Reduction ;
                ctro:hasEndPoint ctro:EndPoint_CT7_A1_OC1 ;
                ctro:hasResult ctro:R_CT7_A1_OC1 ;
                ctro:hasBaselineValue "28.5"^^xsd:float ;
                ctro:hasTimePoints "EndPoint"^^xsd:string .


###  http://www.semanticweb.org/root/ontologies/2018/6/ctro#CT7_A2_AE1
ctro:CT7_A2_AE1 rdf:type owl:NamedIndividual ,
                         ctro:AdverseEffect ;
                ctro:hasAEname ctro:Conjunctival_hyperemia ;
                ctro:hasNumAffectedAE "10"^^xsd:string .


###  http://www.semanticweb.org/root/ontologies/2018/6/ctro#CT7_A2_M1
ctro:CT7_A2_M1 rdf:type owl:NamedIndividual ,
                        ctro:Medication ;
               ctro:hasDeliveryMethod ctro:Eyedrops ;
               ctro:hasDoseUnit ctro:Percentage ;
               ctro:hasDrug ctro:Timolol ;
               ctro:hasDoseValue "0.5"^^xsd:string ;
               ctro:isControl "no"^^xsd:string .


###  http://www.semanticweb.org/root/ontologies/2018/6/ctro#CT7_A2_OC1
ctro:CT7_A2_OC1 rdf:type owl:NamedIndividual ,
                         ctro:Outcome ;
                ctro:hasAnalysisMetric ctro:ChangeFromBaseline ;
                ctro:hasDesiredEffectDirection ctro:Reduction ;
                ctro:hasEndPoint ctro:EndPoint_CT7_A2_OC1 ;
                ctro:hasResult ctro:R_CT7_A2_OC1 ;
                ctro:hasBaselineValue "24.2"^^xsd:float ;
                ctro:hasTimePoints "EndPoint"^^xsd:string .


###  http://www.semanticweb.org/root/ontologies/2018/6/ctro#CT7_Intervention1
ctro:CT7_Intervention1 rdf:type owl:NamedIndividual ,
                                ctro:Intervention ;
                       ctro:hasInterval ctro:Daily ;
                       ctro:hasMedication ctro:CT7_A1_M1 ;
                       ctro:hasDuration "1 week"^^xsd:string ;
                       ctro:hasFrequency "twice daily"^^xsd:string .


###  http://www.semanticweb.org/root/ontologies/2018/6/ctro#CT7_Intervention2
ctro:CT7_Intervention2 rdf:type owl:NamedIndividual ,
                                ctro:Intervention ;
                       ctro:hasInterval ctro:Daily ;
                       ctro:hasMedication ctro:CT7_A2_M1 ;
                       ctro:hasDuration "1 week"^^xsd:string ;
                       ctro:hasFrequency "twice daily"^^xsd:string .


###  http://www.semanticweb.org/root/ontologies/2018/6/ctro#CT7_Population
ctro:CT7_Population rdf:type owl:NamedIndividual ,
                             ctro:Population ;
                    ctro:hasCountry ctro:Holland ;
                    ctro:hasAvgAge 63 ;
                    ctro:hasGender "Mixed"^^xsd:string ;
                    ctro:hasMaxAge 84 ;
                    ctro:hasMinAge 40 ;
                    ctro:hasPreconditionDescription "Patients with Glaucoma"^^xsd:string .


###  http://www.semanticweb.org/root/ontologies/2018/6/ctro#CT8_A1_AE1
ctro:CT8_A1_AE1 rdf:type owl:NamedIndividual ,
                         ctro:AdverseEffect ;
                ctro:hasAEname ctro:Conjunctival_hyperemia ;
                ctro:hasNumAffectedAE "2"^^xsd:string .


###  http://www.semanticweb.org/root/ontologies/2018/6/ctro#CT8_A1_M1
ctro:CT8_A1_M1 rdf:type owl:NamedIndividual ,
                        ctro:Medication ;
               ctro:hasDeliveryMethod ctro:Eyedrops ;
               ctro:hasDoseUnit ctro:Percentage ;
               ctro:hasDrug ctro:Latanoprost ;
               ctro:hasDoseValue "0.005"^^xsd:string ;
               ctro:isControl "no"^^xsd:string .


###  http://www.semanticweb.org/root/ontologies/2018/6/ctro#CT8_A1_OC1
ctro:CT8_A1_OC1 rdf:type owl:NamedIndividual ,
                         ctro:Outcome ;
                ctro:hasAnalysisMetric ctro:ChangeFromBaseline ;
                ctro:hasDesiredEffectDirection ctro:Reduction ;
                ctro:hasEndPoint ctro:EndPoint_CT8_A1_OC1 ;
                ctro:hasResult ctro:R_CT8_A1_OC1 ;
                ctro:hasBaselineValue "25.2"^^xsd:float ;
                ctro:hasTimePoints "EndPoint"^^xsd:string .


###  http://www.semanticweb.org/root/ontologies/2018/6/ctro#CT8_A2_AE1
ctro:CT8_A2_AE1 rdf:type owl:NamedIndividual ,
                         ctro:AdverseEffect ;
                ctro:hasAEname ctro:Conjunctival_hyperemia ;
                ctro:hasNumAffectedAE "1"^^xsd:string .


###  http://www.semanticweb.org/root/ontologies/2018/6/ctro#CT8_A2_M1
ctro:CT8_A2_M1 rdf:type owl:NamedIndividual ,
                        ctro:Medication ;
               ctro:hasDeliveryMethod ctro:Eyedrops ;
               ctro:hasDoseUnit ctro:Percentage ;
               ctro:hasDrug ctro:Timolol ;
               ctro:hasDoseValue "0.5"^^xsd:string ;
               ctro:isControl "no"^^xsd:string .


###  http://www.semanticweb.org/root/ontologies/2018/6/ctro#CT8_A2_OC1
ctro:CT8_A2_OC1 rdf:type owl:NamedIndividual ,
                         ctro:Outcome ;
                ctro:hasAnalysisMetric ctro:ChangeFromBaseline ;
                ctro:hasDesiredEffectDirection ctro:Reduction ;
                ctro:hasEndPoint ctro:EndPoint_CT8_A2_OC1 ;
                ctro:hasResult ctro:R_CT8_A2_OC1 ;
                ctro:hasBaselineValue "25.4"^^xsd:float ;
                ctro:hasTimePoints "EndPoint"^^xsd:string .


###  http://www.semanticweb.org/root/ontologies/2018/6/ctro#CT8_Intervention1
ctro:CT8_Intervention1 rdf:type owl:NamedIndividual ,
                                ctro:Intervention ;
                       ctro:hasInterval ctro:Daily ;
                       ctro:hasMedication ctro:CT8_A1_M1 ;
                       ctro:hasDuration "6 months"^^xsd:string ;
                       ctro:hasFrequency "once daily"^^xsd:string .


###  http://www.semanticweb.org/root/ontologies/2018/6/ctro#CT8_Intervention2
ctro:CT8_Intervention2 rdf:type owl:NamedIndividual ,
                                ctro:Intervention ;
                       ctro:hasInterval ctro:Daily ;
                       ctro:hasMedication ctro:CT8_A2_M1 ;
                       ctro:hasDuration "6 months"^^xsd:string ;
                       ctro:hasFrequency "twice daily"^^xsd:string .


###  http://www.semanticweb.org/root/ontologies/2018/6/ctro#CT8_Population
ctro:CT8_Population rdf:type owl:NamedIndividual ,
                             ctro:Population ;
                    ctro:hasCountry ctro:USA ;
                    ctro:hasAvgAge 65 ;
                    ctro:hasGender "Mixed"^^xsd:string ;
                    ctro:hasMaxAge 88 ;
                    ctro:hasMinAge 39 ;
                    ctro:hasPreconditionDescription "Patients with Glaucoma"^^xsd:string .


###  http://www.semanticweb.org/root/ontologies/2018/6/ctro#CT9_A1_AE1
ctro:CT9_A1_AE1 rdf:type owl:NamedIndividual ,
                         ctro:AdverseEffect ;
                ctro:hasAEname ctro:Conjunctival_hyperemia ;
                ctro:hasNumAffectedAE "0"^^xsd:string .


###  http://www.semanticweb.org/root/ontologies/2018/6/ctro#CT9_A1_M1
ctro:CT9_A1_M1 rdf:type owl:NamedIndividual ,
                        ctro:Medication ;
               ctro:hasDeliveryMethod ctro:Eyedrops ;
               ctro:hasDoseUnit ctro:Percentage ;
               ctro:hasDrug ctro:Latanoprost ;
               ctro:hasDoseValue "0.0015"^^xsd:string ;
               ctro:isControl "no"^^xsd:string .


###  http://www.semanticweb.org/root/ontologies/2018/6/ctro#CT9_A1_M2
ctro:CT9_A1_M2 rdf:type owl:NamedIndividual ,
                        ctro:Medication ;
               ctro:hasDeliveryMethod ctro:Eyedrops ;
               ctro:hasDoseUnit ctro:Percentage ;
               ctro:hasDrug ctro:Latanoprost ;
               ctro:hasDoseValue "0.005"^^xsd:string ;
               ctro:isControl "no"^^xsd:string .


###  http://www.semanticweb.org/root/ontologies/2018/6/ctro#CT9_A1_OC1
ctro:CT9_A1_OC1 rdf:type owl:NamedIndividual ,
                         ctro:Outcome ;
                ctro:hasAnalysisMetric ctro:ChangeFromBaseline ;
                ctro:hasDesiredEffectDirection ctro:Reduction ;
                ctro:hasEndPoint ctro:EndPoint_CT9_A1_OC1 ;
                ctro:hasResult ctro:R_CT9_A1_OC1 ;
                ctro:hasBaselineValue "28.1"^^xsd:float ;
                ctro:hasTimePoints "EndPoint"^^xsd:string .


###  http://www.semanticweb.org/root/ontologies/2018/6/ctro#CT9_A2_AE1
ctro:CT9_A2_AE1 rdf:type owl:NamedIndividual ,
                         ctro:AdverseEffect ;
                ctro:hasAEname ctro:Conjunctival_hyperemia ;
                ctro:hasNumAffectedAE "0"^^xsd:string .


###  http://www.semanticweb.org/root/ontologies/2018/6/ctro#CT9_A2_M1
ctro:CT9_A2_M1 rdf:type owl:NamedIndividual ,
                        ctro:Medication ;
               ctro:hasDeliveryMethod ctro:Eyedrops ;
               ctro:hasDoseUnit ctro:Percentage ;
               ctro:hasDrug ctro:Timolol ;
               ctro:hasDoseValue "0.5"^^xsd:string ;
               ctro:isControl "no"^^xsd:string .


###  http://www.semanticweb.org/root/ontologies/2018/6/ctro#CT9_A2_OC1
ctro:CT9_A2_OC1 rdf:type owl:NamedIndividual ,
                         ctro:Outcome ;
                ctro:hasAnalysisMetric ctro:ChangeFromBaseline ;
                ctro:hasDesiredEffectDirection ctro:Reduction ;
                ctro:hasEndPoint ctro:EndPoint_CT9_A2_OC1 ;
                ctro:hasResult ctro:R_CT9_A2_OC1 ;
                ctro:hasBaselineValue "27.2"^^xsd:float ;
                ctro:hasTimePoints "EndPoint"^^xsd:string .


###  http://www.semanticweb.org/root/ontologies/2018/6/ctro#CT9_Intervention1
ctro:CT9_Intervention1 rdf:type owl:NamedIndividual ,
                                ctro:Intervention ;
                       ctro:hasInterval ctro:Daily ;
                       ctro:hasMedication ctro:CT9_A1_M1 ,
                                          ctro:CT9_A1_M2 ;
                       ctro:hasDuration "3 weeks"^^xsd:string ;
                       ctro:hasFrequency "once daily"^^xsd:string .


###  http://www.semanticweb.org/root/ontologies/2018/6/ctro#CT9_Intervention2
ctro:CT9_Intervention2 rdf:type owl:NamedIndividual ,
                                ctro:Intervention ;
                       ctro:hasInterval ctro:Daily ;
                       ctro:hasMedication ctro:CT9_A2_M1 ;
                       ctro:hasDuration "6 weeks"^^xsd:string ;
                       ctro:hasFrequency "twice daily"^^xsd:string .


###  http://www.semanticweb.org/root/ontologies/2018/6/ctro#CT9_Population
ctro:CT9_Population rdf:type owl:NamedIndividual ,
                             ctro:Population ;
                    ctro:hasCountry ctro:Germany ;
                    ctro:hasAvgAge 62 ;
                    ctro:hasGender "Mixed"^^xsd:string ;
                    ctro:hasMaxAge 79 ;
                    ctro:hasMinAge 40 ;
                    ctro:hasPreconditionDescription "Patients with Glaucoma"^^xsd:string .


###  http://www.semanticweb.org/root/ontologies/2018/6/ctro#CT_1
ctro:CT_1 rdf:type owl:NamedIndividual ,
                   ctro:ClinicalTrial ;
          ctro:analysesHealthCondition ctro:Glaucoma ;
          ctro:hasAnalysisApproach ctro:IntentionToTreat ;
          ctro:hasArm ctro:Arm_11 ,
                      ctro:Arm_12 ;
          ctro:hasCTDesign ctro:Crossover ,
                           ctro:DoubleBlinded ,
                           ctro:Randomized ;
          ctro:hasPopulation ctro:CT1_Population ;
          ctro:hasQualityIndicator ctro:EQ_1 ;
          ctro:hasCTduration "24 weeks"^^xsd:string ;
          ctro:hasConclusionComment "The effect on diurnal IOP of latanoprost applied once daily in the evening is superior to that of timolol. The main difference in side effects is increased pigmentation of the iris induced by latanoprost, most likely due to stimulation of melanogenesis in iris stromal melanocytes."^^xsd:string ;
          ctro:hasNumberPatientsCT 267 ;
          ctro:hasObjectiveDescription "To compare the effect on intraocular pressure (IOP) and side effects of 0.005% latanoprost applied once daily, morning or evening, with 0.5% timolol applied twice daily."^^xsd:string .


###  http://www.semanticweb.org/root/ontologies/2018/6/ctro#CT_10
ctro:CT_10 rdf:type owl:NamedIndividual ,
                    ctro:ClinicalTrial ;
           ctro:hasArm ctro:Arm_101 ,
                       ctro:Arm_102 ;
           ctro:hasCTDesign ctro:Crossover ,
                            ctro:DoubleBlinded ;
           ctro:hasPopulation ctro:CT10_Population ;
           ctro:hasQualityIndicator ctro:EQ_10 ;
           ctro:hasCTduration "1 week"^^xsd:string ;
           ctro:hasConclusionComment "Topical timolol and latanoprost significantly reduced the intraocular pressure in ocular hypertensive and glaucoma patients without creating substantial hemodynamic changes in the retrobulbar vessels."^^xsd:string ;
           ctro:hasNumberPatientsCT 15 ;
           ctro:hasObjectiveDescription "To examine the effects of topical timolol and latanoprost on retrobulbar vessel blood velocity in patients with glaucoma or ocular hypertension."^^xsd:string .


###  http://www.semanticweb.org/root/ontologies/2018/6/ctro#CT_11
ctro:CT_11 rdf:type owl:NamedIndividual ,
                    ctro:ClinicalTrial ;
           ctro:analysesHealthCondition ctro:Glaucoma ;
           ctro:hasArm ctro:Arm_111 ,
                       ctro:Arm_112 ;
           ctro:hasCTDesign ctro:DoubleBlinded ,
                            ctro:Randomized ;
           ctro:hasPopulation ctro:CT11_Population ;
           ctro:hasQualityIndicator ctro:EQ_11 ;
           ctro:hasCTduration "3 weeks"^^xsd:string ;
           ctro:hasConclusionComment "Because ocular perfusion pressure may be important in some glaucomatous patients, latanoprost appears to affect ocular perfusion pressure more favorably than timolol does in patients with normal-tension glaucoma."^^xsd:string ;
           ctro:hasNumberPatientsCT 36 ;
           ctro:hasObjectiveDescription "To compare the calculated mean ocular perfusion pressure at the end of 3 weeks' treatment with latanoprost 0.005% once daily or timolol 0.5% twice daily in normal-tension glaucoma patients."^^xsd:string .


###  http://www.semanticweb.org/root/ontologies/2018/6/ctro#CT_2
ctro:CT_2 rdf:type owl:NamedIndividual ,
                   ctro:ClinicalTrial ;
          ctro:analysesHealthCondition ctro:OcularHypertension ,
                                       ctro:OpenAngleGlaucoma ;
          ctro:hasAnalysisApproach ctro:IntentionToTreat ;
          ctro:hasArm ctro:Arm_21 ,
                      ctro:Arm_22 ;
          ctro:hasCTDesign ctro:DoubleBlinded ,
                           ctro:Parallel ,
                           ctro:Randomized ,
                           ctro:SingleCenter ;
          ctro:hasPopulation ctro:CT2_Population ;
          ctro:hasQualityIndicator ctro:EQ_2 ;
          ctro:hasCTduration "12 weeks"^^xsd:string ;
          ctro:hasConclusionComment "Most side effects observed were mild and transient and no serious adverse events were reported. Latanoprost 0.005% administered once daily in the evening was at least as effective as timolol 0.5% twice daily in reducing the mean diurnal IOP after 6 and 12 weeks of treatment. Both medications were well tolerated during the study period. "^^xsd:string ;
          ctro:hasNumberPatientsCT 60 ;
          ctro:hasObjectiveDescription "To compare the effect on intraocular pressure (IOP) of latanoprost 0.005% once daily with timolol 0.5% twice daily in patients with open angle glaucoma or ocular hypertension."^^xsd:string .


###  http://www.semanticweb.org/root/ontologies/2018/6/ctro#CT_21
ctro:CT_21 rdf:type owl:NamedIndividual ,
                    ctro:ClinicalTrial ;
           ctro:hasArm ctro:Arm_211 ,
                       ctro:Arm_212 ;
           ctro:hasCTDesign ctro:OpenLabel ,
                            ctro:Parallel ,
                            ctro:Randomized ;
           ctro:hasPopulation ctro:CT21_Population ;
           ctro:hasQualityIndicator ctro:EQ_21 ;
           ctro:hasCTduration "26 weeks"^^xsd:string ;
           ctro:hasNumberPatientsCT 85 .


###  http://www.semanticweb.org/root/ontologies/2018/6/ctro#CT_22
ctro:CT_22 rdf:type owl:NamedIndividual ,
                    ctro:ClinicalTrial ;
           ctro:hasArm ctro:Arm_221 ,
                       ctro:Arm_222 ;
           ctro:hasCTDesign ctro:OpenLabel ,
                            ctro:Parallel ,
                            ctro:Randomized ;
           ctro:hasPopulation ctro:CT22_Population ;
           ctro:hasQualityIndicator ctro:EQ_22 ;
           ctro:hasCTduration "12 weeks"^^xsd:string ;
           ctro:hasNumberPatientsCT 28 .


###  http://www.semanticweb.org/root/ontologies/2018/6/ctro#CT_23
ctro:CT_23 rdf:type owl:NamedIndividual ,
                    ctro:ClinicalTrial ;
           ctro:hasArm ctro:Arm_231 ,
                       ctro:Arm_232 ;
           ctro:hasCTDesign ctro:OpenLabel ,
                            ctro:Parallel ,
                            ctro:Randomized ;
           ctro:hasPopulation ctro:CT23_Population ;
           ctro:hasQualityIndicator ctro:EQ_23 ;
           ctro:hasCTduration "36 weeks"^^xsd:string ;
           ctro:hasNumberPatientsCT 116 .


###  http://www.semanticweb.org/root/ontologies/2018/6/ctro#CT_24
ctro:CT_24 rdf:type owl:NamedIndividual ,
                    ctro:ClinicalTrial ;
           ctro:hasArm ctro:Arm_241 ,
                       ctro:Arm_242 ;
           ctro:hasCTDesign ctro:OpenLabel ,
                            ctro:Parallel ,
                            ctro:Randomized ;
           ctro:hasPopulation ctro:CT24_Population ;
           ctro:hasQualityIndicator ctro:EQ_24 ;
           ctro:hasCTduration "24 weeks"^^xsd:string ;
           ctro:hasNumberPatientsCT 481 .


###  http://www.semanticweb.org/root/ontologies/2018/6/ctro#CT_25
ctro:CT_25 rdf:type owl:NamedIndividual ,
                    ctro:ClinicalTrial ;
           ctro:hasArm ctro:Arm_251 ,
                       ctro:Arm_252 ;
           ctro:hasCTDesign ctro:OpenLabel ,
                            ctro:Parallel ,
                            ctro:Randomized ;
           ctro:hasPopulation ctro:CT25_Population ;
           ctro:hasQualityIndicator ctro:EQ_25 ;
           ctro:hasCTduration "24 weeks"^^xsd:string ;
           ctro:hasNumberPatientsCT 715 .


###  http://www.semanticweb.org/root/ontologies/2018/6/ctro#CT_26
ctro:CT_26 rdf:type owl:NamedIndividual ,
                    ctro:ClinicalTrial ;
           ctro:hasArm ctro:Arm_261 ,
                       ctro:Arm_262 ;
           ctro:hasCTDesign ctro:OpenLabel ,
                            ctro:Parallel ,
                            ctro:Randomized ;
           ctro:hasPopulation ctro:CT26_Population ;
           ctro:hasQualityIndicator ctro:EQ_26 ;
           ctro:hasCTduration "36 weeks"^^xsd:string ;
           ctro:hasNumberPatientsCT 110 .


###  http://www.semanticweb.org/root/ontologies/2018/6/ctro#CT_27
ctro:CT_27 rdf:type owl:NamedIndividual ,
                    ctro:ClinicalTrial ;
           ctro:hasArm ctro:Arm_271 ,
                       ctro:Arm_272 ;
           ctro:hasCTDesign ctro:Multicenter ,
                            ctro:OpenLabel ,
                            ctro:Parallel ,
                            ctro:Randomized ;
           ctro:hasPopulation ctro:CT27_Population ;
           ctro:hasQualityIndicator ctro:EQ_27 ;
           ctro:hasCTduration "24 weeks"^^xsd:string ;
           ctro:hasNumberPatientsCT 756 .


###  http://www.semanticweb.org/root/ontologies/2018/6/ctro#CT_28
ctro:CT_28 rdf:type owl:NamedIndividual ,
                    ctro:ClinicalTrial ;
           ctro:hasArm ctro:Arm_281 ,
                       ctro:Arm_282 ;
           ctro:hasCTDesign ctro:Multicenter ,
                            ctro:OpenLabel ,
                            ctro:Parallel ,
                            ctro:Randomized ;
           ctro:hasPopulation ctro:CT28_Population ;
           ctro:hasQualityIndicator ctro:EQ_28 ;
           ctro:hasCTduration "52 weeks"^^xsd:string ;
           ctro:hasNumberPatientsCT 570 .


###  http://www.semanticweb.org/root/ontologies/2018/6/ctro#CT_29
ctro:CT_29 rdf:type owl:NamedIndividual ,
                    ctro:ClinicalTrial ;
           ctro:hasArm ctro:Arm_291 ,
                       ctro:Arm_292 ;
           ctro:hasCTDesign ctro:Multicenter ,
                            ctro:OpenLabel ,
                            ctro:Parallel ,
                            ctro:Randomized ;
           ctro:hasPopulation ctro:CT29_Population ;
           ctro:hasQualityIndicator ctro:EQ_29 ;
           ctro:hasCTduration "24 weeks"^^xsd:string ;
           ctro:hasNumberPatientsCT 471 .


###  http://www.semanticweb.org/root/ontologies/2018/6/ctro#CT_3
ctro:CT_3 rdf:type owl:NamedIndividual ,
                   ctro:ClinicalTrial ;
          ctro:hasAnalysisApproach ctro:PreProtocol ;
          ctro:hasArm ctro:Arm_31 ,
                      ctro:Arm_32 ;
          ctro:hasCTDesign ctro:DoubleBlinded ,
                           ctro:Multicenter ,
                           ctro:Parallel ,
                           ctro:Randomized ;
          ctro:hasPopulation ctro:CT3_Population ;
          ctro:hasQualityIndicator ctro:EQ_3 ;
          ctro:hasCTduration "24 weeks"^^xsd:string ;
          ctro:hasConclusionComment "Latanoprost has the potential for becoming a new first-line treatment for glaucoma"^^xsd:string ;
          ctro:hasNumberPatientsCT 268 ;
          ctro:hasObjectiveDescription "Latanoprost, a new prostaglandin analogue, was compared with timolol for ocular hypotensive efficacy and side effects"^^xsd:string .


###  http://www.semanticweb.org/root/ontologies/2018/6/ctro#CT_4
ctro:CT_4 rdf:type owl:NamedIndividual ,
                   ctro:ClinicalTrial ;
          ctro:analysesHealthCondition ctro:OpenAngleGlaucoma ;
          ctro:hasAnalysisApproach ctro:PreProtocol ;
          ctro:hasArm ctro:Arm_41 ,
                      ctro:Arm_42 ;
          ctro:hasCTDesign ctro:DoubleBlinded ,
                           ctro:Multicenter ,
                           ctro:Parallel ,
                           ctro:Randomized ;
          ctro:hasPopulation ctro:CT4_Population ;
          ctro:hasQualityIndicator ctro:EQ_4 ;
          ctro:hasCTduration "4 weeks"^^xsd:string ;
          ctro:hasConclusionComment "This study indicates that a fixed combination of latanoprost 0.005% and timolol 0.5% could be useful in the treatment of glaucoma"^^xsd:string ;
          ctro:hasNumberPatientsCT 139 .


###  http://www.semanticweb.org/root/ontologies/2018/6/ctro#CT_5
ctro:CT_5 rdf:type owl:NamedIndividual ,
                   ctro:ClinicalTrial ;
          ctro:analysesHealthCondition ctro:PigmentaryGlaucoma ;
          ctro:hasArm ctro:Arm_51 ,
                      ctro:Arm_52 ;
          ctro:hasCTDesign ctro:DoubleBlinded ,
                           ctro:Parallel ,
                           ctro:Randomized ;
          ctro:hasPopulation ctro:CT5_Population ;
          ctro:hasQualityIndicator ctro:EQ_5 ;
          ctro:hasCTduration "48 weeks"^^xsd:string ;
          ctro:hasConclusionComment "Although further studies may need to confirm these data on a larger sample and to evaluate the side effect of increased iris pigmentation on long-term follow-up, in patients with pigmentary glaucoma, 0.005% latanoprost taken once daily was well tolerated and more effective in reducing IOP than 0.5% timolol taken twice daily"^^xsd:string ;
          ctro:hasNumberPatientsCT 36 ;
          ctro:hasObjectiveDescription "To compare the efficacy and side effects and the effect on aqueous humor dynamics of 0.005% latanoprost applied topically once daily with 0.5% timolol given twice daily for 12 months to patients with pigmentary glaucoma"^^xsd:string .


###  http://www.semanticweb.org/root/ontologies/2018/6/ctro#CT_6
ctro:CT_6 rdf:type owl:NamedIndividual ,
                   ctro:ClinicalTrial ;
          ctro:analysesHealthCondition ctro:OcularHypertension ,
                                       ctro:OpenAngleGlaucoma ;
          ctro:hasArm ctro:Arm_61 ,
                      ctro:Arm_62 ;
          ctro:hasCTDesign ctro:DoubleBlinded ,
                           ctro:Parallel ,
                           ctro:Randomized ;
          ctro:hasPopulation ctro:CT6_Population ;
          ctro:hasQualityIndicator ctro:EQ_6 ;
          ctro:hasCTduration "12 weeks"^^xsd:string ;
          ctro:hasConclusionComment "The results of this study demonstrated that 0.005% latanoprost taken once daily is well tolerated and more effective in reducing IOP than 0.5% timolol taken twice daily. Thus, latanoprost may become an important choice for the medical treatment of glaucoma"^^xsd:string ;
          ctro:hasNumberPatientsCT 184 ;
          ctro:hasObjectiveDescription "To evaluate the intraocular pressure (IOP)-reducing effect and the side effects of latanoprost (PhXA41), a new phenyl-substituted prostaglandin F2 alpha-isopropyl ester analogue, in patients with elevated IOP, using timolol maleate as the reference drug"^^xsd:string .


###  http://www.semanticweb.org/root/ontologies/2018/6/ctro#CT_7
ctro:CT_7 rdf:type owl:NamedIndividual ,
                   ctro:ClinicalTrial ;
          ctro:analysesHealthCondition ctro:Glaucoma ;
          ctro:hasAnalysisApproach ctro:PreProtocol ;
          ctro:hasArm ctro:Arm_71 ,
                      ctro:Arm_72 ;
          ctro:hasCTDesign ctro:Parallel ,
                           ctro:Randomized ;
          ctro:hasPopulation ctro:CT7_Population ;
          ctro:hasQualityIndicator ctro:EQ_7 ;
          ctro:hasCTduration "1 week"^^xsd:string ;
          ctro:hasConclusionComment "The results indicate that latanoprost and timolol can be combined successfully and that complete or almost complete additivity is reached even at pressure levels below 20 mm Hg."^^xsd:string ;
          ctro:hasNumberPatientsCT 20 .


###  http://www.semanticweb.org/root/ontologies/2018/6/ctro#CT_8
ctro:CT_8 rdf:type owl:NamedIndividual ,
                   ctro:ClinicalTrial ;
          ctro:analysesHealthCondition ctro:Glaucoma ;
          ctro:hasArm ctro:Arm_81 ,
                      ctro:Arm_82 ;
          ctro:hasCTDesign ctro:DoubleBlinded ,
                           ctro:Randomized ;
          ctro:hasPopulation ctro:CT8_Population ;
          ctro:hasQualityIndicator ctro:EQ_8 ;
          ctro:hasCTduration "24 weeks"^^xsd:string ;
          ctro:hasConclusionComment "Latanoprost 0.005% administered once daily in the evening reduced IOP at least as well as timolol 0.5% administered twice daily. Latanoprost was generally well tolerated systemically and in the eye. However, the drug has an unusual side effect of increasing the pigmentation of the iris, particularly in individuals with green-brown or blue-brown eyes."^^xsd:string ;
          ctro:hasNumberPatientsCT 294 ;
          ctro:hasObjectiveDescription "To compare the intraocular pressure (IOP)-reducing effect and side effects of 0.005% latanoprost administered once daily with 0.5% timolol administered twice daily in patients with open-angle glaucoma or ocular hypertension."^^xsd:string .


###  http://www.semanticweb.org/root/ontologies/2018/6/ctro#CT_9
ctro:CT_9 rdf:type owl:NamedIndividual ,
                   ctro:ClinicalTrial ;
          ctro:hasArm ctro:Arm_91 ,
                      ctro:Arm_92 ;
          ctro:hasCTDesign ctro:DoubleBlinded ,
                           ctro:Randomized ;
          ctro:hasPopulation ctro:CT9_Population ;
          ctro:hasQualityIndicator ctro:EQ_9 ;
          ctro:hasCTduration "6 weeks"^^xsd:string ;
          ctro:hasConclusionComment "Both concentrations of latanoprost reduced IOP at least as well as timolol 0.5% eye drops."^^xsd:string ;
          ctro:hasNumberPatientsCT 30 ;
          ctro:hasObjectiveDescription "he objective of this study was to investigate the effect of two different regimens of latanoprost on the diurnal IOP and also the effect of latanoprost on the blood-aqueous barrier measured with a laser flare cell meter (Kowa FM-500). Moreover, the safety aspects of the two regimens regarding hyperemia were studied."^^xsd:string .


###  http://www.semanticweb.org/root/ontologies/2018/6/ctro#Canada
ctro:Canada rdf:type owl:NamedIndividual ,
                     <http://www.bpiresearch.com/BPMO/2004/03/03/cdl/Countries#Country> ;
            rdfs:label "Canada" .


###  http://www.semanticweb.org/root/ontologies/2018/6/ctro#Caucasian
ctro:Caucasian rdf:type owl:NamedIndividual ,
                        ctro:Ethnicity .


###  http://www.semanticweb.org/root/ontologies/2018/6/ctro#ChangeBloodVelocity
ctro:ChangeBloodVelocity rdf:type owl:NamedIndividual ,
                                  ctro:AdverseEffectName .


###  http://www.semanticweb.org/root/ontologies/2018/6/ctro#ChangeFromBaseline
ctro:ChangeFromBaseline rdf:type owl:NamedIndividual ,
                                 ctro:AnalysisMetric .


###  http://www.semanticweb.org/root/ontologies/2018/6/ctro#Conjunctival_hyperemia
ctro:Conjunctival_hyperemia rdf:type owl:NamedIndividual ,
                                     ctro:AdverseEffectName ;
                            rdfs:label "Conjunctival_hyperemia" .


###  http://www.semanticweb.org/root/ontologies/2018/6/ctro#Corneal_PPE
ctro:Corneal_PPE rdf:type owl:NamedIndividual ,
                          ctro:AdverseEffectName .


###  http://www.semanticweb.org/root/ontologies/2018/6/ctro#Crossover
ctro:Crossover rdf:type owl:NamedIndividual ,
                        ctro:CTDesign ;
               rdfs:label "Crossover" .


###  http://www.semanticweb.org/root/ontologies/2018/6/ctro#Daily
ctro:Daily rdf:type owl:NamedIndividual ,
                    ctro:Interval .


###  http://www.semanticweb.org/root/ontologies/2018/6/ctro#Day
ctro:Day rdf:type owl:NamedIndividual ,
                  ctro:TimeUnit .


###  http://www.semanticweb.org/root/ontologies/2018/6/ctro#Diurnal_IOP
ctro:Diurnal_IOP rdf:type owl:NamedIndividual ,
                          ctro:PrimaryOutcomeName ;
                 rdfs:label "Diurnal IOP" .


###  http://www.semanticweb.org/root/ontologies/2018/6/ctro#DoubleBlinded
ctro:DoubleBlinded rdf:type owl:NamedIndividual ,
                            ctro:CTDesign ;
                   rdfs:label "Double-Blinded" .


###  http://www.semanticweb.org/root/ontologies/2018/6/ctro#EQ_1
ctro:EQ_1 rdf:type owl:NamedIndividual ,
                   ctro:EvidenceQuality ;
          ctro:hasAuthorAffilations "1: Dep. of Ophthal., Univ. Hosp., Uppsala, Sweden; 2: Pharmacia Ophthalmics AB"^^xsd:string ;
          ctro:hasBiasSponsor "One of the authors has as affiliation Pharmacia Ophthalmics AB (Now Pharmacia & Upjohn), Uppsala, Sweden. Pharmacia & Upjohn is manufacturer of Latanoprost Ophthalmic (Xalatan)."^^xsd:string ;
          ctro:hasConflictInterest "NA"^^xsd:string ;
          ctro:hasSponsor "NA"^^xsd:string .


###  http://www.semanticweb.org/root/ontologies/2018/6/ctro#EQ_10
ctro:EQ_10 rdf:type owl:NamedIndividual ,
                    ctro:EvidenceQuality ;
           ctro:hasAuthorAffilations "1,4: Dep. of Ophthal., Univ. of British Columbia; 2,3: Dep. of Radiology, Vancouver General Hospital, Univ. of British Columbia, Canada"^^xsd:string ;
           ctro:hasBiasSponsor "This study was supported in part by Pharmacia AB (Now Pharmacia & Upjohn), Uppsala, Sweden."^^xsd:string ;
           ctro:hasConflictInterest "NA"^^xsd:string ;
           ctro:hasSponsor "This study was supported in part by Pharmacia AB, Uppsala, Sweden."^^xsd:string .


###  http://www.semanticweb.org/root/ontologies/2018/6/ctro#EQ_11
ctro:EQ_11 rdf:type owl:NamedIndividual ,
                    ctro:EvidenceQuality ;
           ctro:hasAuthorAffilations "1: Dep. of Ophthal. Univ. of British Columbia, Canada; 2: Glaucoma Clinic, Foothills Hosp., Calgary, Canada; 3: Dep. of Ophthal. Univ. of Washington, USA"^^xsd:string ;
           ctro:hasBiasSponsor "This study was supported by Pharmacia AB (Now Pharmacia & Upjohn), Uppsala, Sweden. Pharmacia & Upjohn is manufacturer of Latanoprost Ophthalmic (Xalatan)."^^xsd:string ;
           ctro:hasConflictInterest "NA"^^xsd:string ;
           ctro:hasSponsor "This study was supported by Pharmacia AB, Uppsala, Sweden."^^xsd:string .


###  http://www.semanticweb.org/root/ontologies/2018/6/ctro#EQ_2
ctro:EQ_2 rdf:type owl:NamedIndividual ,
                   ctro:EvidenceQuality ;
          ctro:hasAuthorAffilations "1,2: Glaucoma Unit, Dep. of Ophthal., Univ. of the Philippines College of Medicine, Manila"^^xsd:string ;
          ctro:hasBiasSponsor "NA"^^xsd:string ;
          ctro:hasConflictInterest "NA"^^xsd:string ;
          ctro:hasSponsor "NA"^^xsd:string .


###  http://www.semanticweb.org/root/ontologies/2018/6/ctro#EQ_21
ctro:EQ_21 rdf:type owl:NamedIndividual ,
                    ctro:EvidenceQuality ;
           ctro:hasAuthorAffilations "1:Div. of Endocrinology, Charles R. Drew, Univ. of Medicine and Science, Los Angeles, USA"^^xsd:string ;
           ctro:hasBiasSponsor "NA"^^xsd:string ;
           ctro:hasConflictInterest "The authors declare that they have no conflict of interest"^^xsd:string ;
           ctro:hasSponsor "The author was funded by research grants from the National Institutes of Health, USA."^^xsd:string .


###  http://www.semanticweb.org/root/ontologies/2018/6/ctro#EQ_22
ctro:EQ_22 rdf:type owl:NamedIndividual ,
                    ctro:EvidenceQuality ;
           ctro:hasAuthorAffilations "1,3,4,5,6,7,8: Inst. for Clinical Research and Development, Clinical Dep., Mainz, Germany; 1: Johannes Gutenberg Univ. Mainz, Dep. of Endocrinology, Germany; 2: Sanofi-aventis, Medical Dep., Berlin, Germany"^^xsd:string ;
           ctro:hasBiasSponsor "The study was sponsored by Sanofi-Aventis. Andreas Pfützner and Thomas Forst received grants and speaker fees from Sanofi-aventis. Martin Larbig works in  Sanofi-aventis. Sanofi-aventis is manufacturer of Insulin Glargine (Latus)"^^xsd:string ;
           ctro:hasConflictInterest "Andreas Pfützner and Thomas Forst received unrestricted research grants and speaker fees from Sanofi‐aventis. Martin Larbig is an employee of Sanofi‐aventis. Cloth Hohberg, Senait Forst, Stepahn Diessel, Marcus Borchert, and Werner Roth have declared no conflict of interest."^^xsd:string ;
           ctro:hasSponsor "This study was supported by an unrestricted fund from Sanofi-Aventis, Berlin, Germany. Editorial support for this article was provided by the Global Publications group of Sanofi-Aventis."^^xsd:string .


###  http://www.semanticweb.org/root/ontologies/2018/6/ctro#EQ_23
ctro:EQ_23 rdf:type owl:NamedIndividual ,
                    ctro:EvidenceQuality ;
           ctro:hasAuthorAffilations "1,2,3,4,5,8,9: Dep. of Geriatrics and Metabolic Diseases, Second Univ. of Naples, Italy; 6: Warwick Medical School, Clinical Science Research Inst., Clinical Sc. Building, Univ. Hospital, Walsgrave Campus, Clifford Bridge Road,UK; 7: Division of Internal Medicine, ASLNA5, Vico Equense/Sorrento, Naples, Italy."^^xsd:string ;
           ctro:hasBiasSponsor "NA"^^xsd:string ;
           ctro:hasConflictInterest "Potential Financial Conflicts of Interest: None disclosed"^^xsd:string ;
           ctro:hasSponsor "Grant Support: In part by the Second University of Naples."^^xsd:string .


###  http://www.semanticweb.org/root/ontologies/2018/6/ctro#EQ_24
ctro:EQ_24 rdf:type owl:NamedIndividual ,
                    ctro:EvidenceQuality ;
           ctro:hasAuthorAffilations "1:Hosp. Heliopolis, Sao Paulo, Brazil; 2: Nuevo Hosp. Civil, Guadalajara, Mexico; 3: Hosp. Coromoto, Maracaibo, Venezuela; 4: Hosp. Clinicas, Buenos Aires, Argentina; 5: Colombian Diabetes Association, Bogota, Colombia; 6: Hospital Nac. Cayetano Heredia, Lima, Peru; 7: Unidad Diagnostica Cardiologica, Guatemala City, Guatemala; 8: Hosp. Clinicas, Asuncion, Paraguay"^^xsd:string ;
           ctro:hasBiasSponsor "The study was fully financially supported by Sanofi-Aventis. Sanofi-Aventis is manufacturer of Insulin Glargine (Latus)."^^xsd:string ;
           ctro:hasConflictInterest "NA"^^xsd:string ;
           ctro:hasSponsor "This study has received full financial support from Sanofi-Aventis."^^xsd:string .


###  http://www.semanticweb.org/root/ontologies/2018/6/ctro#EQ_25
ctro:EQ_25 rdf:type owl:NamedIndividual ,
                    ctro:EvidenceQuality ;
           ctro:hasAuthorAffilations "1,3: Medizinische Klinik, Abteilung fr Endokrinologie, Stoffwechsel und Pathobiochemie, Eberhard-Karls-Universitt, Tbingen; 2: Aventis, Frankfurt, Germany. "^^xsd:string ;
           ctro:hasBiasSponsor "The authors are employees of Aventis Pharma (Now Sanofi-Aventis). Grant received by Aventis Pharma, Bridgewater, New Jersey. Sanofi-Aventis is manufacturer of Insulin Glargine (Latus)."^^xsd:string ;
           ctro:hasConflictInterest "Potential Financial Conf. of Inters.:Employment: M.A. Schweitzer (employee of Aventis Pharma; responsible for scientific develop. of insulin glargine and profiling it with data from clinical studies); Honoraria: A. Fritsche and H.U. Hring (from Aventis Pharma for the presentation of the data in this paper to national and internat. congresses); Expert testimony: H.U. Hring; Grants received: A. Fritsche and H.U. Hring (travel grants from Aventis Pharma for presentation of the data in this paper to national and internat. congresses)."^^xsd:string ;
           ctro:hasSponsor "Grant Support: By Aventis Pharma (Bridgewater, New Jersey)."^^xsd:string .


###  http://www.semanticweb.org/root/ontologies/2018/6/ctro#EQ_26
ctro:EQ_26 rdf:type owl:NamedIndividual ,
                    ctro:EvidenceQuality ;
           ctro:hasAuthorAffilations "1,3: Dep. of Medicine, Univ. of Helsinki, Finland; 2,6: Jorvi Hospital Espoo, Finland; 4,5: City of Turku Health Centre, Turku, Finland; 7: Lappi Central Hosp., Rovaniemi,Finland; 8,9,10: Whiston Hosp., Prescot,UK; 11,12: Mikkeli Health Centre, Mikkeli, Finland; 13,14:Sanofi-Aventis, Helsinki, Finland; 15: Kymenlaakso Central Hospital,Kotka, Finland"^^xsd:string ;
           ctro:hasBiasSponsor "This study was supported by grants from the Academy of Finland and from Aventis (Now Sanofi-Aventis), Bridgewater, NJ, USA. H. Yki-Järvinen has been a consultant or speaker for Amylin, Astra-Zeneca, Aventis, Lilly and MSD and received grant support for investigator-initiated trials from Aventis, Lilly, Novartis and Roche. Sanofi-Aventis is manufacturer of Insulin Glargine (Latus)."^^xsd:string ;
           ctro:hasConflictInterest "Duality of interest: H. Yki-Järvinen has acted as a consultant or speaker for Amylin, Astra-Zeneca, Aventis, Lilly and MSD and received grant support for investigator-initiated trials from Aventis, Lilly, Novartis and Roche."^^xsd:string ;
           ctro:hasSponsor "In Acknowl.: This investigator-initiated study was supported by grants from the Academy of Finland and from Aventis (Bridgewater, NJ, USA)."^^xsd:string .


###  http://www.semanticweb.org/root/ontologies/2018/6/ctro#EQ_27
ctro:EQ_27 rdf:type owl:NamedIndividual ,
                    ctro:EvidenceQuality ;
           ctro:hasAuthorAffilations "1: Oregon Health and Science Univ., Portland, Oregon, USA; 2: Dallas Diabetes and Endocrine Center, Dallas, Texas, USA; 3: Univ. of Rochester Medical Center, Rochester, New York, USA"^^xsd:string ;
           ctro:hasBiasSponsor "This study was sponsored by Aventis Pharma (Now Sanofi-Aventis). Sanofi-Aventis is manufacturer of Insulin Glargine (Latus). M.C.R. has served on advisory panels for, received honoraria or consulting fees from, and received grant support from Aventis, GlaxoSmithKline, and Novo Nordisk. J.R. has served on advisory panels for Aventis, Pfizer, Novo Nordisk, Takeda, and Johnson & Johnson; holds stock in Pfizer, GlaxoSmithKline, and Lilly; has received honoraria or consulting fees from Aventis, Pfizer, Takeda, and GlaxoSmithKline; and has received grant support from Aventis, Novo Nordisk, Lilly, Pfizer, Takeda, GlaxoSmithKline, Novartis, and AstraZeneca. J.G. has served on advisory boards for and has received honoraria and grant support from Pfizer, Novo Nordisk, Aventis, GlaxoSmithKline, and Novartis. "^^xsd:string ;
           ctro:hasConflictInterest "In Footnote: M.C.R. has served on advisory panels for, received honoraria or consulting fees from, and received grant support from Aventis, GlaxoSmithKline, and Novo Nordisk. J.R. has served on advisory panels for Aventis, Pfizer, Novo Nordisk, Takeda, and Johnson & Johnson; holds stock in Pfizer, GlaxoSmithKline, and Lilly; has received honoraria or consulting fees from Aventis, Pfizer, Takeda, and GlaxoSmithKline; and has received grant support from Aventis, Novo Nordisk, Lilly, Pfizer, Takeda, GlaxoSmithKline, Novartis, and AstraZeneca. J.G. has served on advisory boards for and has received honoraria and grant support from Pfizer, Novo Nordisk, Aventis, GlaxoSmithKline, and Novartis."^^xsd:string ;
           ctro:hasSponsor "In Acknowled.: This study was sponsored by Aventis Pharma, which was involved in its design and conduct, the collection and statistical analysis of data, and providing study medications. The primary authors participated in the design and monitoring of the study, controlled data evaluation and interpretation, and prepared the manuscript."^^xsd:string .


###  http://www.semanticweb.org/root/ontologies/2018/6/ctro#EQ_28
ctro:EQ_28 rdf:type owl:NamedIndividual ,
                    ctro:EvidenceQuality ;
           ctro:hasAuthorAffilations "1: University of Perugia, Perugia, Italy; 2,3,4: Aventis Pharma Deutschland GmbH, Bad Soden, Germany"^^xsd:string ;
           ctro:hasBiasSponsor "One of the authors is affilieted to Aventis. Sanofi-Aventis is manufacturer of Insulin Glargine (Latus)."^^xsd:string ;
           ctro:hasConflictInterest "NA"^^xsd:string ;
           ctro:hasSponsor "NA"^^xsd:string .


###  http://www.semanticweb.org/root/ontologies/2018/6/ctro#EQ_29
ctro:EQ_29 rdf:type owl:NamedIndividual ,
                    ctro:EvidenceQuality ;
           ctro:hasAuthorAffilations "1:Dep. of Internal Diseases, Diabetology and Nephrology, Silesian Medical Univ., Zabrze, Poland; 2: i3 Statprobe/UHG, Ann Arbor, MI, USA; 3: i3 Statprobe/UHG, Minneapolis, MN, USA; 4: Eli Lilly and Company, Indianapolis, IN, USA"^^xsd:string ;
           ctro:hasBiasSponsor "Funding for this study was provided by Eli Lilly. K. Strojek has participated in advisory boards and clinical trials from: Eli Lilly, Novo Nordisk, Sanofi-Aventis, Servier, Bristol-Myers-Squibb, Bioton (Poland), Merck-Serono, Astra Zeneca, Takeda and Novartis. C. Shi and M. A. Carey are employees of i3 Statprobe, a division of Ingenix, which is a subsidiary of United Health Group. S. J. Jacober is an employee and shareholder of Eli Lilly. Eli Lilly is manufacturer of Insulin Glargine (Basaglar)."^^xsd:string ;
           ctro:hasConflictInterest "K. Strojek has received honoraria for speaking engagements, participation in advisory boards and clinical trials from the following companies: Eli Lilly and Company, Novo Nordisk, Sanofi-Aventis, Servier, Bristol-Myers-Squibb, Bioton (Poland), Merck-Serono, Astra Zeneca, Takeda and Novartis. C. Shi and M. A. Carey are employees of i3 Statprobe, a division of Ingenix, which is a subsidiary of United Health Group, and have no competing interests to declare. S. J. Jacober is an employee and shareholder of Eli Lilly and Company."^^xsd:string ;
           ctro:hasSponsor "Funding for this study was provided by Eli Lilly and Company."^^xsd:string .


###  http://www.semanticweb.org/root/ontologies/2018/6/ctro#EQ_3
ctro:EQ_3 rdf:type owl:NamedIndividual ,
                   ctro:EvidenceQuality ;
          ctro:hasAuthorAffilations "1: Ophthal., Univ. of Nebraska Medical Center, Omaha, USA."^^xsd:string ;
          ctro:hasBiasSponsor "Dr. Camras is a consultant to Pharmacia Ophthalmics (Now Pharmacia & Upjohn), Uppsala, Sweden, and to Alcon Lab., Fort Worth, Texas. The study was supported by a grant from Pharmacia Pharmaceuticals (Now Pharmacia & Upjohn), Uppsala, Sweden. Pharmacia & Upjohn is manufacturer of Latanoprost Ophthalmic (Xalatan). Alcon, Inc is manufacturer of Timolol Eye Drops (Betimol, Istalol, Timoptic)."^^xsd:string ;
          ctro:hasConflictInterest "Dr. Camras is a consultant to Pharmacia Ophthalmics, Uppsala, Sweden, and to Alcon Laboratories, Fort Worth, Texas. None of the authors has a proprietary interest in the development or marketing of any drug used in this study or in any competing drug."^^xsd:string ;
          ctro:hasSponsor "Supported by a grant from Pharmacia Pharmaceuticals, Uppsala, Sweden."^^xsd:string .


###  http://www.semanticweb.org/root/ontologies/2018/6/ctro#EQ_4
ctro:EQ_4 rdf:type owl:NamedIndividual ,
                   ctro:EvidenceQuality ;
          ctro:hasAuthorAffilations "1: Dep. of Ophthal., Univ. of Cologne; 2: Pharmacia & Upjohn AB, Clinical Research, Ophthal., Uppsala, SwedenSE"^^xsd:string ;
          ctro:hasBiasSponsor "One of the authors has as affiliation Pharmacia & Upjohn. Pharmacia & Upjohn is manufacturer of Latanoprost Ophthalmic (Xalatan)."^^xsd:string ;
          ctro:hasConflictInterest "The authors have no proprietary interest in the study drug"^^xsd:string ;
          ctro:hasSponsor "NA"^^xsd:string .


###  http://www.semanticweb.org/root/ontologies/2018/6/ctro#EQ_5
ctro:EQ_5 rdf:type owl:NamedIndividual ,
                   ctro:EvidenceQuality ;
          ctro:hasAuthorAffilations "1,2,3,4: Inst. of Ophthal. and Legal Medicine Univ. G. D'Annunzio, Chieti, Italy."^^xsd:string ;
          ctro:hasBiasSponsor "NA"^^xsd:string ;
          ctro:hasConflictInterest "The authors have no proprietary interest in the development or marketing of any product mentioned in the article."^^xsd:string ;
          ctro:hasSponsor "NA"^^xsd:string .


###  http://www.semanticweb.org/root/ontologies/2018/6/ctro#EQ_6
ctro:EQ_6 rdf:type owl:NamedIndividual ,
                   ctro:EvidenceQuality ;
          ctro:hasAuthorAffilations "1: Dep. of Ophthal. Hiroshima Univ.; 2: Tokyo Univ.; 3: Gifu University; 4:Osaka Medical College, Japan"^^xsd:string ;
          ctro:hasBiasSponsor "NA"^^xsd:string ;
          ctro:hasConflictInterest "In Affilation: The authors do not have any financial or proprietary interest in the products mentioned."^^xsd:string ;
          ctro:hasSponsor "NA"^^xsd:string .


###  http://www.semanticweb.org/root/ontologies/2018/6/ctro#EQ_7
ctro:EQ_7 rdf:type owl:NamedIndividual ,
                   ctro:EvidenceQuality ;
          ctro:hasAuthorAffilations "1,2: Glaucoma Center of the Univ. of Amsterdam; 3: Netherlands Ophthalmic Research Inst., the Netherlands"^^xsd:string ;
          ctro:hasBiasSponsor "NA"^^xsd:string ;
          ctro:hasConflictInterest "NA"^^xsd:string ;
          ctro:hasSponsor "NA"^^xsd:string .


###  http://www.semanticweb.org/root/ontologies/2018/6/ctro#EQ_8
ctro:EQ_8 rdf:type owl:NamedIndividual ,
                   ctro:EvidenceQuality ;
          ctro:hasAuthorAffilations "1: Addenbrooke's Hospital, Cambridge, England; 2: Pharmacia AB, Pharmaceuticals, Uppsala, Sweden"^^xsd:string ;
          ctro:hasBiasSponsor "One of the authors has as affiliation Pharmacia AB, Pharmaceuticals (Now Pharmacia & Upjohn). The study was supported by a grant from Pharmacia AB (Now Pharmacia & Upjohn), Uppsala, Sweden. Pharmacia & Upjohn is manufacturer of Latanoprost Ophthalmic (Xalatan)."^^xsd:string ;
          ctro:hasConflictInterest "None of the authors has any proprietary interest in the development or marketing of latanoprost."^^xsd:string ;
          ctro:hasSponsor "Supported by Pharmacia AB, Uppsala, Sweden."^^xsd:string .


###  http://www.semanticweb.org/root/ontologies/2018/6/ctro#EQ_9
ctro:EQ_9 rdf:type owl:NamedIndividual ,
                   ctro:EvidenceQuality ;
          ctro:hasAuthorAffilations "1,2,3: Dep. of Ophthal., Univ. of Cologne, Germany"^^xsd:string ;
          ctro:hasBiasSponsor "The coded doses and the ophthalmic solutions were kindly provided by Pharmacia (Now Pharmacia & Upjohn), Uppsala, Sweden. Pharmacia & Upjohn is manufacturer of Latanoprost Ophthalmic (Xalatan)."^^xsd:string ;
          ctro:hasConflictInterest "In Acknow.: The authors have no financial or proprietary interest in the study drugs."^^xsd:string ;
          ctro:hasSponsor "In Acknow.: The coded doses and the ophthalmic solutions were kindly provided by Pharmacia, Uppsala, Sweden."^^xsd:string .


###  http://www.semanticweb.org/root/ontologies/2018/6/ctro#ESIZE_CT2_A1_OC1
ctro:ESIZE_CT2_A1_OC1 rdf:type owl:NamedIndividual ,
                               ctro:EffectSize .


###  http://www.semanticweb.org/root/ontologies/2018/6/ctro#ESIZE_CT2_A2_OC1
ctro:ESIZE_CT2_A2_OC1 rdf:type owl:NamedIndividual ,
                               ctro:EffectSize .


###  http://www.semanticweb.org/root/ontologies/2018/6/ctro#EndPoint_CT10_A1_OC1
ctro:EndPoint_CT10_A1_OC1 rdf:type owl:NamedIndividual ,
                                   ctro:EndPoint ;
                          ctro:hasAggregationMethod ctro:Mean ;
                          ctro:hasEndpointDescription ctro:Diurnal_IOP ;
                          ctro:hasEndpointUnit ctro:mmHg ;
                          ctro:hasDesiredEffectDir "reduction"^^xsd:string .


###  http://www.semanticweb.org/root/ontologies/2018/6/ctro#EndPoint_CT10_A2_OC1
ctro:EndPoint_CT10_A2_OC1 rdf:type owl:NamedIndividual ,
                                   ctro:EndPoint ;
                          ctro:hasAggregationMethod ctro:Mean ;
                          ctro:hasEndpointDescription ctro:Diurnal_IOP ;
                          ctro:hasEndpointUnit ctro:mmHg ;
                          ctro:hasDesiredEffectDir "reduction"^^xsd:string .


###  http://www.semanticweb.org/root/ontologies/2018/6/ctro#EndPoint_CT11_A1_OC1
ctro:EndPoint_CT11_A1_OC1 rdf:type owl:NamedIndividual ,
                                   ctro:EndPoint ;
                          ctro:hasAggregationMethod ctro:Mean ;
                          ctro:hasEndpointDescription ctro:Diurnal_IOP ;
                          ctro:hasEndpointUnit ctro:mmHg ;
                          ctro:hasDesiredEffectDir "reduction"^^xsd:string .


###  http://www.semanticweb.org/root/ontologies/2018/6/ctro#EndPoint_CT11_A2_OC1
ctro:EndPoint_CT11_A2_OC1 rdf:type owl:NamedIndividual ,
                                   ctro:EndPoint ;
                          ctro:hasAggregationMethod ctro:Mean ;
                          ctro:hasEndpointDescription ctro:Diurnal_IOP ;
                          ctro:hasEndpointUnit ctro:mmHg ;
                          ctro:hasDesiredEffectDir "reduction"^^xsd:string .


###  http://www.semanticweb.org/root/ontologies/2018/6/ctro#EndPoint_CT1_A1_OC1
ctro:EndPoint_CT1_A1_OC1 rdf:type owl:NamedIndividual ,
                                  ctro:EndPoint ;
                         ctro:hasAggregationMethod ctro:Mean ;
                         ctro:hasEndpointDescription ctro:Diurnal_IOP ;
                         ctro:hasEndpointUnit ctro:mmHg ;
                         ctro:hasDesiredEffectDir "reduction"^^xsd:string .


###  http://www.semanticweb.org/root/ontologies/2018/6/ctro#EndPoint_CT1_A2_OC1
ctro:EndPoint_CT1_A2_OC1 rdf:type owl:NamedIndividual ,
                                  ctro:EndPoint ;
                         ctro:hasAggregationMethod ctro:Mean ;
                         ctro:hasEndpointDescription ctro:Diurnal_IOP ;
                         ctro:hasEndpointUnit ctro:mmHg ;
                         ctro:hasDesiredEffectDir "reduction"^^xsd:string .


###  http://www.semanticweb.org/root/ontologies/2018/6/ctro#EndPoint_CT1_A3_OC1
ctro:EndPoint_CT1_A3_OC1 rdf:type owl:NamedIndividual ,
                                  ctro:EndPoint ;
                         ctro:hasAggregationMethod ctro:Mean ;
                         ctro:hasEndpointDescription ctro:Diurnal_IOP ;
                         ctro:hasEndpointUnit ctro:mmHg ;
                         ctro:hasDesiredEffectDir "reduction"^^xsd:string .


###  http://www.semanticweb.org/root/ontologies/2018/6/ctro#EndPoint_CT21_A1_OC1
ctro:EndPoint_CT21_A1_OC1 rdf:type owl:NamedIndividual ,
                                   ctro:EndPoint ;
                          ctro:hasAggregationMethod ctro:Mean ;
                          ctro:hasEndpointDescription ctro:HbA1c ;
                          ctro:hasDesiredEffectDir "reduction"^^xsd:string .


###  http://www.semanticweb.org/root/ontologies/2018/6/ctro#EndPoint_CT21_A2_OC1
ctro:EndPoint_CT21_A2_OC1 rdf:type owl:NamedIndividual ,
                                   ctro:EndPoint ;
                          ctro:hasAggregationMethod ctro:Mean ;
                          ctro:hasEndpointDescription ctro:HbA1c ;
                          ctro:hasDesiredEffectDir "reduction"^^xsd:string .


###  http://www.semanticweb.org/root/ontologies/2018/6/ctro#EndPoint_CT22_A1_OC1
ctro:EndPoint_CT22_A1_OC1 rdf:type owl:NamedIndividual ,
                                   ctro:EndPoint ;
                          ctro:hasAggregationMethod ctro:Mean ;
                          ctro:hasEndpointDescription ctro:HbA1c ;
                          ctro:hasDesiredEffectDir "reduction"^^xsd:string .


###  http://www.semanticweb.org/root/ontologies/2018/6/ctro#EndPoint_CT22_A2_OC1
ctro:EndPoint_CT22_A2_OC1 rdf:type owl:NamedIndividual ,
                                   ctro:EndPoint ;
                          ctro:hasAggregationMethod ctro:Mean ;
                          ctro:hasEndpointDescription ctro:HbA1c ;
                          ctro:hasDesiredEffectDir "reduction"^^xsd:string .


###  http://www.semanticweb.org/root/ontologies/2018/6/ctro#EndPoint_CT23_A1_OC1
ctro:EndPoint_CT23_A1_OC1 rdf:type owl:NamedIndividual ,
                                   ctro:EndPoint ;
                          ctro:hasAggregationMethod ctro:Mean ;
                          ctro:hasEndpointDescription ctro:HbA1c ;
                          ctro:hasDesiredEffectDir "reduction"^^xsd:string .


###  http://www.semanticweb.org/root/ontologies/2018/6/ctro#EndPoint_CT23_A2_OC1
ctro:EndPoint_CT23_A2_OC1 rdf:type owl:NamedIndividual ,
                                   ctro:EndPoint ;
                          ctro:hasAggregationMethod ctro:Mean ;
                          ctro:hasEndpointDescription ctro:HbA1c ;
                          ctro:hasDesiredEffectDir "reduction"^^xsd:string .


###  http://www.semanticweb.org/root/ontologies/2018/6/ctro#EndPoint_CT24_A1_OC1
ctro:EndPoint_CT24_A1_OC1 rdf:type owl:NamedIndividual ,
                                   ctro:EndPoint ;
                          ctro:hasAggregationMethod ctro:Mean ;
                          ctro:hasEndpointDescription ctro:HbA1c ;
                          ctro:hasDesiredEffectDir "reduction"^^xsd:string .


###  http://www.semanticweb.org/root/ontologies/2018/6/ctro#EndPoint_CT24_A2_OC1
ctro:EndPoint_CT24_A2_OC1 rdf:type owl:NamedIndividual ,
                                   ctro:EndPoint ;
                          ctro:hasAggregationMethod ctro:Mean ;
                          ctro:hasEndpointDescription ctro:HbA1c ;
                          ctro:hasDesiredEffectDir "reduction"^^xsd:string .


###  http://www.semanticweb.org/root/ontologies/2018/6/ctro#EndPoint_CT25_A1_OC1
ctro:EndPoint_CT25_A1_OC1 rdf:type owl:NamedIndividual ,
                                   ctro:EndPoint ;
                          ctro:hasAggregationMethod ctro:Mean ;
                          ctro:hasEndpointDescription ctro:HbA1c ;
                          ctro:hasDesiredEffectDir "reduction"^^xsd:string .


###  http://www.semanticweb.org/root/ontologies/2018/6/ctro#EndPoint_CT25_A2_OC1
ctro:EndPoint_CT25_A2_OC1 rdf:type owl:NamedIndividual ,
                                   ctro:EndPoint ;
                          ctro:hasAggregationMethod ctro:Mean ;
                          ctro:hasEndpointDescription ctro:HbA1c ;
                          ctro:hasDesiredEffectDir "reduction"^^xsd:string .


###  http://www.semanticweb.org/root/ontologies/2018/6/ctro#EndPoint_CT26_A1_OC1
ctro:EndPoint_CT26_A1_OC1 rdf:type owl:NamedIndividual ,
                                   ctro:EndPoint ;
                          ctro:hasAggregationMethod ctro:Mean ;
                          ctro:hasEndpointDescription ctro:HbA1c ;
                          ctro:hasDesiredEffectDir "reduction"^^xsd:string .


###  http://www.semanticweb.org/root/ontologies/2018/6/ctro#EndPoint_CT26_A2_OC1
ctro:EndPoint_CT26_A2_OC1 rdf:type owl:NamedIndividual ,
                                   ctro:EndPoint ;
                          ctro:hasAggregationMethod ctro:Mean ;
                          ctro:hasEndpointDescription ctro:HbA1c ;
                          ctro:hasDesiredEffectDir "reduction"^^xsd:string .


###  http://www.semanticweb.org/root/ontologies/2018/6/ctro#EndPoint_CT27_A1_OC1
ctro:EndPoint_CT27_A1_OC1 rdf:type owl:NamedIndividual ,
                                   ctro:EndPoint ;
                          ctro:hasAggregationMethod ctro:Mean ;
                          ctro:hasEndpointDescription ctro:HbA1c ;
                          ctro:hasDesiredEffectDir "reduction"^^xsd:string .


###  http://www.semanticweb.org/root/ontologies/2018/6/ctro#EndPoint_CT27_A2_OC1
ctro:EndPoint_CT27_A2_OC1 rdf:type owl:NamedIndividual ,
                                   ctro:EndPoint ;
                          ctro:hasAggregationMethod ctro:Mean ;
                          ctro:hasEndpointDescription ctro:HbA1c ;
                          ctro:hasDesiredEffectDir "reduction"^^xsd:string .


###  http://www.semanticweb.org/root/ontologies/2018/6/ctro#EndPoint_CT28_A1_OC1
ctro:EndPoint_CT28_A1_OC1 rdf:type owl:NamedIndividual ,
                                   ctro:EndPoint ;
                          ctro:hasAggregationMethod ctro:Mean ;
                          ctro:hasEndpointDescription ctro:HbA1c ;
                          ctro:hasDesiredEffectDir "reduction"^^xsd:string .


###  http://www.semanticweb.org/root/ontologies/2018/6/ctro#EndPoint_CT28_A2_OC1
ctro:EndPoint_CT28_A2_OC1 rdf:type owl:NamedIndividual ,
                                   ctro:EndPoint ;
                          ctro:hasAggregationMethod ctro:Mean ;
                          ctro:hasEndpointDescription ctro:HbA1c ;
                          ctro:hasDesiredEffectDir "reduction"^^xsd:string .


###  http://www.semanticweb.org/root/ontologies/2018/6/ctro#EndPoint_CT29_A1_OC1
ctro:EndPoint_CT29_A1_OC1 rdf:type owl:NamedIndividual ,
                                   ctro:EndPoint ;
                          ctro:hasAggregationMethod ctro:Mean ;
                          ctro:hasEndpointDescription ctro:HbA1c ;
                          ctro:hasDesiredEffectDir "reduction"^^xsd:string .


###  http://www.semanticweb.org/root/ontologies/2018/6/ctro#EndPoint_CT29_A2_OC1
ctro:EndPoint_CT29_A2_OC1 rdf:type owl:NamedIndividual ,
                                   ctro:EndPoint ;
                          ctro:hasAggregationMethod ctro:Mean ;
                          ctro:hasEndpointDescription ctro:HbA1c ;
                          ctro:hasDesiredEffectDir "reduction"^^xsd:string .


###  http://www.semanticweb.org/root/ontologies/2018/6/ctro#EndPoint_CT2_A1_OC1
ctro:EndPoint_CT2_A1_OC1 rdf:type owl:NamedIndividual ,
                                  ctro:EndPoint ;
                         ctro:hasAggregationMethod ctro:Mean ;
                         ctro:hasEndpointDescription ctro:Diurnal_IOP ;
                         ctro:hasEndpointUnit ctro:mmHg ;
                         ctro:hasDesiredEffectDir "reduction"^^xsd:string .


###  http://www.semanticweb.org/root/ontologies/2018/6/ctro#EndPoint_CT2_A2_OC1
ctro:EndPoint_CT2_A2_OC1 rdf:type owl:NamedIndividual ,
                                  ctro:EndPoint ;
                         ctro:hasAggregationMethod ctro:Mean ;
                         ctro:hasEndpointDescription ctro:Diurnal_IOP ;
                         ctro:hasEndpointUnit ctro:mmHg ;
                         ctro:hasDesiredEffectDir "reduction"^^xsd:string .


###  http://www.semanticweb.org/root/ontologies/2018/6/ctro#EndPoint_CT3_A1_OC1
ctro:EndPoint_CT3_A1_OC1 rdf:type owl:NamedIndividual ,
                                  ctro:EndPoint ;
                         ctro:hasAggregationMethod ctro:Mean ;
                         ctro:hasEndpointDescription ctro:Diurnal_IOP ;
                         ctro:hasEndpointUnit ctro:mmHg ;
                         ctro:hasDesiredEffectDir "reduction"^^xsd:string .


###  http://www.semanticweb.org/root/ontologies/2018/6/ctro#EndPoint_CT3_A2_OC1
ctro:EndPoint_CT3_A2_OC1 rdf:type owl:NamedIndividual ,
                                  ctro:EndPoint ;
                         ctro:hasAggregationMethod ctro:Mean ;
                         ctro:hasEndpointDescription ctro:Diurnal_IOP ;
                         ctro:hasEndpointUnit ctro:mmHg ;
                         ctro:hasDesiredEffectDir "reduction"^^xsd:string .


###  http://www.semanticweb.org/root/ontologies/2018/6/ctro#EndPoint_CT4_A1_OC1
ctro:EndPoint_CT4_A1_OC1 rdf:type owl:NamedIndividual ,
                                  ctro:EndPoint ;
                         ctro:hasAggregationMethod ctro:Mean ;
                         ctro:hasEndpointDescription ctro:Diurnal_IOP ;
                         ctro:hasEndpointUnit ctro:mmHg ;
                         ctro:hasDesiredEffectDir "reduction"^^xsd:string .


###  http://www.semanticweb.org/root/ontologies/2018/6/ctro#EndPoint_CT4_A2_OC1
ctro:EndPoint_CT4_A2_OC1 rdf:type owl:NamedIndividual ,
                                  ctro:EndPoint ;
                         ctro:hasAggregationMethod ctro:Mean ;
                         ctro:hasEndpointDescription ctro:Diurnal_IOP ;
                         ctro:hasEndpointUnit ctro:mmHg ;
                         ctro:hasDesiredEffectDir "reduction"^^xsd:string .


###  http://www.semanticweb.org/root/ontologies/2018/6/ctro#EndPoint_CT4_A3_OC1
ctro:EndPoint_CT4_A3_OC1 rdf:type owl:NamedIndividual ,
                                  ctro:EndPoint ;
                         ctro:hasAggregationMethod ctro:Mean ;
                         ctro:hasEndpointDescription ctro:Diurnal_IOP ;
                         ctro:hasEndpointUnit ctro:mmHg ;
                         ctro:hasDesiredEffectDir "reduction"^^xsd:string .


###  http://www.semanticweb.org/root/ontologies/2018/6/ctro#EndPoint_CT4_A4_OC1
ctro:EndPoint_CT4_A4_OC1 rdf:type owl:NamedIndividual ,
                                  ctro:EndPoint ;
                         ctro:hasAggregationMethod ctro:Mean ;
                         ctro:hasEndpointDescription ctro:Diurnal_IOP ;
                         ctro:hasEndpointUnit ctro:mmHg ;
                         ctro:hasDesiredEffectDir "reduction"^^xsd:string .


###  http://www.semanticweb.org/root/ontologies/2018/6/ctro#EndPoint_CT5_A1_OC1
ctro:EndPoint_CT5_A1_OC1 rdf:type owl:NamedIndividual ,
                                  ctro:EndPoint ;
                         ctro:hasAggregationMethod ctro:Mean ;
                         ctro:hasEndpointDescription ctro:Diurnal_IOP ;
                         ctro:hasEndpointUnit ctro:mmHg ;
                         ctro:hasDesiredEffectDir "reduction"^^xsd:string .


###  http://www.semanticweb.org/root/ontologies/2018/6/ctro#EndPoint_CT5_A2_OC1
ctro:EndPoint_CT5_A2_OC1 rdf:type owl:NamedIndividual ,
                                  ctro:EndPoint ;
                         ctro:hasAggregationMethod ctro:Mean ;
                         ctro:hasEndpointDescription ctro:Diurnal_IOP ;
                         ctro:hasEndpointUnit ctro:mmHg ;
                         ctro:hasDesiredEffectDir "reduction"^^xsd:string .


###  http://www.semanticweb.org/root/ontologies/2018/6/ctro#EndPoint_CT6_A1_OC1
ctro:EndPoint_CT6_A1_OC1 rdf:type owl:NamedIndividual ,
                                  ctro:EndPoint ;
                         ctro:hasAggregationMethod ctro:Mean ;
                         ctro:hasEndpointDescription ctro:Diurnal_IOP ;
                         ctro:hasEndpointUnit ctro:mmHg ;
                         ctro:hasDesiredEffectDir "reduction"^^xsd:string .


###  http://www.semanticweb.org/root/ontologies/2018/6/ctro#EndPoint_CT6_A2_OC1
ctro:EndPoint_CT6_A2_OC1 rdf:type owl:NamedIndividual ,
                                  ctro:EndPoint ;
                         ctro:hasAggregationMethod ctro:Mean ;
                         ctro:hasEndpointDescription ctro:Diurnal_IOP ;
                         ctro:hasEndpointUnit ctro:mmHg ;
                         ctro:hasDesiredEffectDir "reduction"^^xsd:string .


###  http://www.semanticweb.org/root/ontologies/2018/6/ctro#EndPoint_CT7_A1_OC1
ctro:EndPoint_CT7_A1_OC1 rdf:type owl:NamedIndividual ,
                                  ctro:EndPoint ;
                         ctro:hasAggregationMethod ctro:Mean ;
                         ctro:hasEndpointDescription ctro:Diurnal_IOP ;
                         ctro:hasEndpointUnit ctro:mmHg ;
                         ctro:hasDesiredEffectDir "reduction"^^xsd:string .


###  http://www.semanticweb.org/root/ontologies/2018/6/ctro#EndPoint_CT7_A2_OC1
ctro:EndPoint_CT7_A2_OC1 rdf:type owl:NamedIndividual ,
                                  ctro:EndPoint ;
                         ctro:hasAggregationMethod ctro:Mean ;
                         ctro:hasEndpointDescription ctro:Diurnal_IOP ;
                         ctro:hasEndpointUnit ctro:mmHg ;
                         ctro:hasDesiredEffectDir "reduction"^^xsd:string .


###  http://www.semanticweb.org/root/ontologies/2018/6/ctro#EndPoint_CT8_A1_OC1
ctro:EndPoint_CT8_A1_OC1 rdf:type owl:NamedIndividual ,
                                  ctro:EndPoint ;
                         ctro:hasAggregationMethod ctro:Mean ;
                         ctro:hasEndpointDescription ctro:Diurnal_IOP ;
                         ctro:hasEndpointUnit ctro:mmHg ;
                         ctro:hasDesiredEffectDir "reduction"^^xsd:string .


###  http://www.semanticweb.org/root/ontologies/2018/6/ctro#EndPoint_CT8_A2_OC1
ctro:EndPoint_CT8_A2_OC1 rdf:type owl:NamedIndividual ,
                                  ctro:EndPoint ;
                         ctro:hasAggregationMethod ctro:Mean ;
                         ctro:hasEndpointDescription ctro:Diurnal_IOP ;
                         ctro:hasEndpointUnit ctro:mmHg ;
                         ctro:hasDesiredEffectDir "reduction"^^xsd:string .


###  http://www.semanticweb.org/root/ontologies/2018/6/ctro#EndPoint_CT9_A1_OC1
ctro:EndPoint_CT9_A1_OC1 rdf:type owl:NamedIndividual ,
                                  ctro:EndPoint ;
                         ctro:hasAggregationMethod ctro:Mean ;
                         ctro:hasEndpointDescription ctro:Diurnal_IOP ;
                         ctro:hasEndpointUnit ctro:mmHg ;
                         ctro:hasDesiredEffectDir "reduction"^^xsd:string .


###  http://www.semanticweb.org/root/ontologies/2018/6/ctro#EndPoint_CT9_A2_OC1
ctro:EndPoint_CT9_A2_OC1 rdf:type owl:NamedIndividual ,
                                  ctro:EndPoint ;
                         ctro:hasAggregationMethod ctro:Mean ;
                         ctro:hasEndpointDescription ctro:Diurnal_IOP ;
                         ctro:hasEndpointUnit ctro:mmHg ;
                         ctro:hasDesiredEffectDir "reduction"^^xsd:string .


###  http://www.semanticweb.org/root/ontologies/2018/6/ctro#Europe
ctro:Europe rdf:type owl:NamedIndividual ,
                     <http://www.bpiresearch.com/BPMO/2004/03/03/cdl/Countries#Country> ;
            rdfs:label "Europe" .


###  http://www.semanticweb.org/root/ontologies/2018/6/ctro#Europe-SouthAfrica
ctro:Europe-SouthAfrica rdf:type owl:NamedIndividual ,
                                 <http://www.bpiresearch.com/BPMO/2004/03/03/cdl/Countries#Country> ;
                        rdfs:label "Europe-SouthAfrica" .


###  http://www.semanticweb.org/root/ontologies/2018/6/ctro#Eyedrops
ctro:Eyedrops rdf:type owl:NamedIndividual ,
                       ctro:DeliveryMethod .


###  http://www.semanticweb.org/root/ontologies/2018/6/ctro#FinalValue
ctro:FinalValue rdf:type owl:NamedIndividual ,
                         ctro:AnalysisMetric .


###  http://www.semanticweb.org/root/ontologies/2018/6/ctro#Finland
ctro:Finland rdf:type owl:NamedIndividual ,
                      <http://www.bpiresearch.com/BPMO/2004/03/03/cdl/Countries#Country> ;
             rdfs:label "Finland" .


###  http://www.semanticweb.org/root/ontologies/2018/6/ctro#Germany
ctro:Germany rdf:type owl:NamedIndividual ,
                      <http://www.bpiresearch.com/BPMO/2004/03/03/cdl/Countries#Country> ;
             rdfs:label "Germany" .


###  http://www.semanticweb.org/root/ontologies/2018/6/ctro#Glargine_Insulin
ctro:Glargine_Insulin rdf:type owl:NamedIndividual ,
                               ctro:Drug ;
                      rdfs:label "Insulin Glargine" .


###  http://www.semanticweb.org/root/ontologies/2018/6/ctro#Glaucoma
ctro:Glaucoma rdf:type owl:NamedIndividual ,
                       ctro:DisorderOrSyndrome ;
              ctro:hasSNOMED_id "C0017601" .


###  http://www.semanticweb.org/root/ontologies/2018/6/ctro#HbA1c
ctro:HbA1c rdf:type owl:NamedIndividual ,
                    ctro:EndpointDescription ;
           rdfs:label "HbA1c" .


###  http://www.semanticweb.org/root/ontologies/2018/6/ctro#Holland
ctro:Holland rdf:type owl:NamedIndividual ,
                      <http://www.bpiresearch.com/BPMO/2004/03/03/cdl/Countries#Country> ;
             rdfs:label "Holland" .


###  http://www.semanticweb.org/root/ontologies/2018/6/ctro#IU
ctro:IU rdf:type owl:NamedIndividual ,
                 ctro:Concentration ;
        rdfs:label "IU" .


###  http://www.semanticweb.org/root/ontologies/2018/6/ctro#IncreasedAqueousHumorProtein
ctro:IncreasedAqueousHumorProtein rdf:type owl:NamedIndividual ,
                                           ctro:AdverseEffectName .


###  http://www.semanticweb.org/root/ontologies/2018/6/ctro#IncreasedPigmentation
ctro:IncreasedPigmentation rdf:type owl:NamedIndividual ,
                                    ctro:AdverseEffectName .


###  http://www.semanticweb.org/root/ontologies/2018/6/ctro#Increment
ctro:Increment rdf:type owl:NamedIndividual ,
                        ctro:DesiredEffectDirection .


###  http://www.semanticweb.org/root/ontologies/2018/6/ctro#IntentionToTreat
ctro:IntentionToTreat rdf:type owl:NamedIndividual ,
                               ctro:CTAnalysisApproach .


###  http://www.semanticweb.org/root/ontologies/2018/6/ctro#IrisPigmentationChange
ctro:IrisPigmentationChange rdf:type owl:NamedIndividual ,
                                     ctro:AdverseEffectName .


###  http://www.semanticweb.org/root/ontologies/2018/6/ctro#Italy
ctro:Italy rdf:type owl:NamedIndividual ,
                    <http://www.bpiresearch.com/BPMO/2004/03/03/cdl/Countries#Country> ;
           rdfs:label "Italy" .


###  http://www.semanticweb.org/root/ontologies/2018/6/ctro#Japan
ctro:Japan rdf:type owl:NamedIndividual ,
                    <http://www.bpiresearch.com/BPMO/2004/03/03/cdl/Countries#Country> ;
           rdfs:label "Japan" .


###  http://www.semanticweb.org/root/ontologies/2018/6/ctro#Latanoprost
ctro:Latanoprost rdf:type owl:NamedIndividual ,
                          ctro:Drug ;
                 rdfs:label "Latanoprost" .


###  http://www.semanticweb.org/root/ontologies/2018/6/ctro#LatinAmerica
ctro:LatinAmerica rdf:type owl:NamedIndividual ,
                           <http://www.bpiresearch.com/BPMO/2004/03/03/cdl/Countries#Country> ;
                  rdfs:label "LatinAmerica" .


###  http://www.semanticweb.org/root/ontologies/2018/6/ctro#Mean
ctro:Mean rdf:type owl:NamedIndividual ,
                   ctro:AgreggationMethod .


###  http://www.semanticweb.org/root/ontologies/2018/6/ctro#Minute
ctro:Minute rdf:type owl:NamedIndividual ,
                     ctro:TimeUnit .


###  http://www.semanticweb.org/root/ontologies/2018/6/ctro#Month
ctro:Month rdf:type owl:NamedIndividual ,
                    ctro:TimeUnit .


###  http://www.semanticweb.org/root/ontologies/2018/6/ctro#Multicenter
ctro:Multicenter rdf:type owl:NamedIndividual ,
                          ctro:CTDesign ;
                 rdfs:label "Multicenter" .


###  http://www.semanticweb.org/root/ontologies/2018/6/ctro#Multinational
ctro:Multinational rdf:type owl:NamedIndividual ,
                            <http://www.bpiresearch.com/BPMO/2004/03/03/cdl/Countries#Country> ;
                   rdfs:label "Multinational" .


###  http://www.semanticweb.org/root/ontologies/2018/6/ctro#NA
ctro:NA rdf:type owl:NamedIndividual ,
                 ctro:Other ;
        rdfs:label "NA" .


###  http://www.semanticweb.org/root/ontologies/2018/6/ctro#NPH_Insulin
ctro:NPH_Insulin rdf:type owl:NamedIndividual ,
                          ctro:Drug ;
                 rdfs:label "Insulin NPH" .


###  http://www.semanticweb.org/root/ontologies/2018/6/ctro#NoChange
ctro:NoChange rdf:type owl:NamedIndividual ,
                       ctro:DesiredEffectDirection .


###  http://www.semanticweb.org/root/ontologies/2018/6/ctro#Nocturnal_hypoglycemia
ctro:Nocturnal_hypoglycemia rdf:type owl:NamedIndividual ,
                                     ctro:AdverseEffectName ;
                            rdfs:label "Nocturnal_hypoglycemia" .


###  http://www.semanticweb.org/root/ontologies/2018/6/ctro#NorthAmerica
ctro:NorthAmerica rdf:type owl:NamedIndividual ,
                           <http://www.bpiresearch.com/BPMO/2004/03/03/cdl/Countries#Country> ;
                  rdfs:label "NorthAmerica" .


###  http://www.semanticweb.org/root/ontologies/2018/6/ctro#OcularHypertension
ctro:OcularHypertension rdf:type owl:NamedIndividual ,
                                 ctro:DisorderOrSyndrome ;
                        ctro:hasSNOMED_id "C0028840" .


###  http://www.semanticweb.org/root/ontologies/2018/6/ctro#OpenAngleGlaucoma
ctro:OpenAngleGlaucoma rdf:type owl:NamedIndividual ,
                                ctro:DisorderOrSyndrome ;
                       ctro:hasSNOMED_id "C0017612" .


###  http://www.semanticweb.org/root/ontologies/2018/6/ctro#OpenLabel
ctro:OpenLabel rdf:type owl:NamedIndividual ,
                        ctro:CTDesign ;
               rdfs:label "Open-Label"^^xsd:string .


###  http://www.semanticweb.org/root/ontologies/2018/6/ctro#Parallel
ctro:Parallel rdf:type owl:NamedIndividual ,
                       ctro:CTDesign ;
              rdfs:label "Parallel-Group" .


###  http://www.semanticweb.org/root/ontologies/2018/6/ctro#Percentage
ctro:Percentage rdf:type owl:NamedIndividual ,
                         ctro:Concentration ;
                rdfs:label "%" .


###  http://www.semanticweb.org/root/ontologies/2018/6/ctro#Philippines
ctro:Philippines rdf:type owl:NamedIndividual ,
                          <http://www.bpiresearch.com/BPMO/2004/03/03/cdl/Countries#Country> ;
                 rdfs:label "Philippines" .


###  http://www.semanticweb.org/root/ontologies/2018/6/ctro#PigmentaryGlaucoma
ctro:PigmentaryGlaucoma rdf:type owl:NamedIndividual ,
                                 ctro:DisorderOrSyndrome ;
                        ctro:hasSNOMED_id "C0017612" .


###  http://www.semanticweb.org/root/ontologies/2018/6/ctro#Placebo
ctro:Placebo rdf:type owl:NamedIndividual ,
                      ctro:Drug ;
             rdfs:label "Placebo" .


###  http://www.semanticweb.org/root/ontologies/2018/6/ctro#PreProtocol
ctro:PreProtocol rdf:type owl:NamedIndividual ,
                          ctro:CTAnalysisApproach .


###  http://www.semanticweb.org/root/ontologies/2018/6/ctro#Pub_1
ctro:Pub_1 rdf:type owl:NamedIndividual ,
                    ctro:Publication ;
           ctro:describes ctro:CT_1 ;
           ctro:hasAbstract "PURPOSE: To compare the effect on intraocular pressure (IOP) and side effects of 0.005% latanoprost applied once daily, morning or evening, with 0.5% timolol applied twice daily. METHODS: A 6-month randomized, double-masked, multicenter study with three parallel groups was undertaken. Two hundred sixty-seven patients were randomized, 84 to timolol, 89 to latanoprost in the morning for 3 months and then in the evening for another 3 months, and 94 to latanoprost with the treatment schedule reversed. RESULTS: After 6 months, timolol reduced diurnal IOP from 24.6 to 17.9 mmHg (27%); latanoprost applied in the morning, from 25.5 to 17.7 mmHg (31%); and latanoprost applied in the evening, from 24.8 to 16.2 mmHg (35%). The efficacy of latanoprost applied in the evening was statistically superior to latanoprost applied in the morning and to timolol (P < 0.001). Latanoprost induced a slight increase in conjunctival hyperemia in 31.4% of treated patients, compared with 15.9% for timolol. Sporadic episodes of mild punctate corneal epithelial erosions were three times as frequent in latanoprost-treated eyes as in timolol-treated eyes. The most significant ocular side effect was increased pigmentation of the iris observed in five and suspected in seven more latanoprost-treated eyes. All these eyes had a mixed green-brown or blue/gray-brown iris color. Timolol reduced heart rate by 3 beats/minute (P < 0.005). CONCLUSIONS: The effect on diurnal IOP of latanoprost applied once daily in the evening is superior to that of timolol. The main difference in side effects is increased pigmentation of the iris induced by latanoprost, most likely due to stimulation of melanogenesis in iris stromal melanocytes."^^xsd:string ;
           ctro:hasAuthor "Alm A"^^xsd:string ,
                          "Stjernschantz J."^^xsd:string ;
           ctro:hasJournal "Ophthalmology"^^xsd:string ;
           ctro:hasPMID 9098273 ;
           ctro:hasPublicationYear 1995 ;
           ctro:hasTitle "Effects on intraocular pressure and side effects of 0.005% latanoprost applied once daily, evening or morning. A comparison with timolol. Scandinavian Latanoprost Study Group"^^xsd:string ;
           rdfs:label "Alm A, Stjernschantz J"^^xsd:string .


###  http://www.semanticweb.org/root/ontologies/2018/6/ctro#Pub_10
ctro:Pub_10 rdf:type owl:NamedIndividual ,
                     ctro:Publication ;
            ctro:describes ctro:CT_10 ;
            ctro:hasAbstract "PURPOSE: To examine the effects of topical timolol and latanoprost on retrobulbar vessel blood velocity in patients with glaucoma or ocular hypertension. METHODS: Nine patients with primary open-angle glaucoma and six patients with ocular hypertension were enrolled for this study. All patients were treated topically with 0.5% timolol or 0.005% latanoprost, using a double-masked crossover design with a 3-week washout before administration of each drug. Each patient had a baseline color Doppler imaging ultrasound of the central retinal artery, short posterior ciliary arteries, and ophthalmic artery and two other ultrasound examinations during the 1-week treatment with each drug, performed 12  hours after the first dose of the drug and 12 hours after the last dose, 7 days later. RESULTS: Both topical timolol and topical latanoprost significantly reduced the intraocular pressure. The only significant change observed in the retrobulbar blood velocity with timolol was a reduction of end diastolic velocity in the ophthalmic artery 12 hours after the first dose, accompanied by a trend toward a  decrease in the peak systolic velocity and an increase in the resistance index in the same vessel. No change in blood velocity was observed with latanoprost. CONCLUSION: Topical timolol and latanoprost significantly reduced the intraocular pressure in ocular hypertensive and glaucoma patients without creating substantial hemodynamic changes in the retrobulbar vessels."^^xsd:string ;
            ctro:hasAuthor "Nicolela MT"^^xsd:string ;
            ctro:hasJournal "American Journal Ophthalmology"^^xsd:string ;
            ctro:hasPMID 8956632 ;
            ctro:hasPublicationYear 1996 ;
            ctro:hasTitle "A comparative study of the effects of timolol and latanoprost on blood flow velocity of the retrobulbar vessels."^^xsd:string ;
            rdfs:label "Nicolela MT, Buckley AR, Walman BE, Drance SM"^^xsd:string .


###  http://www.semanticweb.org/root/ontologies/2018/6/ctro#Pub_11
ctro:Pub_11 rdf:type owl:NamedIndividual ,
                     ctro:Publication ;
            ctro:describes ctro:CT_11 ;
            ctro:hasAbstract "PURPOSE: To compare the calculated mean ocular perfusion pressure at the end of 3 weeks' treatment with latanoprost 0.005% once daily or timolol 0.5% twice daily in normal-tension glaucoma patients. METHODS: In a three-center, double-masked, randomized, crossover study, 36 patients were allocated to two treatment groups; one received 3 weeks each of placebo, latanoprost, placebo, and timolol, whereas the other group had placebo,  timolol, placebo, and latanoprost. Intraocular pressure and resting systemic blood pressure were measured at 9 AM, 12 noon, and 4 PM. Ocular perfusion pressure was calculated for each time period as well as the mean of three values  (daytime average). Systemic blood pressure and heart rate were also recorded at 30-minute intervals during the last 24 hours of each treatment period. RESULTS: The average daytime mean ocular perfusion pressure (mean +/- SEM) following latanoprost treatment was 53.2 +/- 1.4 mm Hg, an increase of 8% from the latanoprost run-in period, compared with 50.9 +/- 1.1 mm Hg following timolol treatment, an increase of 2% from the timolol run-in period (P < .05, ANOVA). Timolol reduced the blood pressure. The difference in mean daytime and nighttime  systolic blood pressure measurements as well as nighttime diastolic blood pressure was about 5 mm Hg between the latanoprost and timolol treatments. The daytime and nighttime heart rates were also slower during the timolol treatment. CONCLUSION: Because ocular perfusion pressure may be important in some glaucomatous patients, latanoprost appears to affect ocular perfusion pressure more favorably than timolol does in patients with normal-tension glaucoma."^^xsd:string ;
            ctro:hasAuthor "Drance SM"^^xsd:string ;
            ctro:hasJournal "American Journal Ophthalmology"^^xsd:string ;
            ctro:hasPMID 9625541 ;
            ctro:hasPublicationYear 1998 ;
            ctro:hasTitle "Comparison of the effect of latanoprost 0.005% and timolol 0.5% on the calculated ocular perfusion pressure in patients with normal-tension glaucoma."^^xsd:string ;
            rdfs:label "Drance SM, Crichton A, Mills RP"^^xsd:string .


###  http://www.semanticweb.org/root/ontologies/2018/6/ctro#Pub_2
ctro:Pub_2 rdf:type owl:NamedIndividual ,
                    ctro:Publication ;
           ctro:describes ctro:CT_2 ;
           ctro:hasAbstract "The objective of this study was to compare the effect on intraocular pressure (IOP) of latanoprost 0.005% once daily with timolol 0.5% twice daily in patients with open angle glaucoma or ocular hypertension. The study was designed as a single-centre, randomised, double-masked parallel-group comparison of latanoprost with timolol after 12 weeks of treatment. 60 patients with open angle glaucoma or ocular hypertension with IOP of at least 22 mm Hg were included. Administration of previous ocular hypotensive medication necessitated a wash-out period of 5 to 21 days before the start of the study treatment. The patients were randomised to treatment with latanoprost 0.005% once daily or timolol 0.5% twice daily. Mean diurnal IOP was measured at baseline and after 6 and 12 weeks of treatment. After 6 weeks of treatment, the diurnal IOP reduction (mean± standard error of the mean [SEM]) in the latanoprost group was 12.1±1.1 mm Hg (41%;p<0.001; analysis of covariance [ANCOVA]) and 8.7 ± 1.1 mm Hg (30%; p < 0.001; ANCOVA) in the timolol group. The difference of 3.4 ± 1.6 mm Hg was statistically significant in favour of latanoprost (p = 0.034; ANCOVA). A 30% reduction or more in mean diurnal IOP was achieved by 71 % of patients in the latanoprost group and by 34% of patients in the timolol group. After 12 weeks of treatment, the diurnal IOP reduction (mean± SEM) in the latanoprost group was 11.1±1.2 mm Hg (39%; p < 0.001; ANCOVA) and 9.1 ± 1.1 mm Hg (32%; p < 0.001; ANCOVA) in the timolol group. Most side effects observed were mild and transient and no serious adverse events were reported. Latanoprost 0.005% administered once daily in the evening was at least as effective as timolol 0.5% twice daily in reducing the mean diurnal IOP after 6 and 12 weeks of treatment. Both medications were well tolerated during the study period."^^xsd:string ;
           ctro:hasAuthor "Aquino MV"^^xsd:string ,
                          "Lat-Luna M"^^xsd:string ;
           ctro:hasJournal " Asian Journal of Ophthalmology"^^xsd:string ;
           ctro:hasPMID "https://www.asianjo.com/index.php/AsianJO/article/view/295"^^rdfs:Literal ;
           ctro:hasPublicationYear 1999 ;
           ctro:hasTitle "The effect of latanoprost vs timolol on intraocular pressure in patients with glaucoma and ocular hypertension"^^xsd:string ;
           rdfs:label "Aquino MV, Lat-Luna M"^^xsd:string .


###  http://www.semanticweb.org/root/ontologies/2018/6/ctro#Pub_21
ctro:Pub_21 rdf:type owl:NamedIndividual ,
                     ctro:Publication ;
            ctro:describes ctro:CT_21 ;
            ctro:hasAbstract "AIMS: We compared basal regimens of glargine or NPH among insulin-naïve, U.S. inner city, ethnic minority type 2 diabetic patients who were sub-optimally controlled on maximally tolerated doses of combination oral agents.  METHODS: Eighty-five subjects were randomized to 26 weeks of open-label, add-on therapy using single doses of bedtime NPH, bedtime glargine, or morning glargine; initially through an 8-week dose titration phase, followed by a 16-week maintenance phase during which insulin doses were adjusted only to avoid symptomatic hypoglycemia.  RESULTS: All three groups were comparable at baseline (mean HbA(1c) 9.3 ± 1.4%), and improved their HbA(1c) (to 7.8 ± 1.3%), fasting, and pre-supper glucose readings, with no significant between-group differences. Weight gain was greater with either glargine regimen (+3.1 ± 4.1 kg and +1.7 ± 4.2 kg) compared to NPH (-0.2 ± 3.9 kg), despite comparable total insulin doses. Pre-supper hypoglycemia occurred more frequently with morning glargine, but nocturnal hypoglycemia and improvements in treatment satisfaction did not differ among groups.  CONCLUSIONS: Among inner city ethnic minority type 2 diabetic patients in the U.S., we found no differences in basal glycemic control or nocturnal hypoglycemia between glargine and NPH, although glargine precipitated greater weight gain."^^xsd:string ;
            ctro:hasAuthor "Hsia, SH"^^xsd:string ;
            ctro:hasPMID 21146881 ;
            ctro:hasPublicationYear 2011 ;
            ctro:hasTitle "Insulin glargine compared to NPH among insulin-naıve, U.S. inner city, ethnic minority type 2 diabetic patient."^^xsd:string ;
            rdfs:label "Hsia, SH"^^xsd:string .


###  http://www.semanticweb.org/root/ontologies/2018/6/ctro#Pub_22
ctro:Pub_22 rdf:type owl:NamedIndividual ,
                     ctro:Publication ;
            ctro:describes ctro:CT_22 ;
            ctro:hasAbstract "AIM: Postprandial release of intact proinsulin (IP) is an independent marker for beta-cell dysfunction in patients with type 2 diabetes. This open-label, parallel-group, two-arm, pilot study compared the beta-cell protective effect of adding insulin glargine (GLA) vs. NPH insulin to ongoing metformin.  MATERIAL AND METHODS: Overall, 28 insulin-naive type 2 diabetes subjects (mean +/- SD age, 61.5 +/- 6.7 years; diabetes duration, 9.8 +/- 6.5 years; HbA1c, 7.1 +/- 0.5%; BMI, 30.7 +/- 4.3 kg/m(2)) treated with metformin and sulfonylurea were randomized to add once-daily GLA or NPH at bedtime. At baseline and after 3 months, subjects received a standardized breakfast, lunch and dinner, with pre- and postprandial blood sampling to measure plasma IP, total insulin and blood glucose (BG).  RESULTS: Insulin dose after 3 months was comparable in both groups (GLA vs. NPH: 23.6 +/- 13.4 vs. 23.3 +/- 12.7; p = NS ). Both treatments significantly reduced fasting BG levels (GLA: 158 +/- 19 to 121 +/- 23 mg/dl; NPH: 156 +/- 34 to 119 +/- 29 mg/dl; both p < 0.01 vs. baseline). Fasting and postprandial BG levels did not differ between groups. IP levels decreased in both groups (p < 0.05 at all timepoints). Although IP release after breakfast did not differ between treatments, GLA induced a greater reduction in IP release after lunch (p = 0.08) and dinner (p = 0.04). Total plasma insulin levels did not differ between groups.  CONCLUSIONS: Adding basal insulin to metformin reduces postprandial beta-cell load. While GLA and NPH had comparable effects at breakfast, GLA reduces beta-cell stress more effectively at dinner, and with a trend at lunch, most probably because of its longer lasting pharmacodynamic profile."^^xsd:string ;
            ctro:hasAuthor "Forst T et al."^^xsd:string ;
            ctro:hasPMID 20415692 ;
            ctro:hasPublicationYear 2010 ;
            ctro:hasTitle "Adding insulin glargine vs. NPH insulin to metformin results in a more efficient postprandial beta-cell protection in individuals with type 2 diabetes."^^xsd:string ;
            rdfs:label "Forst T, Larbig M, Hohberg C, Forst S, Diessel S, Borchert M, Roth W, Pfützner A"^^xsd:string .


###  http://www.semanticweb.org/root/ontologies/2018/6/ctro#Pub_23
ctro:Pub_23 rdf:type owl:NamedIndividual ,
                     ctro:Publication ;
            ctro:describes ctro:CT_23 ;
            ctro:hasAbstract "BACKGROUND: Injection of long-acting insulin at bedtime is a common therapeutic approach for patients with type 2 diabetes that is poorly controlled with oral regimens. Neutral protamine lispro (NPL) insulin has demonstrated better glycemic control and similar incidence of hypoglycemic events than that of neutral protamine Hagedorn insulin.  OBJECTIVE: To compare the clinical efficacy and safety of bedtime NPL insulin or insulin glargine in patients with type 2 diabetes who had suboptimal glycemic control while receiving stable doses of metformin and sulfonylurea.  DESIGN: Open-label, randomized trial.  SETTING: Teaching hospital (Azienda Ospedaliera Universitaria, Second University of Naples), Naples, Italy.  PATIENTS: 116 adults receiving stable doses of metformin plus sulfonylurea for longer than 90 days with hemoglobin A(1c) (HbA(1c)) levels of 7.5% to 10% and fasting plasma glucose levels of 6.7 mmol/L or greater (> or =120 mg/dL).  INTERVENTION: 10 IU of NPL insulin or insulin glargine injected subcutaneously at bedtime with weekly dose titrations to target fasting glucose levels less than 5.6 mmol/L (<100 mg/dL) in addition to stable oral regimens. Patients receiving nighttime sulfonylurea before the study were switched to metformin.  MEASUREMENTS: The primary outcome was change in HbA(1c) levels from baseline to week 36. Secondary outcomes were HbA(1c) levels less than 7%, self-reported hypoglycemic episodes, insulin dose, self-monitored glucose level, and body weight. Twenty patients in each group had continuous glucose monitoring for 3 consecutive days before adding insulin and at week 36.  RESULTS: Improvement in HbA(1c) levels was similar in both groups (1.83% and 1.89% for NPL and glargine, respectively). The difference between the groups was 0.06 percentage point (95% CI, -0.1 to 0.15 percentage points). Secondary outcomes did not differ between groups. Hemoglobin A(1c) levels less than 7% occurred in 62% of patients receiving NPL and 64% of patients receiving glargine (difference, 2.0 percentage points [CI, -1.1 to 5.0 percentage points]). Fasting plasma glucose levels less than 5.6 mmol/L (<100 mg/dL) occurred in 40% of patients receiving NPL and 41% of patients receiving glargine (difference, 1.0 percentage point [CI, -0.9 to 3.0 percentage points]). Any hypoglycemic event occurred in 74% of patients receiving NPL and 67% of patients receiving glargine (difference, 7 percentage points [CI, -5 to 13 percentage points]). Continuous glucose level monitoring in the patients who had this measurement did not differ statistically.  LIMITATION: The study was not blinded, had limited power to detect differences in hypoglycemic events, and did not obtain continuous glucose level monitoring for all patients.  CONCLUSION: Similar glycemic control occurred with the addition of NPL or glargine insulin to oral regimens in patients with poorly controlled type 2 diabetes. Hypoglycemia was similar in the 2 groups, but sample size limited the ability to make a definite safety assessment."^^xsd:string ;
            ctro:hasAuthor "Esposito K et al."^^xsd:string ;
            ctro:hasPMID 18936501 ;
            ctro:hasPublicationYear 2008 ;
            ctro:hasTitle "Addition of neutral protamine lispro insulin or insulin glargine to oral type 2 diabetes regimens for patients with suboptimal glycemic control: a randomized trial. "^^xsd:string ;
            rdfs:label "Esposito K, Ciotola M, Maiorino MI, Gualdiero R, Schisano B, Ceriello A, Beneduce F, Feola G, Giugliano D"^^xsd:string .


###  http://www.semanticweb.org/root/ontologies/2018/6/ctro#Pub_24
ctro:Pub_24 rdf:type owl:NamedIndividual ,
                     ctro:Publication ;
            ctro:describes ctro:CT_24 ;
            ctro:hasAbstract "BACKGROUND: Type 2 diabetes (T2DM) patients often fail to achieve adequate glycemic control with oral antidiabetic drugs (OADs). Insulin has been shown to improve glycemic control in these patients but with increased risk of hypoglycemia. This study compared the efficacy and safety of insulin glargine and NPH insulin, both in combination with a once-daily fixed dose of glimepiride, in terms of glycemic control and incidence of hypoglycemia.  METHODS: In this open-label, 24-week randomized trial in ten Latin American countries, T2DM patients poorly controlled on OADs (HbA1c > or = 7.5 and < or = 10.5%) received glimepiride plus insulin glargine (n = 231) or NPH insulin (n = 250) using a forced titration algorithm. The primary endpoint was the equivalence of 24-week mean changes in HbA1c.  RESULTS: Insulin glargine and NPH insulin achieved similar HbA1c reductions (adjusted mean difference -0.047; 90% CI -0.232, 0.138; per-protocol analysis). Confirmed nocturnal hypoglycemia was significantly lower with insulin glargine vs. NPH insulin (16.9 vs. 30.0%; p <0.01; safety analysis). Patients receiving insulin glargine were significantly more likely to achieve HbA1c levels < 7.0% without hypoglycemia (27 vs. 17%; p = 0.014; per-protocol analysis). There was a more pronounced treatment satisfaction improvement with insulin glargine vs. NPH insulin (p <0.02; full analysis). The proportion of patients who lost time from work or normal activities due to diabetes was lower with insulin glargine vs. NPH (1.8 vs. 3.3%; full analysis).  CONCLUSIONS: In patients with T2DM, inadequately controlled on OADs, once-daily insulin glargine plus glimepiride is effective in improving metabolic control with a reduced incidence of nocturnal hypoglycemia compared with NPH insulin."^^xsd:string ;
            ctro:hasAuthor "Eliaschewitz FG et al."^^xsd:string ;
            ctro:hasPMID 16715577 ;
            ctro:hasPublicationYear 2006 ;
            ctro:hasTitle "Therapy in type 2 diabetes: insulin glargine vs. NPH insulin both in combination with glimepiride."^^xsd:string ;
            rdfs:label "Eliaschewitz FG, Calvo C, Valbuena H, Ruiz M, Aschner P, Villena J, Ramirez LA, Jimenez J; HOE 901/4013 LA Study Group"^^xsd:string .


###  http://www.semanticweb.org/root/ontologies/2018/6/ctro#Pub_25
ctro:Pub_25 rdf:type owl:NamedIndividual ,
                     ctro:Publication ;
            ctro:describes ctro:CT_25 ;
            ctro:hasAbstract "BACKGROUND: Patients with type 2 diabetes are often treated with oral antidiabetic agents plus a basal insulin. OBJECTIVE: To investigate the efficacy and safety of glimepiride combined with either morning or bedtime insulin glargine or bedtime neutral protamine Hagedorn  (NPH) insulin in patients with type 2 diabetes. DESIGN: Open-label, randomized, controlled trial. SETTING: 111 centers in 13 European countries. PATIENTS: 695 patients with type 2 diabetes who were previously treated with oral antidiabetic agents. INTERVENTION: Randomization to treatment with morning insulin glargine, bedtime NPH insulin, or bedtime insulin glargine for 24 weeks in addition to 3 mg of glimepiride. The insulin dose was titrated by using a predefined regimen to achieve fasting blood glucose levels of 5.56 mmol/L or lower (< or =100 mg/dL). MEASUREMENTS: Hemoglobin A(1c) values, blood glucose levels, insulin dose, and body weight. RESULTS: Hemoglobin A(1c) levels improved by -1.24% (two-sided 90% CI, -1.10% to  -1.38%) with morning insulin glargine, by -0.96% (CI, -0.81% to -1.10%) with bedtime insulin glargine, and by -0.84% (CI, -0.69% to -0.98%) with bedtime NPH insulin. Hemoglobin A(1c) improvement was more pronounced with morning insulin glargine than with NPH insulin (0.40% [CI, 0.23% to 0.58%]; P = 0.001) or bedtime insulin glargine (0.28% [CI, 0.11% to 0.46%]; P = 0.008). Baseline to end-point fasting blood glucose levels improved similarly in all three groups. Nocturnal hypoglycemia was less frequent with morning (39 of 236 patients [17%]) and bedtime insulin glargine (52 of 227 patients [23%]) than with bedtime NPH insulin (89 of 232 patients [38%]) (P < 0.001). CONCLUSION: The risk for nocturnal hypoglycemia was lower with glimepiride in combination with morning and bedtime insulin glargine than with glimepiride in combination with bedtime NPH insulin in patients with type 2 diabetes. Morning insulin glargine provided better glycemic control than did bedtime insulin glargine or bedtime NPH insulin."^^xsd:string ;
            ctro:hasAuthor "Fritsche A, Schweitzer MA, Haring H-U"^^xsd:string ;
            ctro:hasPMID 12809451 ;
            ctro:hasPublicationYear 2003 ;
            ctro:hasTitle "Glimepiride combined with morning insulin glargine, bedtime neutral protamine hagedorn insulin, or bedtime insulin glargine in patients with type 2 diabetes. A randomized, controlled trial."^^xsd:string ;
            rdfs:label "Fritsche A, , Schweitzer MA, Häring HU; 4001 Study Group"^^xsd:string .


###  http://www.semanticweb.org/root/ontologies/2018/6/ctro#Pub_26
ctro:Pub_26 rdf:type owl:NamedIndividual ,
                     ctro:Publication ;
            ctro:describes ctro:CT_26 ;
            ctro:hasAbstract "AIMS/HYPOTHESIS: In type 2 diabetic patients we compared 9 months of combination therapy with insulin glargine and metformin with 9 months of NPH insulin combined with metformin. The primary focus was changes in HbA(1c); secondary focus was diurnal glucose profiles and symptomatic hypoglycaemia.  METHODS: In this investigator-initiated open, parallel-group clinical trial involving seven centres, 110 insulin-naive type 2 diabetic patients with poor glycaemic control (HbA(1c) >or=8.0%) on oral hypoglycaemic agents (90% using sulfonylurea plus metformin) were randomised to receive bedtime insulin glargine with metformin (G+MET) or bedtime NPH with metformin (NPH+MET) for 36 weeks. The patients were taught how to self-adjust their insulin dose and use a modem to send the results of home glucose monitoring to treatment centres. The goal was to achieve a fasting plasma glucose (FPG) of 4.0 to 5.5 mmol/l in both groups.  RESULTS: During the last 12 weeks, FPGs averaged 5.75+/-0.02 and 5.96+/-0.03 mmol/l (p<0.001) and insulin doses were 68+/-5 and 70+/-6 IU/day (0.69+/-0.05 and 0.66+/-0.04 IU kg(-1) day(-1), NS) in the G+MET and NPH+MET groups, respectively. At 36 weeks, mean HbA(1c) was 7.14+/-0.12 and 7.16+/-0.14%, respectively (NS). Symptomatic, but not confirmed symptomatic, hypoglycaemia was significantly lower during the first 12 weeks in the G+MET group (4.1+/-0.8 episodes/patient-year) than in the NPH+MET group (9.0+/-2.3 episodes/patient-year, p<0.05), but not significantly different thereafter. Glucose levels before dinner were higher in the NPH+MET group (10.1+/-0.3 mmol/l) than in the G+MET group (8.6+/-0.3 mmol/l, p=0.002) throughout the 36-week study. With regard to baseline characteristics such as initial glycaemia or C-peptide, there was no difference between patients who achieved good glycaemic control (HbA(1c) <7.0%) and those who did not. Differences were seen in the following: between study centres, weight gain during the run-in period and insulin therapy, and FPG during the last 12 weeks (5.7+/-0.2 vs 6.7+/-0.3 mmol/l for patients reaching vs those not reaching target, p<0.01).  CONCLUSIONS/INTERPRETATION: Good glycaemic control can be achieved with both G+MET and NPH+MET. Use of G+MET reduces symptomatic hypoglycaemia during the first 12 weeks and dinner time hyperglycaemia compared with NPH+MET."^^xsd:string ;
            ctro:hasAuthor "Yki-Jarvinen H et al."^^xsd:string ;
            ctro:hasPMID 16456680 ;
            ctro:hasPublicationYear 2006 ;
            ctro:hasTitle "Insulin glargine or NPH combined with metformin in type 2 diabetes: the LANMET study."^^xsd:string ;
            rdfs:label "Yki-Jarvinen H, Kauppinen-Mäkelin R, Tiikkainen M, Vähätalo M, Virtamo H, Nikkilä K, Tulokas T, Hulme S, Hardy K, McNulty S, Hänninen J, Levänen H, Lahdenperä S, Lehtonen R, Ryysy L"^^xsd:string .


###  http://www.semanticweb.org/root/ontologies/2018/6/ctro#Pub_27
ctro:Pub_27 rdf:type owl:NamedIndividual ,
                     ctro:Publication ;
            ctro:describes ctro:CT_27 ;
            ctro:hasAbstract "OBJECTIVE: To compare the abilities and associated hypoglycemia risks of insulin glargine and human NPH insulin added to oral therapy of type 2 diabetes to achieve 7% HbA(1c).  RESEARCH DESIGN AND METHODS: In a randomized, open-label, parallel, 24-week multicenter trial, 756 overweight men and women with inadequate glycemic control (HbA(1c) >7.5%) on one or two oral agents continued prestudy oral agents and received bedtime glargine or NPH once daily, titrated using a simple algorithm seeking a target fasting plasma glucose (FPG) <or=100 mg/dl (5.5 mmol/l). Outcome measures were FPG, HbA(1c), hypoglycemia, and percentage of patients reaching HbA(1c) <or=7% without documented nocturnal hypoglycemia.  RESULTS: Mean FPG at end point was similar with glargine and NPH (117 vs. 120 mg/dl [6.5 vs. 6.7 mmol/l]), as was HbA(1c) (6.96 vs. 6.97%). A majority of patients ( approximately 60%) attained HbA(1c) <or=7% with each insulin type. However, nearly 25% more patients attained this without documented nocturnal hypoglycemia (<or=72 mg/dl [4.0 mmol/l]) with glargine (33.2 vs. 26.7%, P < 0.05). Moreover, rates of other categories of symptomatic hypoglycemia were 21-48% lower with glargine.  CONCLUSIONS: Systematically titrating bedtime basal insulin added to oral therapy can safely achieve 7% HbA(1c) in a majority of overweight patients with type 2 diabetes with HbA(1c) between 7.5 and 10.0% on oral agents alone. In doing this, glargine causes significantly less nocturnal hypoglycemia than NPH, thus reducing a leading barrier to initiating insulin. This simple regimen may facilitate earlier and effective insulin use in routine medical practice, improving achievement of recommended standards of diabetes care."^^xsd:string ;
            ctro:hasAuthor "Riddle MC, Rosenstock J, Gerich J"^^xsd:string ;
            ctro:hasPMID 14578243 ;
            ctro:hasPublicationYear 2003 ;
            ctro:hasTitle "The treat-to-target trial: randomized addition of glargine or human NPH insulin to oral therapy of type 2 diabetic patients."^^xsd:string ;
            rdfs:label "Riddle MC, Rosenstock J, Gerich J; Insulin Glargine 4002 Study Investigators"^^xsd:string .


###  http://www.semanticweb.org/root/ontologies/2018/6/ctro#Pub_28
ctro:Pub_28 rdf:type owl:NamedIndividual ,
                     ctro:Publication ;
            ctro:describes ctro:CT_28 ;
            ctro:hasAbstract "AIMS: The aim of the trial was to compare the efficacy and safety of the new, long-acting basal insulin, insulin glargine (LANTUS(R)), with NPH human insulin, each administered in a combination regimen with oral antidiabetic drugs in patients with Type 2 diabetes.  METHODS: In a multicentre, open, randomised study, 570 patients with Type 2 diabetes, aged 34 - 80 years, were treated for 52 weeks with insulin glargine or NPH insulin given once daily at bedtime. Previous oral antidiabetic therapy was continued throughout the study.  RESULTS: There was a clinically relevant decrease in glycosylated haemoglobin (GHb) values from baseline to endpoint with both drugs (insulin glargine: - 0.46 %; NPH insulin: - 0.38 %; p = 0.415); also, this difference was statistically significant in the subgroup of overweight patients with BMI > 28 kg/m 2 (insulin glargine: - 0.42 %, NPH insulin: - 0.11 %; p = 0.0237). Over the entire treatment period, NPH insulin-treated patients (41 %) and insulin glargine-treated patients (35 %) experienced a similar level of symptomatic hypoglycaemia. A statistically significant difference was observed in the number of patients treated with NPH insulin who reported at least one episode of nocturnal hypoglycaemia compared with those treated with insulin glargine in the overall population and in the overweight subgroup (overall: 24 % vs. 12 %, p = 0.002; overweight: 22.2 % vs. 9.5 %, p = 0.0006), using the Cochran-Mantel-Haenszel test. These differences were most pronounced in insulin-naïve and overweight (BMI > 28 kg/m 2) sub-groups. The incidence of adverse events was similar for the two treatments.  CONCLUSIONS: This study demonstrated that insulin glargine is as effective as NPH insulin in achieving glycaemic control in patients with Type 2 diabetes, and is associated with fewer episodes of symptomatic hypoglycaemia, particularly nocturnal episodes."^^xsd:string ;
            ctro:hasAuthor "Massi Benedetti M, Humburg E, Dressler A, Ziemen M"^^xsd:string ;
            ctro:hasPMID 12734781 ;
            ctro:hasPublicationYear 2003 ;
            ctro:hasTitle "A one-year, randomised, multicentre trial comparing insulin glargine with NPH insulin in combination with oral agents in patients with type 2 diabetes. "^^xsd:string ;
            rdfs:label "Massi Benedetti M, Humburg E, Dressler A, Ziemen M"^^xsd:string .


###  http://www.semanticweb.org/root/ontologies/2018/6/ctro#Pub_29
ctro:Pub_29 rdf:type owl:NamedIndividual ,
                     ctro:Publication ;
            ctro:describes ctro:CT_29 ;
            ctro:hasAbstract "AIMS: The addition of basal insulin to existing oral therapy can help patients with type 2 diabetes (T2D) achieve glycaemic targets. This study compares the efficacy and safety of insulin lispro protamine suspension (ILPS) and insulin glargine in insulin-naive patients with T2D and inadequate control on oral antihyperglycaemic medication (OAM).  MATERIALS AND METHODS: An open-label, randomized, multicentre, multinational 24-week study of 471 patients receiving ≥2 OAMs for ≥3 months with a body mass index between 25 and 45 kg/m(2) and HbA1c 7.5-10.0% was conducted. ILPS was injected once or twice daily vs. glargine injected once daily plus prestudy OAMs. Primary objective compared the HbA1c change from baseline.  RESULTS: HbA1c change from baseline to endpoint was similar in both groups [-1.46% (ILPS) and -1.41% (glargine)]. Least-squares mean difference (95% CI) for HbA1c (-0.05 [-0.21, 0.11]%), glycaemic variability (0.06 [-0.06, 0.19] mmol/l) and weight change (-0.01 [-0.61, 0.59] kg) showed non-inferiority (margins of 0.4%, 0.8 mmol/l and 1.5 kg, respectively). Percentages of patients achieving HbA1c <7.0% were 43.8% ILPS and 41.2% glargine. Mean daily insulin dose was 0.39 vs. 0.35 U/kg (p = 0.02) and weight gain was 1.04 vs. 1.07 kg for ILPS vs. glargine (p = 0.98). Overall hypoglycaemia (episodes/patient/year) was similar for ILPS and glargine (24.2 ± 28.8 vs. 23.0 ± 30.9); nocturnal (6.1 ± 10.6 vs. 4.1 ± 9.4, p < 0.001) rates were higher for ILPS. Severe hypoglycaemia was higher for ILPS vs. glargine (n = 9 vs. n = 2; p = 0.04).  CONCLUSIONS: At endpoint, ILPS was non-inferior to glargine in HbA1c change from baseline, but associated with increased risk of hypoglycaemia."^^xsd:string ;
            ctro:hasAuthor "Strojek k K, Shi C, Carey MA, Jacober SJ"^^xsd:string ;
            ctro:hasPMID 20920045 ;
            ctro:hasPublicationYear 2010 ;
            ctro:hasTitle "Addition of insulin lispro protamine suspension or insulin glargine to oral type 2 diabetes regimens: a randomized trial."^^xsd:string ;
            rdfs:label "Strojek k K, Shi C, Carey MA, Jacober SJ"^^xsd:string .


###  http://www.semanticweb.org/root/ontologies/2018/6/ctro#Pub_3
ctro:Pub_3 rdf:type owl:NamedIndividual ,
                    ctro:Publication ;
           ctro:describes ctro:CT_3 ;
           ctro:hasAbstract "PURPOSE: Latanoprost, a new prostaglandin analogue, was compared with timolol for ocular hypotensive efficacy and side effects. METHODS: In a multicenter, randomized, double-masked, parallel group study, 268 patients with ocular hypertension or early primary open-angle glaucoma received either 0.005% latanoprost once daily or 0.5% timolol twice daily for 6 months. All except ten patients from each group successfully completed the study. RESULTS: Intraocular pressure (IOP) was significantly (P<0.001) reduced and maintained by both medications without evidence of a long-term drift over 6 months. Comparing 6-month with baseline diurnal IOP values, the IOP reduction (mean +/- standard deviation) achieved with latanoprost (-6.7 +/- 3.4 mmHg) was significantly (P<0.001) greater than that produced with timolol (4.9 +/- 2.9 mmHg). Four patients treated with timolol and none treated with latanoprost were  withdrawn from the study because of inadequate IOP control. Pulse rate was significantly reduced with timolol, but not with latanoprost. Slightly more conjunctival hyperemia appeared in latanoprost-treated compared with timolol-treated eyes. Fewer subjective side effects occurred in latanoprost-treated eyes. Both eyes of a patient with a characteristic, concentric iris heterochromia (darker centrally) at baseline showed a definite, photographically documented increase in pigmentation during latanoprost treatment, making the irides uniformly darker. Three additional patients treated  with latanoprost were suspects for this color change. Otherwise, no significant difference between treatment groups occurred visual acuity, slit-lamp examination, blood pressure, and laboratory values. CONCLUSION: Latanoprost has the potential for becoming a new first-line treatment for glaucoma."^^xsd:string ;
           ctro:hasAuthor "Camras CB"^^xsd:string ;
           ctro:hasJournal "Ophthalmology"^^xsd:string ;
           ctro:hasPMID 8628544 ;
           ctro:hasPublicationYear 1996 ;
           ctro:hasTitle "Comparison of latanoprost and timolol in patients with ocular hypertension and glaucoma: a six-month masked, multicenter trial in the United States"^^xsd:string ;
           rdfs:label "Camras CB"^^xsd:string .


###  http://www.semanticweb.org/root/ontologies/2018/6/ctro#Pub_4
ctro:Pub_4 rdf:type owl:NamedIndividual ,
                    ctro:Publication ;
           ctro:describes ctro:CT_4 ;
           ctro:hasAbstract "OBJECTIVE: To compare the intraocular pressure (IOP)-reducing effect of the fixed combinations of timolol 0.5% and latanoprost 0.001% or 0.005% after 4 weeks' treatment. DESIGN: Following a 1-week run-in period on timolol 0.5% once daily, 139 patients were randomized to once-daily treatment with a fixed combination of timolol 0.5%  and latanoprost 0.001% (comb. 10) or latanoprost 0.005% (comp. 50) or to the individual monotherapies. The IOP was measured at inclusion and at 8 a.m., noon and 4 p.m. on days 1, 7 and 28. RESULTS: Comb. 10, comb. 50, latanoprost and timolol reduced IOP by 3.7, 6.1, 4.9 and 2.1 mmHg, respectively, from a baseline mean diurnal IOP (+/- SEM) of 24.8 +/- 0.5, 24.1 +/- 0.4, 25.2 +/- 1.2 and 24.8 +/- 0.9 mmHg, respectively. The difference in IOP reduction was significant between comb. 50 and comb. 10 (P < 0.001), latanoprost (P = 0.046) and timolol (P < 0.001) in favor of comb. 50. There was also a significant difference between latanoprost and timolol (P = 0.007), in favor of latanoprost. All treatments were generally well tolerated. CONCLUSION: This study indicates that a fixed combination of latanoprost 0.005% and timolol 0.5% could be useful in the treatment of glaucoma."^^xsd:string ;
           ctro:hasAuthor "Almegård B"^^xsd:string ,
                          "Diestelhorst M"^^xsd:string ;
           ctro:hasJournal "Graefes Arch Clin Exp Ophthalmology"^^xsd:string ;
           ctro:hasPMID 9717652 ;
           ctro:hasPublicationYear 1998 ;
           ctro:hasTitle "Comparison of two fixed combinations of latanoprost and timolol in open-angle glaucoma"^^xsd:string ;
           rdfs:label "Diestelhorst M, Almegård B"^^xsd:string .


###  http://www.semanticweb.org/root/ontologies/2018/6/ctro#Pub_5
ctro:Pub_5 rdf:type owl:NamedIndividual ,
                    ctro:Publication ;
           ctro:describes ctro:CT_5 ;
           ctro:hasAbstract "OBJECTIVE: To compare the efficacy and side effects and the effect on aqueous humor dynamics of 0.005% latanoprost applied topically once daily with 0.5% timolol given twice daily for 12 months to patients with pigmentary glaucoma. DESIGN: Prospective, randomized, double-masked, clinical study. PARTICIPANTS: Thirty-six patients affected with bilateral pigmentary glaucoma controlled with no more than a single hypotensive medication were enrolled in the study. INTERVENTION: The sample population was randomly divided into 2 age- and gender-matched groups each of 18 patients. Group 1 received 0.005% latanoprost eyedrops once daily and the vehicle (placebo) once daily; group 2 was assigned to timolol 0.5% eyedrops twice daily. MAIN OUTCOME MEASURES: Diurnal curves of intraocular pressure (IOP) were performed on the baseline day and after 0.5, 3, 6, and 12 months of treatment. The IOP measurements were performed at 8:00 AM, 12:00 noon, 4:00 PM, and 8:00 PM. Outflow facility (\"C\") was measured on the baseline day and on the last day of the study with a Schiotz electronic tonometer. A two-tailed Student's t test for  paired or unpaired data was used for statistical evaluation of differences between treatment and baseline values or between the latanoprost and timolol group. Diurnal IOP measurements were compared hour by hour. Mean values of the two eyes IOP and \"C\" were used for analysis. RESULTS: Compared with baseline measurements, both latanoprost and timolol caused a significant (P < 0.001) reduction of IOP at each hour of diurnal curve throughout the duration of therapy. Reduction of IOP was 6.0 +/- 4.5 and 5.9 +/-  4.6 with latanoprost and 4.8 +/- 3.0 and 4.6 +/- 3.1 with timolol after 6 and 12  months, respectively. Comparison of mean diurnal measurements with latanoprost and timolol showed a statistical significant (P < 0.001) difference at 3, 6, and  12 months. Mean \"C\" was found to be significantly enhanced (+30%) only in the latanoprost-treated group compared with the baseline (P = 0.017). Mean conjunctival hyperemia was graded at 0.3 in latanoprost-treated eyes and 0.2 in timolol-treated eyes. A remarkable change in iris color was observed in both eyes of 1 of the 18 patients treated with latanoprost and none of the 18 patients who  received timolol. Darkening of the peripheral iris stroma was suspected in two patients treated with latanoprost. In the timolol group, heart rate was significantly reduced from 72 +/- 9 at baseline to 67 +/- 10 beats per minute at  12 months. CONCLUSIONS: Although further studies may need to confirm these data on a larger  sample and to evaluate the side effect of increased iris pigmentation on long-term follow-up, in patients with pigmentary glaucoma, 0.005% latanoprost taken once daily was well tolerated and more effective in reducing IOP than 0.5%  timolol taken twice daily."^^xsd:string ;
           ctro:hasAuthor "Carpineto P"^^xsd:string ,
                          "Ciancaglini M"^^xsd:string ,
                          "Gallenga PE"^^xsd:string ,
                          "Mastropasqua L "^^xsd:string ;
           ctro:hasJournal "Ophthalmology"^^xsd:string ;
           ctro:hasPMID 10080213 ;
           ctro:hasPublicationYear 1999 ;
           ctro:hasTitle "A 12-month, randomized, double-masked study comparing latanoprost with timolol in pigmentary glaucoma"^^xsd:string ;
           rdfs:label "Mastropasqua L, Carpineto P, Ciancaglini M, Gallenga PE"^^xsd:string .


###  http://www.semanticweb.org/root/ontologies/2018/6/ctro#Pub_6
ctro:Pub_6 rdf:type owl:NamedIndividual ,
                    ctro:Publication ;
           ctro:describes ctro:CT_6 ;
           ctro:hasAbstract "OBJECTIVE: To evaluate the intraocular pressure (IOP)-reducing effect and the side effects of latanoprost (PhXA41), a new phenyl-substituted prostaglandin F2 alpha-isopropyl ester analogue, in patients with elevated IOP, using timolol maleate as the reference drug. METHODS: A total of 184 patients with primary open-angle glaucoma or ocular hypertension at 35 medical centers participated in this randomized double-masked  study. The patients were randomized to receive either 0.005% latanoprost once daily or 0.5% timolol maleate twice daily, for a period of 12 weeks. Intraocular  pressure was measured 24 hours after the administration of timolol, at 2, 4, 8, and 12 weeks of treatment. RESULTS: Latanoprost reduced IOP at the end of 12 weeks by 6.2 +/- 2.7 mm Hg (mean +/- SD) (26.8%), while timolol reduced IOP by 4.4 +/- 2.3 mm Hg (19.9%). At all visits latanoprost reduced IOP significantly more than timolol did. The main  ocular side effects observed in both groups were conjunctival hyperemia and smarting. The main systemic side effect was a reduced pulse rate, which occurred  in patients treated with timolol. CONCLUSIONS: The results of this study demonstrated that 0.005% latanoprost taken once daily is well tolerated and more effective in reducing IOP than 0.5% timolol taken twice daily. Thus, latanoprost may become an important choice for the medical treatment of glaucoma."^^xsd:string ;
           ctro:hasAuthor "Araie M"^^xsd:string ,
                          "Azuma I"^^xsd:string ,
                          "Kitazawa Y"^^xsd:string ,
                          "Masuda K"^^xsd:string ,
                          "Mishima HK"^^xsd:string ;
           ctro:hasJournal "Ophthalmology"^^xsd:string ;
           ctro:hasPMID 8694726 ;
           ctro:hasPublicationYear 1996 ;
           ctro:hasTitle "A comparison of latanoprost and timolol in primary open-angle glaucoma and ocular hypertension. A 12-week study"^^xsd:string ;
           rdfs:label "Mishima HK, Masuda K, Kitazawa Y, Azuma I, Araie M"^^xsd:string .


###  http://www.semanticweb.org/root/ontologies/2018/6/ctro#Pub_7
ctro:Pub_7 rdf:type owl:NamedIndividual ,
                    ctro:Publication ;
           ctro:describes ctro:CT_7 ;
           ctro:hasAbstract "A randomised observer masked clinical study was conducted to assess the additive  effect of latanoprost (13,14-dihydro-17-phenyl-18,19,20-trinorprostaglandin F2 alpha-isopropylester) to timolol maleate in patients with elevated intraocular pressure (IOP). Patients were randomly assigned to two treatment groups. One group (n = 10) received timolol, the other group (n = 9) received latanoprost twice daily for 1 week. After 1 week all patients received both timolol and latanoprost. Eyes treated with timolol (mean diurnal IOP (SD) day 0, 24.2 (2.8) mm Hg) and latanoprost (mean diurnal IOP day 0, 28.5 (5.6) mm Hg) showed an IOP reduction of 5.9 (2.3) mm Hg (24%) and 8.9 (2.5) mm Hg (31%), respectively after  the first week. Adding latanoprost to the eyes treated with timolol as well as timolol to the eyes receiving latanoprost gave a further reduction of 2.6 (1.1) mm Hg (13%) and 2.6 (2.2) mm Hg (14%), respectively. Only mild transient hyperaemia was observed in patients receiving latanoprost. The results indicate that latanoprost and timolol can be combined successfully and that complete or almost complete additivity is reached even at pressure levels below 20 mm Hg."^^xsd:string ;
           ctro:hasAuthor "Greve EL"^^xsd:string ,
                          "Hoyng PF"^^xsd:string ,
                          "Rulo AH"^^xsd:string ;
           ctro:hasJournal "British Journal Ophthalmology"^^xsd:string ;
           ctro:hasPMID 7819171 ;
           ctro:hasPublicationYear 1994 ;
           ctro:hasTitle "Additive effect of latanoprost, a prostaglandin F2 alpha analogue, and timolol in patients with elevated intraocular pressure"^^xsd:string ;
           rdfs:label "Rulo AH, Greve EL, Hoyng PF"^^xsd:string .


###  http://www.semanticweb.org/root/ontologies/2018/6/ctro#Pub_8
ctro:Pub_8 rdf:type owl:NamedIndividual ,
                    ctro:Publication ;
           ctro:describes ctro:CT_8 ;
           ctro:hasAbstract "PURPOSE: To compare the intraocular pressure (IOP)-reducing effect and side effects of 0.005% latanoprost administered once daily with 0.5% timolol administered twice daily in patients with open-angle glaucoma or ocular hypertension. METHODS: This was a randomized, double-masked study with two parallel groups and  a treatment period of 6 months. The primary objective of the study is to compare  the IOP-reducing effect of lantanoprost with that of timolol at the end of the 6-month treatment period. A total of 294 patients were included: 149 were in the  latanoprost group and 145 were in timolol group. Latanoprost was administered in  the evening. RESULTS: Diurnal IOP (9:00 am, 1:00 pm, 5:00 pm) was reduced from 25.2 to 16.7 mmHg (33.7%) with lantanoprost and from 25.4 to 17.1 mmHg (32.7%) with timolol as determined at the end of the 6-month treatment period. No upward drift in IOP occurred with either drug during the treatment period. Latanoprost caused a somewhat more conjunctival hyperemia than timolol and more corneal punctuate epithelial erosions. However, both drugs were generally well tolerated. The most  significant side effect of latanoprost was increased pigmentation of the iris which was observed in 15 patients (10.1%). Timolol caused more systemic side effects than latanoprost. CONCLUSIONS: Latanoprost 0.005% administered once daily in the evening reduced IOP at least as well as timolol 0.5% administered twice daily. Latanoprost was generally well tolerated systemically and in the eye. However, the drug has an unusual side effect of increasing the pigmentation of the iris, particularly in individuals with green-brown or blue-brown eyes."^^xsd:string ;
           ctro:hasAuthor "Stjernschantz J"^^xsd:string ,
                          "Watson P"^^xsd:string ;
           ctro:hasJournal "Ophthalmology"^^xsd:string ;
           ctro:hasPMID 8628543 ;
           ctro:hasPublicationYear 1996 ;
           ctro:hasTitle "A six-month, randomized, double-masked study comparing latanoprost with timolol in open-angle glaucoma and ocular hypertension. The Latanoprost Study Group"^^xsd:string ;
           rdfs:label "Watson P, Stjernschantz J"^^xsd:string .


###  http://www.semanticweb.org/root/ontologies/2018/6/ctro#Pub_9
ctro:Pub_9 rdf:type owl:NamedIndividual ,
                    ctro:Publication ;
           ctro:describes ctro:CT_9 ;
           ctro:hasAbstract "BACKGROUND: Latanoprost is a PGF2 alpha analogue which reduces the intraocular pressure (IOP) by increasing the uveoscleral outflow. The objective of this study was to investigate the effect of two different regimens of latanoprost on the diurnal IOP and also the effect of latanoprost on the blood-aqueous barrier measured with a laser flare cell meter (Kowa FM-500). Moreover, the safety aspects of the two regimens regarding hyperemia were studied. METHODS: A double-masked, randomized study was performed in 30 patients (9 males, 21 females; mean age 61.9 years) with primary open-angle glaucoma or pseudoexfoliation glaucoma. Twenty patients were treated with latanoprost 0.0015% twice daily or 0.005% once daily for 3 weeks in a cross-over design. Ten patients received timolol 0.5% twice daily as control. RESULTS: Latanoprost 0.005% once daily reduced IOP (+/- SEM) more effectively than latanoprost 0.0015% twice daily (9.8 +/- 0.9 mm Hg and 6.7 +/- 0.9 mm Hg, respectively). There was a statistically significant increase in the aqueous humour protein concentration within the timolol group (P = 0.004), but not within the latanoprost group (P = 0.97). There was no statistically significant difference in the change in aqueous humour protein concentration from baseline between latanoprost and timolol groups (P = 0.08). No statistically significant difference in conjunctival hyperemia between the two latanoprost regimens was found (P = 0.37). CONCLUSION: Latanoprost 0.005% once daily reduced IOP more effectively than latanoprost 0.0015% twice daily (P < 0.001). Latanoprost had no statistically or  clinically significant effect on the blood-aqueous barrier. There was no difference in hyperemia between the two regimens. Both concentrations of latanoprost reduced IOP at least as well as timolol 0.5% eye drops."^^xsd:string ;
           ctro:hasAuthor "Diestelhorst M"^^xsd:string ;
           ctro:hasJournal "Graefes Arch Clin Exp Ophthalmology"^^xsd:string ;
           ctro:hasPMID 9034838 ;
           ctro:hasPublicationYear 1997 ;
           ctro:hasTitle "The effect of latanoprost 0.005% once daily versus 0.0015% twice daily on intraocular pressure and aqueous humour protein concentration in glaucoma patients. A randomized, double-masked comparison with timolol 0.5%."^^xsd:string ;
           rdfs:label "Diestelhorst M, Roters S, Krieglstein GK"^^xsd:string .


###  http://www.semanticweb.org/root/ontologies/2018/6/ctro#R_CT10_A1_OC1
ctro:R_CT10_A1_OC1 rdf:type owl:NamedIndividual ,
                            ctro:Result ;
                   ctro:hasAbsoluteValue "6.8"^^xsd:float ;
                   ctro:hasResultDirection "reduction"^^xsd:string .


###  http://www.semanticweb.org/root/ontologies/2018/6/ctro#R_CT10_A2_OC1
ctro:R_CT10_A2_OC1 rdf:type owl:NamedIndividual ,
                            ctro:Result ;
                   ctro:hasAbsoluteValue "5.3"^^xsd:float ;
                   ctro:hasResultDirection "reduction"^^xsd:string .


###  http://www.semanticweb.org/root/ontologies/2018/6/ctro#R_CT11_A1_OC1
ctro:R_CT11_A1_OC1 rdf:type owl:NamedIndividual ,
                            ctro:Result ;
                   ctro:hasAbsoluteValue "3.6"^^xsd:float ;
                   ctro:hasResultDirection "reduction"^^xsd:string .


###  http://www.semanticweb.org/root/ontologies/2018/6/ctro#R_CT11_A2_OC1
ctro:R_CT11_A2_OC1 rdf:type owl:NamedIndividual ,
                            ctro:Result ;
                   ctro:hasAbsoluteValue "3.1"^^xsd:float ;
                   ctro:hasResultDirection "reduction"^^xsd:string .


###  http://www.semanticweb.org/root/ontologies/2018/6/ctro#R_CT1_A1_OC1
ctro:R_CT1_A1_OC1 rdf:type owl:NamedIndividual ,
                           ctro:Result ;
                  ctro:hasAbsoluteValue "8.3"^^xsd:float ;
                  ctro:hasResultDirection "reduction"^^xsd:string .


###  http://www.semanticweb.org/root/ontologies/2018/6/ctro#R_CT1_A2_OC1
ctro:R_CT1_A2_OC1 rdf:type owl:NamedIndividual ,
                           ctro:Result ;
                  ctro:hasStatisticalMeasure ctro:STAT_CT1_A2_OC1 ;
                  ctro:hasAbsoluteValue "6.7"^^xsd:float ;
                  ctro:hasResultDirection "reduction"^^xsd:string .


###  http://www.semanticweb.org/root/ontologies/2018/6/ctro#R_CT21_A1_OC1
ctro:R_CT21_A1_OC1 rdf:type owl:NamedIndividual ,
                            ctro:Result ;
                   ctro:hasAbsoluteValue "1.3"^^xsd:float ;
                   ctro:hasResultDirection "reduction"^^xsd:string .


###  http://www.semanticweb.org/root/ontologies/2018/6/ctro#R_CT21_A2_OC1
ctro:R_CT21_A2_OC1 rdf:type owl:NamedIndividual ,
                            ctro:Result ;
                   ctro:hasAbsoluteValue "1.4"^^xsd:float ;
                   ctro:hasResultDirection "reduction"^^xsd:string .


###  http://www.semanticweb.org/root/ontologies/2018/6/ctro#R_CT22_A1_OC1
ctro:R_CT22_A1_OC1 rdf:type owl:NamedIndividual ,
                            ctro:Result ;
                   ctro:hasAbsoluteValue "0.2"^^xsd:float ;
                   ctro:hasResultDirection "reduction"^^xsd:string .


###  http://www.semanticweb.org/root/ontologies/2018/6/ctro#R_CT22_A2_OC1
ctro:R_CT22_A2_OC1 rdf:type owl:NamedIndividual ,
                            ctro:Result ;
                   ctro:hasAbsoluteValue "0.3"^^xsd:float ;
                   ctro:hasResultDirection "reduction"^^xsd:string .


###  http://www.semanticweb.org/root/ontologies/2018/6/ctro#R_CT23_A1_OC1
ctro:R_CT23_A1_OC1 rdf:type owl:NamedIndividual ,
                            ctro:Result ;
                   ctro:hasAbsoluteValue "1.89"^^xsd:float ;
                   ctro:hasResultDirection "reduction"^^xsd:string .


###  http://www.semanticweb.org/root/ontologies/2018/6/ctro#R_CT23_A2_OC1
ctro:R_CT23_A2_OC1 rdf:type owl:NamedIndividual ,
                            ctro:Result ;
                   ctro:hasAbsoluteValue "1.83"^^xsd:float ;
                   ctro:hasResultDirection "reduction"^^xsd:string .


###  http://www.semanticweb.org/root/ontologies/2018/6/ctro#R_CT24_A1_OC1
ctro:R_CT24_A1_OC1 rdf:type owl:NamedIndividual ,
                            ctro:Result ;
                   ctro:hasAbsoluteValue "1.38"^^xsd:float ;
                   ctro:hasResultDirection "reduction"^^xsd:string .


###  http://www.semanticweb.org/root/ontologies/2018/6/ctro#R_CT24_A2_OC1
ctro:R_CT24_A2_OC1 rdf:type owl:NamedIndividual ,
                            ctro:Result ;
                   ctro:hasAbsoluteValue "1.43"^^xsd:float ;
                   ctro:hasResultDirection "reduction"^^xsd:string .


###  http://www.semanticweb.org/root/ontologies/2018/6/ctro#R_CT25_A1_OC1
ctro:R_CT25_A1_OC1 rdf:type owl:NamedIndividual ,
                            ctro:Result ;
                   ctro:hasAbsoluteValue "1.24"^^xsd:float ;
                   ctro:hasResultDirection "reduction"^^xsd:string .


###  http://www.semanticweb.org/root/ontologies/2018/6/ctro#R_CT25_A2_OC1
ctro:R_CT25_A2_OC1 rdf:type owl:NamedIndividual ,
                            ctro:Result ;
                   ctro:hasAbsoluteValue "0.84"^^xsd:float ;
                   ctro:hasResultDirection "reduction"^^xsd:string .


###  http://www.semanticweb.org/root/ontologies/2018/6/ctro#R_CT26_A1_OC1
ctro:R_CT26_A1_OC1 rdf:type owl:NamedIndividual ,
                            ctro:Result ;
                   ctro:hasAbsoluteValue "2.36"^^xsd:float ;
                   ctro:hasResultDirection "reduction"^^xsd:string .


###  http://www.semanticweb.org/root/ontologies/2018/6/ctro#R_CT26_A2_OC1
ctro:R_CT26_A2_OC1 rdf:type owl:NamedIndividual ,
                            ctro:Result ;
                   ctro:hasAbsoluteValue "2.44"^^xsd:float ;
                   ctro:hasResultDirection "reduction"^^xsd:string .


###  http://www.semanticweb.org/root/ontologies/2018/6/ctro#R_CT27_A1_OC1
ctro:R_CT27_A1_OC1 rdf:type owl:NamedIndividual ,
                            ctro:Result ;
                   ctro:hasAbsoluteValue "1.65"^^xsd:float ;
                   ctro:hasResultDirection "reduction"^^xsd:string .


###  http://www.semanticweb.org/root/ontologies/2018/6/ctro#R_CT27_A2_OC1
ctro:R_CT27_A2_OC1 rdf:type owl:NamedIndividual ,
                            ctro:Result ;
                   ctro:hasAbsoluteValue "1.59"^^xsd:float ;
                   ctro:hasResultDirection "reduction"^^xsd:string .


###  http://www.semanticweb.org/root/ontologies/2018/6/ctro#R_CT28_A1_OC1
ctro:R_CT28_A1_OC1 rdf:type owl:NamedIndividual ,
                            ctro:Result ;
                   ctro:hasAbsoluteValue "0.46"^^xsd:float ;
                   ctro:hasResultDirection "reduction"^^xsd:string .


###  http://www.semanticweb.org/root/ontologies/2018/6/ctro#R_CT28_A2_OC1
ctro:R_CT28_A2_OC1 rdf:type owl:NamedIndividual ,
                            ctro:Result ;
                   ctro:hasAbsoluteValue "0.38"^^xsd:float ;
                   ctro:hasResultDirection "reduction"^^xsd:string .


###  http://www.semanticweb.org/root/ontologies/2018/6/ctro#R_CT29_A1_OC1
ctro:R_CT29_A1_OC1 rdf:type owl:NamedIndividual ,
                            ctro:Result ;
                   ctro:hasAbsoluteValue "1.41"^^xsd:float ;
                   ctro:hasResultDirection "reduction"^^xsd:string .


###  http://www.semanticweb.org/root/ontologies/2018/6/ctro#R_CT29_A2_OC1
ctro:R_CT29_A2_OC1 rdf:type owl:NamedIndividual ,
                            ctro:Result ;
                   ctro:hasAbsoluteValue "1.46"^^xsd:float ;
                   ctro:hasResultDirection "reduction"^^xsd:string .


###  http://www.semanticweb.org/root/ontologies/2018/6/ctro#R_CT2_A1_OC1
ctro:R_CT2_A1_OC1 rdf:type owl:NamedIndividual ,
                           ctro:Result ;
                  ctro:hasStatisticalMeasure ctro:STAT_CT2_A1_OC1 ;
                  ctro:hasAbsoluteValue "11.1"^^xsd:float ;
                  ctro:hasNumberAffected 71 ;
                  ctro:hasResultDirection "reduction"^^xsd:string .


###  http://www.semanticweb.org/root/ontologies/2018/6/ctro#R_CT2_A2_OC1
ctro:R_CT2_A2_OC1 rdf:type owl:NamedIndividual ,
                           ctro:Result ;
                  ctro:hasStatisticalMeasure ctro:STAT_CT2_A2_OC1 ;
                  ctro:hasAbsoluteValue "9.4"^^xsd:float ;
                  ctro:hasNumberAffected 34 ;
                  ctro:hasResultDirection "reduction"^^xsd:string .


###  http://www.semanticweb.org/root/ontologies/2018/6/ctro#R_CT3_A1_OC1
ctro:R_CT3_A1_OC1 rdf:type owl:NamedIndividual ,
                           ctro:Result ;
                  ctro:hasStatisticalMeasure ctro:STAT_CT3_A1_OC1 ;
                  ctro:hasAbsoluteValue "6.7"^^xsd:float ;
                  ctro:hasResultDirection "reduction"^^xsd:string .


###  http://www.semanticweb.org/root/ontologies/2018/6/ctro#R_CT3_A2_OC1
ctro:R_CT3_A2_OC1 rdf:type owl:NamedIndividual ,
                           ctro:Result ;
                  ctro:hasStatisticalMeasure ctro:STAT_CT3_A2_OC1 ;
                  ctro:hasAbsoluteValue "4.9"^^xsd:float ;
                  ctro:hasResultDirection "reduction"^^xsd:string .


###  http://www.semanticweb.org/root/ontologies/2018/6/ctro#R_CT4_A1_OC1
ctro:R_CT4_A1_OC1 rdf:type owl:NamedIndividual ,
                           ctro:Result ;
                  ctro:hasAbsoluteValue "4.9"^^xsd:float ;
                  ctro:hasResultDirection "reduction"^^xsd:string .


###  http://www.semanticweb.org/root/ontologies/2018/6/ctro#R_CT4_A2_OC1
ctro:R_CT4_A2_OC1 rdf:type owl:NamedIndividual ,
                           ctro:Result ;
                  ctro:hasAbsoluteValue "2.1"^^xsd:float ;
                  ctro:hasResultDirection "reduction"^^xsd:string .


###  http://www.semanticweb.org/root/ontologies/2018/6/ctro#R_CT4_A3_OC1
ctro:R_CT4_A3_OC1 rdf:type owl:NamedIndividual ,
                           ctro:Result ;
                  ctro:hasAbsoluteValue "4.9"^^xsd:float ;
                  ctro:hasResultDirection "reduction"^^xsd:string .


###  http://www.semanticweb.org/root/ontologies/2018/6/ctro#R_CT4_A4_OC1
ctro:R_CT4_A4_OC1 rdf:type owl:NamedIndividual ,
                           ctro:Result ;
                  ctro:hasAbsoluteValue "2.1"^^xsd:float ;
                  ctro:hasResultDirection "reduction"^^xsd:string .


###  http://www.semanticweb.org/root/ontologies/2018/6/ctro#R_CT5_A1_OC1
ctro:R_CT5_A1_OC1 rdf:type owl:NamedIndividual ,
                           ctro:Result ;
                  ctro:hasStatisticalMeasure ctro:STAT_CT5_A1_OC1 ;
                  ctro:hasAbsoluteValue "4.8"^^xsd:float ;
                  ctro:hasResultDirection "reduction"^^xsd:string .


###  http://www.semanticweb.org/root/ontologies/2018/6/ctro#R_CT5_A2_OC1
ctro:R_CT5_A2_OC1 rdf:type owl:NamedIndividual ,
                           ctro:Result ;
                  ctro:hasStatisticalMeasure ctro:STAT_CT5_A2_OC1 ;
                  ctro:hasAbsoluteValue "4.6"^^xsd:float ;
                  ctro:hasResultDirection "reduction"^^xsd:string .


###  http://www.semanticweb.org/root/ontologies/2018/6/ctro#R_CT6_A1_OC1
ctro:R_CT6_A1_OC1 rdf:type owl:NamedIndividual ,
                           ctro:Result ;
                  ctro:hasAbsoluteValue "6.3"^^xsd:float ;
                  ctro:hasResultDirection "reduction"^^xsd:string .


###  http://www.semanticweb.org/root/ontologies/2018/6/ctro#R_CT6_A2_OC1
ctro:R_CT6_A2_OC1 rdf:type owl:NamedIndividual ,
                           ctro:Result ;
                  ctro:hasAbsoluteValue "4.3"^^xsd:float ;
                  ctro:hasResultDirection "reduction"^^xsd:string .


###  http://www.semanticweb.org/root/ontologies/2018/6/ctro#R_CT7_A1_OC1
ctro:R_CT7_A1_OC1 rdf:type owl:NamedIndividual ,
                           ctro:Result ;
                  ctro:hasAbsoluteValue "8.9"^^xsd:float ;
                  ctro:hasResultDirection "reduction"^^xsd:string .


###  http://www.semanticweb.org/root/ontologies/2018/6/ctro#R_CT7_A2_OC1
ctro:R_CT7_A2_OC1 rdf:type owl:NamedIndividual ,
                           ctro:Result ;
                  ctro:hasAbsoluteValue "5.9"^^xsd:float ;
                  ctro:hasResultDirection "reduction"^^xsd:string .


###  http://www.semanticweb.org/root/ontologies/2018/6/ctro#R_CT8_A1_OC1
ctro:R_CT8_A1_OC1 rdf:type owl:NamedIndividual ,
                           ctro:Result ;
                  ctro:hasAbsoluteValue "9.1"^^xsd:float ;
                  ctro:hasResultDirection "reduction"^^xsd:string .


###  http://www.semanticweb.org/root/ontologies/2018/6/ctro#R_CT8_A2_OC1
ctro:R_CT8_A2_OC1 rdf:type owl:NamedIndividual ,
                           ctro:Result ;
                  ctro:hasAbsoluteValue "8.8"^^xsd:float ;
                  ctro:hasResultDirection "reduction"^^xsd:string .


###  http://www.semanticweb.org/root/ontologies/2018/6/ctro#R_CT9_A1_OC1
ctro:R_CT9_A1_OC1 rdf:type owl:NamedIndividual ,
                           ctro:Result ;
                  ctro:hasStatisticalMeasure ctro:STAT_CT9_A1_OC1 ;
                  ctro:hasAbsoluteValue "8.3"^^xsd:float ;
                  ctro:hasResultDirection "reduction"^^xsd:string .


###  http://www.semanticweb.org/root/ontologies/2018/6/ctro#R_CT9_A2_OC1
ctro:R_CT9_A2_OC1 rdf:type owl:NamedIndividual ,
                           ctro:Result ;
                  ctro:hasStatisticalMeasure ctro:STAT_CT9_A2_OC1 ;
                  ctro:hasAbsoluteValue "4.6"^^xsd:float ;
                  ctro:hasResultDirection "reduction"^^xsd:string .


###  http://www.semanticweb.org/root/ontologies/2018/6/ctro#Randomized
ctro:Randomized rdf:type owl:NamedIndividual ,
                         ctro:CTDesign ;
                rdfs:label "Randomized" .


###  http://www.semanticweb.org/root/ontologies/2018/6/ctro#ReducedBloodPreasure
ctro:ReducedBloodPreasure rdf:type owl:NamedIndividual ,
                                   ctro:AdverseEffectName .


###  http://www.semanticweb.org/root/ontologies/2018/6/ctro#ReducedHeartRate
ctro:ReducedHeartRate rdf:type owl:NamedIndividual ,
                               ctro:AdverseEffectName .


###  http://www.semanticweb.org/root/ontologies/2018/6/ctro#ReducedPulseRate
ctro:ReducedPulseRate rdf:type owl:NamedIndividual ,
                               ctro:AdverseEffectName .


###  http://www.semanticweb.org/root/ontologies/2018/6/ctro#Reduction
ctro:Reduction rdf:type owl:NamedIndividual ,
                        ctro:DesiredEffectDirection .


###  http://www.semanticweb.org/root/ontologies/2018/6/ctro#STAT_CT1_A2_OC1
ctro:STAT_CT1_A2_OC1 rdf:type owl:NamedIndividual ,
                              ctro:StatisticalMeasure ;
                     ctro:hasPValue "< 0.001"^^xsd:string .


###  http://www.semanticweb.org/root/ontologies/2018/6/ctro#STAT_CT2_A1_OC1
ctro:STAT_CT2_A1_OC1 rdf:type owl:NamedIndividual ,
                              ctro:StatisticalMeasure ;
                     ctro:hasPValue "< 0.001"^^xsd:string ;
                     ctro:hasStatisticalTestName "ANCOVA"^^xsd:string ;
                     ctro:hasStatisticalTestValue "39.0"^^xsd:float .


###  http://www.semanticweb.org/root/ontologies/2018/6/ctro#STAT_CT2_A2_OC1
ctro:STAT_CT2_A2_OC1 rdf:type owl:NamedIndividual ,
                              ctro:StatisticalMeasure ;
                     ctro:hasPValue "< 0.001"^^xsd:string ;
                     ctro:hasStatisticalTestName "ANCOVA"^^xsd:string ;
                     ctro:hasStatisticalTestValue "32.0"^^xsd:float .


###  http://www.semanticweb.org/root/ontologies/2018/6/ctro#STAT_CT3_A1_OC1
ctro:STAT_CT3_A1_OC1 rdf:type owl:NamedIndividual ,
                              ctro:StatisticalMeasure ;
                     ctro:hasPValue "< 0.001"^^xsd:string .


###  http://www.semanticweb.org/root/ontologies/2018/6/ctro#STAT_CT3_A2_OC1
ctro:STAT_CT3_A2_OC1 rdf:type owl:NamedIndividual ,
                              ctro:StatisticalMeasure ;
                     ctro:hasPValue "< 0.001"^^xsd:string .


###  http://www.semanticweb.org/root/ontologies/2018/6/ctro#STAT_CT5_A1_OC1
ctro:STAT_CT5_A1_OC1 rdf:type owl:NamedIndividual ,
                              ctro:StatisticalMeasure ;
                     ctro:hasPValue "< 0.001"^^xsd:string ;
                     ctro:hasStatisticalTestName "Two-tailed T-test"^^xsd:string .


###  http://www.semanticweb.org/root/ontologies/2018/6/ctro#STAT_CT5_A2_OC1
ctro:STAT_CT5_A2_OC1 rdf:type owl:NamedIndividual ,
                              ctro:StatisticalMeasure ;
                     ctro:hasPValue "< 0.001"^^xsd:string ;
                     ctro:hasStatisticalTestName "Two-tailed T-test"^^xsd:string .


###  http://www.semanticweb.org/root/ontologies/2018/6/ctro#STAT_CT9_A1_OC1
ctro:STAT_CT9_A1_OC1 rdf:type owl:NamedIndividual ,
                              ctro:StatisticalMeasure ;
                     ctro:hasPValue "< 0.001"^^xsd:string ;
                     ctro:hasStatisticalTestName "ANOVA"^^xsd:string .


###  http://www.semanticweb.org/root/ontologies/2018/6/ctro#STAT_CT9_A2_OC1
ctro:STAT_CT9_A2_OC1 rdf:type owl:NamedIndividual ,
                              ctro:StatisticalMeasure ;
                     ctro:hasPValue "< 0.001"^^xsd:string ;
                     ctro:hasStatisticalTestName "ANOVA"^^xsd:string .


###  http://www.semanticweb.org/root/ontologies/2018/6/ctro#Second
ctro:Second rdf:type owl:NamedIndividual ,
                     ctro:TimeUnit .


###  http://www.semanticweb.org/root/ontologies/2018/6/ctro#SingleCenter
ctro:SingleCenter rdf:type owl:NamedIndividual ,
                           ctro:CTDesign ;
                  rdfs:label "Singlecenter"^^xsd:string .


###  http://www.semanticweb.org/root/ontologies/2018/6/ctro#Smarting
ctro:Smarting rdf:type owl:NamedIndividual ,
                       ctro:AdverseEffectName .


###  http://www.semanticweb.org/root/ontologies/2018/6/ctro#Sweden
ctro:Sweden rdf:type owl:NamedIndividual ,
                     <http://www.bpiresearch.com/BPMO/2004/03/03/cdl/Countries#Country> ;
            rdfs:label "Sweden" .


###  http://www.semanticweb.org/root/ontologies/2018/6/ctro#Timolol
ctro:Timolol rdf:type owl:NamedIndividual ,
                      ctro:Drug ;
             rdfs:label "Timolol" .


###  http://www.semanticweb.org/root/ontologies/2018/6/ctro#Titration
ctro:Titration rdf:type owl:NamedIndividual ,
                        ctro:Other ;
               rdfs:label "Titration" .


###  http://www.semanticweb.org/root/ontologies/2018/6/ctro#USA
ctro:USA rdf:type owl:NamedIndividual ,
                  <http://www.bpiresearch.com/BPMO/2004/03/03/cdl/Countries#Country> ;
         rdfs:label "USA" .


###  http://www.semanticweb.org/root/ontologies/2018/6/ctro#Week
ctro:Week rdf:type owl:NamedIndividual ,
                   ctro:TimeUnit .


###  http://www.semanticweb.org/root/ontologies/2018/6/ctro#Year
ctro:Year rdf:type owl:NamedIndividual ,
                   ctro:TimeUnit .


###  http://www.semanticweb.org/root/ontologies/2018/6/ctro#mmHg
ctro:mmHg rdf:type owl:NamedIndividual ,
                   ctro:Pressure ;
          ctro:hasDoseUnit ctro:mmHg ;
          rdfs:comment "mmHg" .


#################################################################
#    Annotations
#################################################################

ctro:Glargine_Insuline rdfs:label "Insulin Glargine" .


#################################################################
#    General axioms
#################################################################

[ rdf:type owl:AllDifferent ;
  owl:distinctMembers ( ctro:Conjunctival_hyperemia
                      )
] .


###  Generated by the OWL API (version 4.2.8.20170104-2310) https://github.com/owlcs/owlapi
